1	The	DT	O	the	det	4	SENT_1	[p1l672t81r718b102],
2	NEW	NNP	O	NEW	nn	4	SENT_1	[p1l736t83r821b102],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_1	[p1l840t83r1028b102],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_1	[p1l1047t83r1227b109],
5	of	IN	O	of	_	0	SENT_1	[p1l1247t81r1275b108],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_1	[p1l1287t83r1486b102],

1	|	NN	O	|	nn	3	SENT_2	[p1l235t184r238b385],
2	E	NN	O	e	nn	3	SENT_2	[p1l875t257r903b289],
3	D	NN	O	d	dep	8	SENT_2	[p1l918t257r954b289],
4	I	PRP	O	I	dep	5	SENT_2	[p1l968t257r984b289],
5	T	NN	O	t	dep	3	SENT_2	[p1l998t257r1030b289],
6	O	NN	O	o	nn	7	SENT_2	[p1l1043t257r1078b289],
7	R	NN	O	r	dep	8	SENT_2	[p1l1092t257r1128b290],
8	I	PRP	O	I	_	0	SENT_2	[p1l1142t257r1158b289],
9	A	DT	O	a	det	11	SENT_2	[p1l1172t257r1207b289],
10	L	NN	O	l	nn	11	SENT_2	[p1l1221t257r1248b289],
11	S	NN	O	s	dep	8	SENT_2	[p1l1263t257r1284b289],
12	|	IN	O	|	dep	8	SENT_2	[p1l1921t184r1924b385],

1	E	NN	O	e	dep	6	SENT_3	[p1l1009t450r1024b476],
2	[	NN	O	[	nn	3	SENT_3	[p1l1033t443r1078b471],
3	B	NN	O	b	dep	1	SENT_3	[p1l1033t443r1078b471],
4	1325	CD	DATE	1325	num	5	SENT_3	[p1l1091t461r1116b471],
5	E	NN	O	e	dep	6	SENT_3	[p1l1123t442r1141b475],
6	“	CD	NUMBER	“	dep	11	SENT_3	[p1l1012t484r1032b503],
7	6	CD	NUMBER	6	number	8	SENT_3	[p1l1012t484r1032b503],
8	192	CD	NUMBER	192	dep	6	SENT_3	[p1l1052t472r1098b502],
9	§	NN	O	§	dep	8	SENT_3	[p1l1117t476r1138b504],
10	'	''	O	'	_	0	SENT_3	[p1l1032t503r1044b519],
11	uno	FW	O	uno	_	0	SENT_3	[p1l1065t498r1126b533],
12	‘	FW	O	‘	nn	13	SENT_3	[p1l1065t498r1126b533],
13	°	FW	O	°	dep	11	SENT_3	[p1l1065t498r1126b533],

1	Pharmacogenetics	NNS	O	pharmacogenetic	_	0	SENT_4	[p1l317t620r801b684],
2	—	CD	NUMBER	—	num	4	SENT_4	[p1l818t650r883b656],
3	Tailoring	NNP	O	Tailoring	nn	4	SENT_4	[p1l899t620r1134b684],
4	Treatment	NN	O	treatment	dep	1	SENT_4	[p1l1150t625r1426b669],
5	for	IN	O	for	_	0	SENT_4	[p1l1441t620r1515b669],
6	the	DT	O	the	det	7	SENT_4	[p1l1530t620r1614b669],
7	Outliers	NNS	O	outlier	prep_for	4	SENT_4	[p1l1632t620r1844b669],

1	Janet	NNP	PERSON	Janet	nn	2	SENT_5	[p1l557t705r647b742],
2	Woodcock	NNP	PERSON	Woodcock	_	0	SENT_5	[p1l660t702r848b738],
3	,	,	O	,	_	0	SENT_5	[p1l660t702r848b738],
4	M.D.	NNP	O	M.D.	appos	2	SENT_5	[p1l867t705r957b739],
5	,	,	O	,	_	0	SENT_5	[p1l867t705r957b739],
6	and	CC	O	and	_	0	SENT_5	[p1l974t702r1033b733],
7	Lawrence	NNP	PERSON	Lawrence	nn	8	SENT_5	[p1l1052t705r1242b742],
8	]	NNP	O	]	appos	2	SENT_5	[p1l1052t705r1242b742],
9	.	.	O	.	_	0	SENT_5	[p1l1052t705r1242b742],

1	Lesko	NNP	PERSON	Lesko	_	0	SENT_6	[p1l1261t702r1364b738],
2	,	,	O	,	_	0	SENT_6	[p1l1261t702r1364b738],
3	Ph.D.	NNP	O	Ph.D.	nn	5	SENT_6	[p1l1383t702r1482b738],
4	,	,	O	,	_	0	SENT_6	[p1l1383t702r1482b738],
5	F.C.P.	NNP	O	F.C.P.	appos	1	SENT_6	[p1l1501t704r1595b733],

1	If	IN	O	if	mark	3	SENT_7	[p1l138t912r221b990],
2	it	PRP	O	it	nsubj	3	SENT_7	[p1l229t913r291b991],
3	were	VBD	O	be	advcl	18	SENT_7	[p1l309t938r514b992],
4	not	RB	O	not	neg	3	SENT_7	[p1l542t929r689b991],
5	for	IN	O	for	_	0	SENT_7	[p1l711t912r838b991],
6	the	DT	O	the	det	8	SENT_7	[p1l862t912r995b991],
7	great	JJ	O	great	amod	8	SENT_7	[p1l1022t929r1244b1013],
8	variability	NN	O	variability	prep_for	3	SENT_7	[p1l1262t912r1693b1013],
9	among	IN	O	among	_	0	SENT_7	[p1l1716t938r2022b1013],
10	individuals	NNS	O	individual	prep_among	8	SENT_7	[p1l139t1040r640b1136],
11	,	,	O	,	_	0	SENT_7	[p1l139t1040r640b1136],
12	medicine	NN	O	medicine	nsubj	18	SENT_7	[p1l698t1040r1095b1119],
13	might	MD	O	might	aux	18	SENT_7	[p1l1148t1040r1412b1141],
14	as	RB	O	as	advmod	15	SENT_7	[p1l1459t1067r1545b1119],
15	well	RB	O	well	advmod	18	SENT_7	[p1l1594t1040r1774b1119],
16	be	VB	O	be	cop	18	SENT_7	[p1l1826t1040r1923b1119],
17	a	DT	O	a	det	18	SENT_7	[p1l1975t1067r2020b1119],
18	science	NN	O	science	_	0	SENT_7	[p1l141t1170r453b1248],
19	and	CC	O	and	_	0	SENT_7	[p1l490t1169r649b1248],
20	not	RB	O	not	conj_and	18	SENT_7	[p1l685t1186r832b1248],
21	an	DT	O	a	det	22	SENT_7	[p1l863t1195r965b1248],
22	art	NN	O	art	dep	18	SENT_7	[p1l1001t1186r1140b1248],
23	.	.	O	.	_	0	SENT_7	[p1l1001t1186r1140b1248],

1	—	NN	O	—	_	0	SENT_8	[p1l926t1473r1034b1481],
2	Sir	NNP	O	Sir	nn	4	SENT_8	[p1l1069t1429r1185b1507],
3	William	NNP	PERSON	William	nn	4	SENT_8	[p1l1216t1428r1563b1507],
4	Osler	NNP	PERSON	Osler	dep	1	SENT_8	[p1l1599t1428r1832b1507],
5	(	CD	NUMBER	(	number	6	SENT_8	[p1l1871t1434r2143b1520],
6	1892	CD	DATE	1892	num	7	SENT_8	[p1l1871t1434r2143b1520],
7	)	NN	O	)	dep	4	SENT_8	[p1l1871t1434r2143b1520],

1	Over	IN	O	over	_	0	SENT_9	[p1l10t1693r208b1766],
2	the	DT	DATE	the	det	5	SENT_9	[p1l237t1687r368b1766],
3	past	JJ	DATE	past	amod	5	SENT_9	[p1l398t1704r577b1788],
4	half	JJ	DATE	half	amod	5	SENT_9	[p1l603t1687r787b1766],
5	century	NN	DATE	century	prep_over	10	SENT_9	[p1l800t1704r1133b1788],
6	,	,	O	,	_	0	SENT_9	[p1l800t1704r1133b1788],
7	biomedical	JJ	O	biomedical	amod	8	SENT_9	[p1l1170t1687r1639b1766],
8	science	NN	O	science	nsubj	10	SENT_9	[p1l1671t1688r1971b1766],
9	has	VBZ	O	have	aux	10	SENT_9	[p1l2003t1687r2146b1766],
10	developed	VBN	O	develop	_	0	SENT_9	[p1l11t1815r441b1916],
11	randomized	VBN	O	randomize	dep	10	SENT_9	[p1l501t1815r1049b1911],
12	,	,	O	,	_	0	SENT_9	[p1l501t1815r1049b1911],
13	controlled	VBN	O	control	dep	10	SENT_9	[p1l1116t1815r1557b1894],
14	clinical	JJ	O	clinical	amod	17	SENT_9	[p1l1618t1815r2149b1894],
15	—	NN	O	—	nn	17	SENT_9	[p1l1618t1815r2149b1894],
16	trial	NN	O	trial	nn	17	SENT_9	[p1l1618t1815r2149b1894],
17	methods	NNS	O	method	dobj	13	SENT_9	[p1l10t1943r386b2022],
18	that	WDT	O	that	nsubj	20	SENT_9	[p1l436t1943r610b2022],
19	can	MD	O	can	aux	20	SENT_9	[p1l653t1969r804b2022],
20	distinguish	VB	O	distinguish	rcmod	17	SENT_9	[p1l852t1943r1345b2044],
21	treatment	NN	O	treatment	nn	22	SENT_9	[p1l1393t1960r1820b2022],
22	effects	NNS	O	effect	dobj	20	SENT_9	[p1l1863t1943r2147b2022],
23	from	IN	O	from	_	0	SENT_9	[p1l10t2071r222b2150],
24	the	DT	O	the	det	25	SENT_9	[p1l262t2071r396b2150],
25	noise	NN	O	noise	prep_from	20	SENT_9	[p1l436t2072r662b2150],
26	of	IN	O	of	_	0	SENT_9	[p1l703t2071r804b2150],
27	human	JJ	O	human	amod	28	SENT_9	[p1l825t2071r1132b2150],
28	variability	NN	O	variability	prep_of	25	SENT_9	[p1l1167t2071r1619b2172],
29	.	.	O	.	_	0	SENT_9	[p1l1167t2071r1619b2172],

1	Positive	JJ	O	positive	amod	2	SENT_10	[p1l1663t2072r1993b2150],
2	results	NNS	O	result	nsubj	14	SENT_10	[p1l2033t2097r2147b2150, p1l11t2199r209b2279],
3	from	IN	O	from	_	0	SENT_10	[p1l249t2199r461b2278],
4	tests	NNS	O	test	prep_from	2	SENT_10	[p1l498t2216r694b2278],
5	of	IN	O	of	_	0	SENT_10	[p1l735t2199r835b2278],
6	a	DT	O	a	det	7	SENT_10	[p1l853t2226r898b2278],
7	treatment	NN	O	treatment	prep_of	4	SENT_10	[p1l934t2216r1361b2278],
8	in	IN	O	in	advmod	10	SENT_10	[p1l1393t2200r1477b2277],
9	a	DT	O	a	dep	8	SENT_10	[p1l1514t2226r1559b2278],
10	randomized	VBN	O	randomize	partmod	7	SENT_10	[p1l1594t2199r2142b2295],
11	,	,	O	,	_	0	SENT_10	[p1l1594t2199r2142b2295],
12	controlled	VBN	O	control	dep	10	SENT_10	[p1l11t2328r451b2407],
13	trial	NN	O	trial	dobj	10	SENT_10	[p1l490t2328r669b2407],
14	provide	VBP	O	provide	_	0	SENT_10	[p1l706t2328r1027b2429],
15	great	JJ	O	great	amod	16	SENT_10	[p1l1066t2345r1289b2429],
16	confidence	NN	O	confidence	dobj	14	SENT_10	[p1l1324t2328r1798b2407],
17	that	IN	O	that	complm	20	SENT_10	[p1l1838t2328r2012b2407],
18	an	DT	O	a	det	19	SENT_10	[p1l2045t2354r2148b2407],
19	intervention	NN	O	intervention	nsubj	20	SENT_10	[p1l9t2457r537b2535],
20	improves	VBZ	O	improve	ccomp	14	SENT_10	[p1l574t2457r967b2557],
21	a	DT	O	a	det	23	SENT_10	[p1l1006t2483r1051b2535],
22	prespecified	JJ	O	prespecified	amod	23	SENT_10	[p1l1085t2456r1618b2557],
23	outcome	NN	O	outcome	dobj	20	SENT_10	[p1l1656t2473r2027b2535],
24	in	IN	O	in	_	0	SENT_10	[p1l2064t2457r2148b2534],
25	a	DT	O	a	det	26	SENT_10	[p1l9t2611r54b2663],
26	population	NN	O	population	prep_in	23	SENT_10	[p1l107t2584r581b2685],
27	defined	VBN	O	define	partmod	26	SENT_10	[p1l637t2584r966b2663],
28	by	IN	O	by	_	0	SENT_10	[p1l1022t2584r1120b2685],
29	explicit	JJ	O	explicit	amod	31	SENT_10	[p1l1173t2584r1487b2685],
30	entry	NN	O	entry	nn	31	SENT_10	[p1l1538t2601r1762b2685],
31	criteria	NNS	O	criterion	agent	27	SENT_10	[p1l1814t2585r2143b2663],
32	.	.	O	.	_	0	SENT_10	[p1l1814t2585r2143b2663],

1	These	DT	O	these	det	2	SENT_11	[p1l7t2712r255b2791],
2	methods	NNS	O	method	nsubjpass	5	SENT_11	[p1l289t2712r659b2791],
3	are	VBP	O	be	auxpass	5	SENT_11	[p1l695t2738r822b2791],
4	rightly	RB	O	rightly	advmod	5	SENT_11	[p1l857t2712r1138b2813],
5	venerated	VBN	O	venerate	_	0	SENT_11	[p1l1163t2712r1570b2791],
6	because	IN	O	because	mark	9	SENT_11	[p1l1605t2712r1937b2791],
7	they	PRP	O	they	nsubj	9	SENT_11	[p1l1972t2712r2153b2813],
8	have	VBP	O	have	aux	9	SENT_11	[p1l10t2840r201b2919],
9	helped	VBN	O	help	advcl	5	SENT_11	[p1l260t2840r548b2941],
10	move	VB	O	move	ccomp	9	SENT_11	[p1l606t2866r833b2919],
11	medicine	NN	O	medicine	dobj	10	SENT_11	[p1l893t2840r1288b2919],
12	from	IN	O	from	_	0	SENT_11	[p1l1347t2840r1559b2919],
13	anecdote	NN	O	anecdote	prep_from	10	SENT_11	[p1l1619t2840r2005b2919],
14	to	TO	O	to	_	0	SENT_11	[p1l2065t2857r2147b2919],
15	science	NN	O	science	prep_to	10	SENT_11	[p1l11t2969r318b3047],
16	and	CC	O	and	_	0	SENT_11	[p1l357t2968r516b3047],
17	have	VBP	O	have	aux	19	SENT_11	[p1l554t2968r746b3047],
18	largely	RB	O	largely	advmod	19	SENT_11	[p1l784t2968r1077b3069],
19	brought	VBN	O	bring	conj_and	10	SENT_11	[p1l1112t2968r1458b3069],
20	about	IN	O	about	_	0	SENT_11	[p1l1491t2968r1737b3047],
21	the	DT	O	the	det	23	SENT_11	[p1l1771t2968r1905b3047],
22	therapeutic	JJ	O	therapeutic	amod	23	SENT_11	[p1l1944t2968r2147b3047, p1l9t3097r320b3197],
23	advances	NNS	O	advance	prep_about	19	SENT_11	[p1l362t3096r747b3175],
24	of	IN	O	of	_	0	SENT_11	[p1l792t3096r893b3175],
25	the	DT	DURATION	the	det	28	SENT_11	[p1l918t3096r1051b3175],
26	past	JJ	DURATION	past	amod	28	SENT_11	[p1l1093t3113r1275b3197],
27	50	CD	DURATION	50	num	28	SENT_11	[p1l1314t3102r1412b3175],
28	years	NNS	NUMBER	year	prep_of	23	SENT_11	[p1l1451t3122r1697b3197],
29	.	.	O	.	_	0	SENT_11	[p1l1451t3122r1697b3197],

1	However	RB	O	however	advmod	23	SENT_12	[p1l1745t3104r2143b3192],
2	,	,	O	,	_	0	SENT_12	[p1l1745t3104r2143b3192],
3	although	IN	O	although	mark	14	SENT_12	[p1l9t3224r399b3325],
4	population	NN	O	population	nsubj	14	SENT_12	[p1l472t3224r1253b3325],
5	—	CD	NUMBER	—	num	4	SENT_12	[p1l472t3224r1253b3325],
6	based	VBN	O	base	partmod	4	SENT_12	[p1l472t3224r1253b3325],
7	,	,	O	,	_	0	SENT_12	[p1l472t3224r1253b3325],
8	randomized	VBN	O	randomize	dep	6	SENT_12	[p1l1333t3224r1881b3320],
9	,	,	O	,	_	0	SENT_12	[p1l1333t3224r1881b3320],
10	controlled	VBN	O	control	dep	6	SENT_12	[p1l1962t3250r2147b3303, p1l11t3352r293b3431],
11	trials	NNS	O	trial	dobj	10	SENT_12	[p1l346t3352r567b3431],
12	of	IN	O	of	_	0	SENT_12	[p1l623t3352r723b3431],
13	drugs	NNS	O	drug	prep_of	11	SENT_12	[p1l758t3352r1004b3453],
14	control	VBP	O	control	advcl	23	SENT_12	[p1l1060t3352r1368b3431],
15	for	IN	O	for	_	0	SENT_12	[p1l1420t3352r1544b3431],
16	disease	NN	O	disease	nn	17	SENT_12	[p1l1594t3352r1906b3431],
17	variability	NN	O	variability	prep_for	14	SENT_12	[p1l1955t3353r2147b3431, p1l9t3480r294b3581],
18	,	,	O	,	_	0	SENT_12	[p1l1955t3353r2147b3431, p1l9t3480r294b3581],
19	they	PRP	O	they	nsubj	23	SENT_12	[p1l355t3480r539b3581],
20	generally	RB	O	generally	advmod	23	SENT_12	[p1l589t3480r986b3581],
21	do	VBP	O	do	aux	23	SENT_12	[p1l1038t3480r1141b3559],
22	not	RB	O	not	neg	23	SENT_12	[p1l1197t3497r1341b3559],
23	reveal	VB	O	reveal	_	0	SENT_12	[p1l1390t3480r1642b3559],
24	Why	WRB	O	why	advmod	29	SENT_12	[p1l1692t3480r1871b3581],
25	some	DT	O	some	det	26	SENT_12	[p1l1923t3506r2148b3559],
26	people	NNS	O	people	nsubj	29	SENT_12	[p1l8t3608r292b3709],
27	do	VBP	O	do	aux	29	SENT_12	[p1l329t3608r432b3687],
28	not	RB	O	not	neg	29	SENT_12	[p1l468t3625r612b3687],
29	have	VB	O	have	advcl	23	SENT_12	[p1l642t3608r833b3687],
30	a	DT	O	a	det	31	SENT_12	[p1l867t3635r912b3687],
31	response	NN	O	response	dobj	29	SENT_12	[p1l946t3634r1329b3709],
32	to	TO	O	to	_	0	SENT_12	[p1l1365t3625r1447b3687],
33	treatment	NN	O	treatment	prep_to	29	SENT_12	[p1l1484t3625r1932b3704],
34	,	,	O	,	_	0	SENT_12	[p1l1484t3625r1932b3704],
35	others	NNS	O	other	appos	33	SENT_12	[p1l1973t3608r2147b3687, p2l11t46r132b99],

1	have	VB	O	have	_	0	SENT_13	[p2l168t20r359b99],
2	excessive	JJ	O	excessive	amod	4	SENT_13	[p2l394t21r781b99],
3	pharmacologic	JJ	O	pharmacologic	amod	4	SENT_13	[p2l814t20r1466b121],
4	responses	NNS	O	response	nsubj	9	SENT_13	[p2l1499t46r1950b121],
5	,	,	O	,	_	0	SENT_13	[p2l1499t46r1950b121],
6	and	CC	O	and	_	0	SENT_13	[p2l1989t20r2148b99],
7	still	RB	O	still	advmod	4	SENT_13	[p2l11t149r174b229],
8	others	NNS	O	other	conj_and	4	SENT_13	[p2l215t149r484b229],
9	have	VBP	O	have	ccomp	1	SENT_13	[p2l527t149r718b229],
10	side	JJ	O	side	amod	11	SENT_13	[p2l761t149r926b229],
11	effects	NNS	O	effect	dobj	9	SENT_13	[p2l967t149r1250b229],
12	that	WDT	O	that	nsubj	13	SENT_13	[p2l1294t149r1467b229],
13	occur	VBP	O	occur	rcmod	11	SENT_13	[p2l1503t175r1744b229],
14	in	IN	O	in	_	0	SENT_13	[p2l1781t150r1865b227],
15	a	DT	O	a	det	16	SENT_13	[p2l1905t176r1950b229],
16	distinctive	JJ	O	distinctive	prep_in	13	SENT_13	[p2l1989t149r2147b229, p2l11t279r328b357],

1	pattern	NN	O	pattern	_	0	SENT_14	[p2l360t295r674b379],
2	for	IN	O	for	_	0	SENT_14	[p2l708t278r832b357],
3	a	DT	O	a	det	5	SENT_14	[p2l862t305r907b357],
4	given	VBN	O	give	amod	5	SENT_14	[p2l939t279r1167b379],
5	drug	NN	O	drug	prep_for	1	SENT_14	[p2l1201t278r1425b379],
6	.	.	O	.	_	0	SENT_14	[p2l1201t278r1425b379],

1	Addressing	VBG	O	address	csubj	7	SENT_15	[p2l1461t278r1954b379],
2	this	DT	O	this	det	3	SENT_15	[p2l1985t278r2146b357],
3	question	NN	O	question	dobj	1	SENT_15	[p2l11t407r382b507],
4	is	VBZ	O	be	cop	7	SENT_15	[p2l419t407r485b485],
5	our	PRP$	O	we	poss	7	SENT_15	[p2l527t432r673b485],
6	next	JJ	O	next	amod	7	SENT_15	[p2l709t423r895b485],
7	challenge	NN	O	challenge	_	0	SENT_15	[p2l928t406r1364b507],
8	.	.	O	.	_	0	SENT_15	[p2l928t406r1364b507],

1	Currently	RB	DATE	currently	advmod	5	SENT_16	[p2l140t534r564b635],
2	,	,	O	,	_	0	SENT_16	[p2l140t534r564b635],
3	medicine	NN	O	medicine	nsubj	5	SENT_16	[p2l623t534r1018b613],
4	is	VBZ	O	be	aux	5	SENT_16	[p2l1073t535r1139b613],
5	addressing	VBG	O	address	_	0	SENT_16	[p2l1195t534r1668b635],
6	this	DT	O	this	det	7	SENT_16	[p2l1719t534r1880b613],
7	challenge	NN	O	challenge	dobj	5	SENT_16	[p2l1937t534r2147b613, p2l8t662r236b763],
8	through	IN	O	through	_	0	SENT_16	[p2l274t662r625b763],
9	the	DT	O	the	det	10	SENT_16	[p2l662t662r796b741],
10	lens	NN	O	lens	prep_through	5	SENT_16	[p2l832t662r1002b741],
11	of	IN	O	of	_	0	SENT_16	[p2l1042t662r1142b741],
12	genomic	JJ	O	genomic	amod	13	SENT_16	[p2l1160t663r1533b763],
13	technologies	NNS	O	technology	prep_of	10	SENT_16	[p2l1569t662r2143b763],
14	.	.	O	.	_	0	SENT_16	[p2l1569t662r2143b763],

1	There	EX	O	there	expl	2	SENT_17	[p2l7t790r253b869],
2	is	VBZ	O	be	_	0	SENT_17	[p2l304t791r370b869],
3	considerable	JJ	O	considerable	amod	4	SENT_17	[p2l425t790r966b869],
4	debate	NN	O	debate	nsubj	2	SENT_17	[p2l1019t790r1298b869],
5	about	IN	O	about	_	0	SENT_17	[p2l1350t790r1596b869],
6	the	DT	O	the	det	7	SENT_17	[p2l1643t790r1777b869],
7	quality	NN	O	quality	prep_about	4	SENT_17	[p2l1830t790r2143b891],
8	,	,	O	,	_	0	SENT_17	[p2l1830t790r2143b891],
9	quantity	NN	O	quantity	prep_about	4	SENT_17	[p2l11t919r372b1019],
10	,	,	O	,	_	0	SENT_17	[p2l11t919r372b1019],
11	and	CC	O	and	_	0	SENT_17	[p2l410t918r565b997],
12	type	NN	O	type	prep_about	4	SENT_17	[p2l597t935r774b1019],
13	of	IN	O	of	_	0	SENT_17	[p2l807t918r906b997],
14	evidence	NN	O	evidence	prep_of	7	SENT_17	[p2l919t918r1276b997],
15	that	WDT	O	that	nsubjpass	18	SENT_17	[p2l1308t918r1477b997],
16	would	MD	O	would	aux	18	SENT_17	[p2l1499t918r1760b998],
17	be	VB	O	be	auxpass	18	SENT_17	[p2l1792t918r1887b997],
18	needed	VBN	O	need	rcmod	4	SENT_17	[p2l1919t918r2147b997, p2l11t1046r106b1125],
19	to	TO	O	to	aux	20	SENT_17	[p2l138t1063r218b1125],
20	change	VB	O	change	xcomp	18	SENT_17	[p2l251t1046r551b1147],
21	clinical	JJ	O	clinical	amod	22	SENT_17	[p2l583t1046r887b1125],
22	practice	NN	O	practice	dobj	20	SENT_17	[p2l916t1047r1246b1147],
23	by	IN	O	by	_	0	SENT_17	[p2l1278t1046r1374b1147],
24	introducing	VBG	O	introduce	prepc_by	20	SENT_17	[p2l1400t1046r1896b1147],
25	phar	JJ	O	phar	amod	28	SENT_17	[p2l1923t1046r2147b1147],
26	—	NN	O	—	nn	28	SENT_17	[p2l1923t1046r2147b1147],
27	macogenetic	JJ	O	macogenetic	amod	28	SENT_17	[p2l10t1175r542b1275],
28	testing	NN	O	testing	dobj	24	SENT_17	[p2l576t1175r866b1275],
29	for	IN	O	for	_	0	SENT_17	[p2l897t1174r1018b1253],
30	a	DT	O	a	det	32	SENT_17	[p2l1048t1201r1093b1253],
31	given	VBN	O	give	amod	32	SENT_17	[p2l1126t1175r1347b1275],
32	drug	NN	O	drug	prep_for	28	SENT_17	[p2l1382t1174r1601b1275],
33	.	.	O	.	_	0	SENT_17	[p2l1382t1174r1601b1275],

1	What	WDT	O	what	det	2	SENT_18	[p2l1637t1174r1870b1253],
2	methods	NNS	O	method	nsubjpass	5	SENT_18	[p2l1899t1174r2147b1253, p2l11t1303r155b1383],
3	should	MD	O	should	aux	5	SENT_18	[p2l222t1303r510b1383],
4	be	VB	O	be	auxpass	5	SENT_18	[p2l577t1303r675b1383],
5	used	VBN	O	use	_	0	SENT_18	[p2l741t1303r939b1383],
6	to	TO	O	to	aux	7	SENT_18	[p2l1005t1320r1087b1383],
7	understand	VB	O	understand	xcomp	5	SENT_18	[p2l1155t1303r1649b1383],
8	individual	JJ	O	individual	amod	9	SENT_18	[p2l1714t1303r2149b1383],
9	responses	NNS	O	response	dobj	7	SENT_18	[p2l10t1458r427b1533],
10	once	IN	DATE	once	mark	17	SENT_18	[p2l470t1458r665b1511],
11	an	DT	O	a	det	14	SENT_18	[p2l703t1458r806b1511],
12	overall	JJ	O	overall	amod	14	SENT_18	[p2l846t1432r1127b1511],
13	population	NN	O	population	nn	14	SENT_18	[p2l1164t1432r1629b1533],
14	benefit	NN	O	benefit	nsubj	17	SENT_18	[p2l1668t1432r1970b1511],
15	has	VBZ	O	have	aux	17	SENT_18	[p2l2003t1432r2146b1511],
16	been	VBN	O	be	aux	17	SENT_18	[p2l11t1561r214b1640],
17	shown	VBN	O	show	advcl	7	SENT_18	[p2l253t1561r536b1641],
18	in	IN	O	in	_	0	SENT_18	[p2l575t1562r658b1639],
19	randomized	VBN	O	randomize	prepc_in	17	SENT_18	[p2l696t1561r1244b1657],
20	,	,	O	,	_	0	SENT_18	[p2l696t1561r1244b1657],
21	controlled	VBN	O	control	dep	17	SENT_18	[p2l1289t1561r1729b1640],
22	trials	NNS	O	trial	dobj	21	SENT_18	[p2l1768t1558r2027b1640],
23	?	.	O	?	_	0	SENT_18	[p2l1768t1558r2027b1640],

1	In	IN	O	in	_	0	SENT_19	[p2l138t1697r228b1767],
2	this	DT	O	this	det	3	SENT_19	[p2l279t1689r440b1768],
3	issue	NN	O	issue	prep_in	11	SENT_19	[p2l492t1690r705b1768],
4	of	IN	O	of	_	0	SENT_19	[p2l757t1689r857b1768],
5	the	DT	O	the	det	6	SENT_19	[p2l890t1689r1024b1768],
6	journal	NN	O	journal	prep_of	3	SENT_19	[p2l1058t1689r1373b1790],
7	,	,	O	,	_	0	SENT_19	[p2l1058t1689r1373b1790],
8	an	DT	O	a	det	10	SENT_19	[p2l1429t1715r1532b1768],
9	international	JJ	O	international	amod	10	SENT_19	[p2l1582t1689r2149b1768],
10	consortium	NN	O	consortium	nsubj	11	SENT_19	[p2l11t1818r511b1896],
11	reports	VBZ	O	report	_	0	SENT_19	[p2l548t1834r857b1918],
12	the	DT	O	the	det	13	SENT_19	[p2l897t1817r1030b1896],
13	results	NNS	O	result	dobj	11	SENT_19	[p2l1068t1817r1353b1896],
14	of	IN	O	of	_	0	SENT_19	[p2l1393t1817r1493b1896],
15	a	DT	O	a	det	17	SENT_19	[p2l1512t1844r1556b1896],
16	retrospective	JJ	O	retrospective	amod	17	SENT_19	[p2l1592t1818r2148b1918],
17	study	NN	O	study	prep_of	13	SENT_19	[p2l11t1945r238b2046],
18	of	IN	O	of	_	0	SENT_19	[p2l268t1945r367b2024],
19	the	DT	O	the	det	20	SENT_19	[p2l382t1945r513b2024],
20	initiation	NN	O	initiation	prep_of	17	SENT_19	[p2l546t1946r939b2024],
21	of	IN	O	of	_	0	SENT_19	[p2l973t1945r1072b2024],
22	Warfarin	NN	O	warfarin	nn	23	SENT_19	[p2l1082t1945r1451b2024],
23	therapy	NN	O	therapy	prep_of	20	SENT_19	[p2l1485t1945r1802b2046],
24	in	IN	O	in	_	0	SENT_19	[p2l1830t1946r1913b2023],
25	5052	CD	DATE	5052	num	26	SENT_19	[p2l1948t1951r2147b2024],
26	patients	NNS	O	patient	prep_in	11	SENT_19	[p2l18t2074r359b2174],
27	who	WP	O	who	nsubj	28	SENT_19	[p2l411t2073r593b2152],
28	required	VBD	O	require	rcmod	26	SENT_19	[p2l650t2073r1011b2174],
29	therapeutic	JJ	O	therapeutic	amod	31	SENT_19	[p2l1065t2073r1551b2174],
30	anticoagulation	NN	O	anticoagulation	nn	31	SENT_19	[p2l1604t2073r2140b2174, p2l20t2202r241b2280],
31	.1	NN	NUMBER	.1	dobj	28	SENT_19	[p2l1604t2073r2140b2174, p2l20t2202r241b2280],
32	For	IN	O	for	_	0	SENT_19	[p2l277t2209r415b2280],
33	each	DT	O	each	det	34	SENT_19	[p2l450t2201r635b2280],
34	patient	NN	O	patient	prep_for	38	SENT_19	[p2l670t2202r978b2302],
35	,	,	O	,	_	0	SENT_19	[p2l670t2202r978b2302],
36	the	DT	O	the	det	37	SENT_19	[p2l1020t2201r1148b2280],
37	investigators	NNS	O	investigator	nsubj	38	SENT_19	[p2l1184t2202r1707b2302],
38	identiﬁed	VBD	O	identiﬁed	rcmod	31	SENT_19	[p2l1745t2201r2143b2280],
39	the	DT	O	the	det	43	SENT_19	[p2l20t2330r150b2409],
40	stable	JJ	O	stable	amod	43	SENT_19	[p2l188t2330r431b2409],
41	warfarin	NN	O	warfarin	nn	43	SENT_19	[p2l463t2330r829b2409],
42	maintenance	NN	O	maintenance	nn	43	SENT_19	[p2l866t2331r1413b2409],
43	dose	NN	O	dose	dobj	38	SENT_19	[p2l1451t2330r1641b2409],
44	that	WDT	O	that	nsubj	45	SENT_19	[p2l1679t2330r1848b2409],
45	resulted	VBD	O	result	rcmod	43	SENT_19	[p2l1879t2330r2140b2409, p2l20t2458r114b2537],

1	in	IN	O	in	_	0	SENT_20	[p2l145t2459r227b2536],
2	the	DT	O	the	prep_in	6	SENT_20	[p2l259t2458r387b2537],
3	desired	VBN	O	desire	amod	2	SENT_20	[p2l419t2458r716b2537],
4	therapeutic	JJ	O	therapeutic	amod	5	SENT_20	[p2l748t2458r1211b2559],
5	international	JJ	O	international	nsubj	6	SENT_20	[p2l1242t2458r1778b2537],
6	normalized	VBD	O	normalize	_	0	SENT_20	[p2l1810t2458r2140b2537, p2l19t2586r189b2665],
7	ratio	NN	O	ratio	nsubj	10	SENT_20	[p2l237t2587r434b2665],
8	(	CD	NUMBER	(	num	10	SENT_20	[p2l490t2593r753b2678],
9	INR	NN	O	inr	nn	10	SENT_20	[p2l490t2593r753b2678],
10	)	NN	O	)	xcomp	6	SENT_20	[p2l490t2593r753b2678],
11	.	.	O	.	_	0	SENT_20	[p2l490t2593r753b2678],

1	The	DT	O	the	det	2	SENT_21	[p2l805t2586r966b2665],
2	range	NN	O	range	nsubjpass	22	SENT_21	[p2l1015t2612r1255b2687],
3	of	IN	O	of	_	0	SENT_21	[p2l1306t2586r1406b2665],
4	doses	NNS	O	dose	prep_of	2	SENT_21	[p2l1438t2586r1675b2665],
5	that	WDT	O	that	nsubjpass	7	SENT_21	[p2l1727t2586r1900b2665],
6	were	VBD	O	be	auxpass	7	SENT_21	[p2l1940t2612r2142b2666],
7	needed	VBN	O	need	rcmod	4	SENT_21	[p2l19t2714r312b2793],
8	to	TO	O	to	aux	9	SENT_21	[p2l345t2731r425b2793],
9	achieve	VB	O	achieve	xcomp	7	SENT_21	[p2l460t2714r757b2793],
10	the	DT	O	the	det	13	SENT_21	[p2l792t2714r920b2793],
11	target	NN	O	target	nn	13	SENT_21	[p2l954t2731r1200b2815],
12	pharmacodynamic	JJ	O	pharmacodynamic	amod	13	SENT_21	[p2l1227t2714r2008b2815],
13	effect	NN	O	effect	dobj	9	SENT_21	[p2l2042t2714r2140b2793, p2l19t2842r173b2921],
14	in	IN	O	in	_	0	SENT_21	[p2l205t2843r286b2920],
15	this	DT	O	this	det	20	SENT_21	[p2l325t2842r480b2921],
16	large	JJ	O	large	amod	19	SENT_21	[p2l518t2842r748b2943],
17	,	,	O	,	_	0	SENT_21	[p2l518t2842r748b2943],
18	geographically	RB	O	geographically	advmod	19	SENT_21	[p2l791t2842r1409b2943],
19	diverse	JJ	O	diverse	amod	20	SENT_21	[p2l1443t2842r1731b2921],
20	cohort	NN	O	cohort	prep_in	13	SENT_21	[p2l1770t2842r2043b2921],
21	is	VBZ	O	be	auxpass	22	SENT_21	[p2l2075t2843r2140b2921],
22	shown	VBN	O	show	_	0	SENT_21	[p2l21t2970r303b3050],
23	in	IN	O	in	_	0	SENT_21	[p2l341t2971r424b3048],
24	Figure	NNP	O	Figure	prep_in	22	SENT_21	[p2l462t2971r740b3071],
25	1	CD	NUMBER	1	num	24	SENT_21	[p2l785t2976r853b3049],
26	.	.	O	.	_	0	SENT_21	[p2l785t2976r853b3049],

1	The	DT	O	the	det	2	SENT_22	[p2l895t2970r1055b3049],
2	investigators	NNS	O	investigator	nsubj	3	SENT_22	[p2l1094t2971r1642b3071],
3	found	VBD	O	find	_	0	SENT_22	[p2l1683t2970r1935b3049],
4	that	IN	O	that	complm	6	SENT_22	[p2l1975t2970r2147b3049],
5	doses	NNS	O	dose	nsubj	6	SENT_22	[p2l20t3098r256b3177],
6	predicted	VBN	O	predict	ccomp	3	SENT_22	[p2l291t3098r694b3199],
7	by	IN	O	by	_	0	SENT_22	[p2l728t3098r826b3199],
8	a	DT	O	a	det	10	SENT_22	[p2l855t3125r899b3177],
9	pharmacogenetic	JJ	O	pharmacogenetic	amod	10	SENT_22	[p2l930t3098r1680b3199],
10	algorithm	NN	O	algorithm	prep_by	6	SENT_22	[p2l1713t3098r2142b3199],
11	—	CD	NUMBER	—	num	12	SENT_22	[p2l15t3271r123b3279],
12	one	CD	NUMBER	one	dobj	6	SENT_22	[p2l171t3252r322b3305],
13	that	WDT	O	that	nsubj	14	SENT_22	[p2l375t3226r547b3305],
14	included	VBD	O	include	rcmod	12	SENT_22	[p2l593t3226r960b3305],
15	both	DT	O	both	preconj	16	SENT_22	[p2l1011t3226r1209b3305],
16	clinical	JJ	O	clinical	nsubjpass	23	SENT_22	[p2l1261t3226r1575b3305],
17	and	CC	O	and	_	0	SENT_22	[p2l1625t3226r1783b3305],
18	genetic	JJ	O	genetic	amod	20	SENT_22	[p2l1834t3227r2143b3327],
19	factors	NNS	O	factor	nn	20	SENT_22	[p2l19t3354r309b3433],
20	—	NN	O	—	nsubjpass	23	SENT_22	[p2l354t3399r462b3407],
21	were	VBD	O	be	auxpass	23	SENT_22	[p2l541t3381r743b3434],
22	better	RB	O	better	advmod	23	SENT_22	[p2l790t3354r1042b3433],
23	correlated	VBN	O	correlate	ccomp	14	SENT_22	[p2l1086t3354r1517b3433],
24	with	IN	O	with	_	0	SENT_22	[p2l1559t3354r1754b3434],
25	the	DT	O	the	prep_with	23	SENT_22	[p2l1801t3354r1934b3433],
26	empirically	RB	O	empirically	advmod	23	SENT_22	[p2l1981t3380r2140b3433, p2l18t3482r357b3583],

1	determined	VBN	O	determine	_	0	SENT_23	[p2l383t3482r863b3561],
2	maintenance	NN	O	maintenance	nn	3	SENT_23	[p2l892t3483r1434b3561],
3	doses	NNS	O	dose	dobj	1	SENT_23	[p2l1465t3482r1695b3561],
4	than	IN	O	than	mark	6	SENT_23	[p2l1727t3482r1919b3561],
5	were	VBD	O	be	cop	6	SENT_23	[p2l1945t3509r2142b3561],
6	those	DT	O	those	advcl	1	SENT_23	[p2l20t3610r251b3689],
7	predicted	VBN	O	predict	partmod	6	SENT_23	[p2l290t3610r693b3711],
8	by	IN	O	by	_	0	SENT_23	[p2l733t3610r830b3711],
9	a	DT	O	a	det	11	SENT_23	[p2l865t3637r909b3689],
10	clinical	JJ	O	clinical	amod	11	SENT_23	[p2l948t3610r1262b3689],
11	algorithm	NN	O	algorithm	agent	7	SENT_23	[p2l1300t3610r1753b3711],
12	;	:	O	;	_	0	SENT_23	[p2l1300t3610r1753b3711],
13	both	CC	O	both	dep	6	SENT_23	[p2l1798t3610r1996b3689],
14	algorithms	NNS	O	algorithm	conj	6	SENT_23	[p2l2035t3610r2140b3689, p3l19t20r413b121],

1	outperformed	VBD	O	outperform	_	0	SENT_24	[p3l451t20r1049b121],
2	a	DT	O	a	det	4	SENT_24	[p3l1083t47r1127b99],
3	standard	JJ	O	standard	amod	4	SENT_24	[p3l1162t20r1541b99],
4	dose	NN	O	dose	dobj	1	SENT_24	[p3l1577t20r1770b99],
5	of	IN	O	of	_	0	SENT_24	[p3l1807t20r1907b99],
6	5	CD	NUMBER	5	num	7	SENT_24	[p3l1926t28r1968b99],
7	mg	NN	O	mg	prep_of	4	SENT_24	[p3l2006t46r2145b121],
8	per	IN	O	per	_	0	SENT_24	[p3l18t174r160b249],
9	day	NN	DURATION	day	prep_per	7	SENT_24	[p3l218t148r380b249],
10	.	.	O	.	_	0	SENT_24	[p3l218t148r380b249],

1	However	RB	O	however	advmod	7	SENT_25	[p3l446t156r848b244],
2	,	,	O	,	_	0	SENT_25	[p3l446t156r848b244],
3	this	DT	O	this	det	4	SENT_25	[p3l915t148r1077b227],
4	improvement	NN	O	improvement	nsubjpass	7	SENT_25	[p3l1140t149r1724b249],
5	Was	VBD	O	be	auxpass	7	SENT_25	[p3l1775t175r1940b228],
6	not	RB	O	not	neg	7	SENT_25	[p3l2002t165r2148b227],
7	spread	VBN	O	spread	_	0	SENT_25	[p3l21t276r295b377],
8	equally	RB	O	equally	advmod	7	SENT_25	[p3l327t276r629b377],
9	across	IN	O	across	_	0	SENT_25	[p3l655t302r916b355],
10	the	DT	O	the	det	11	SENT_25	[p3l949t276r1080b355],
11	population	NN	O	population	prep_across	7	SENT_25	[p3l1110t276r1593b377],
12	.	.	O	.	_	0	SENT_25	[p3l1110t276r1593b377],

1	For	IN	O	for	_	0	SENT_26	[p3l1629t284r1770b355],
2	the	DT	O	the	det	4	SENT_26	[p3l1798t276r1929b355],
3	54	CD	PERCENT	54	num	4	SENT_26	[p3l1962t281r2143b355],
4	%	NN	PERCENT	%	prep_for	16	SENT_26	[p3l1962t281r2143b355],
5	of	IN	O	of	_	0	SENT_26	[p3l20t404r120b483],
6	people	NNS	O	people	prep_of	4	SENT_26	[p3l145t404r428b505],
7	in	IN	O	in	_	0	SENT_26	[p3l473t405r556b482],
8	the	DT	O	the	det	9	SENT_26	[p3l602t404r735b483],
9	middle	NN	O	middle	prep_in	6	SENT_26	[p3l781t404r1078b483],
10	of	IN	O	of	_	0	SENT_26	[p3l1126t404r1225b483],
11	the	DT	O	the	det	12	SENT_26	[p3l1253t404r1386b483],
12	range	NN	O	range	prep_of	9	SENT_26	[p3l1432t430r1695b505],
13	,	,	O	,	_	0	SENT_26	[p3l1432t430r1695b505],
14	the	DT	O	the	det	15	SENT_26	[p3l1747t404r1880b483],
15	algorithms	NNS	O	algorithm	nsubj	16	SENT_26	[p3l1925t404r2140b505, p3l19t532r304b611],
16	performed	VBD	O	perform	_	0	SENT_26	[p3l345t532r802b633],
17	no	RB	O	no	advmod	18	SENT_26	[p3l842t558r948b611],
18	better	JJR	O	better	advmod	16	SENT_26	[p3l990t532r1242b611],
19	than	IN	O	than	_	0	SENT_26	[p3l1280t532r1476b611],
20	the	DT	O	the	det	23	SENT_26	[p3l1517t532r1650b611],
21	fixed	VBN	O	fix	amod	23	SENT_26	[p3l1690t532r1907b611],
22	dose	NN	O	dose	nn	23	SENT_26	[p3l1948t532r2142b611],
23	(	NN	O	(	prep_than	16	SENT_26	[p3l24t660r282b752],
24	Table	NNP	O	Table	tmod	23	SENT_26	[p3l24t660r282b752],
25	3	CD	NUMBER	3	num	24	SENT_26	[p3l324t666r369b739],
26	in	IN	O	in	_	0	SENT_26	[p3l412t661r496b738],
27	the	DT	O	the	det	28	SENT_26	[p3l538t660r671b739],
28	article	NN	O	article	prep_in	23	SENT_26	[p3l712t660r979b739],
29	by	IN	O	by	_	0	SENT_26	[p3l1022t660r1119b761],
30	the	DT	O	the	det	35	SENT_26	[p3l1157t660r1289b739],
31	International	NNP	O	International	nn	35	SENT_26	[p3l1330t660r1898b739],
32	Warfarin	NNP	O	Warfarin	nn	35	SENT_26	[p3l1935t668r2140b739, p3l19t788r222b867],
33	Pharmacogenetics	NNP	O	Pharmacogenetics	nn	35	SENT_26	[p3l260t788r1032b889],
34	Consortiuml	NNP	O	Consortiuml	nn	35	SENT_26	[p3l1074t789r1667b880],
35	)	NN	O	)	prep_by	28	SENT_26	[p3l1074t789r1667b880],
36	.	.	O	.	_	0	SENT_26	[p3l1074t789r1667b880],

1	This	DT	O	this	det	2	SENT_27	[p3l1709t788r1894b867],
2	finding	NN	O	finding	nsubj	5	SENT_27	[p3l1935t788r2140b867, p3l19t917r156b1017],
3	is	VBZ	O	be	cop	5	SENT_27	[p3l199t917r264b995],
4	not	RB	O	not	neg	5	SENT_27	[p3l315t933r458b995],
5	surprising	JJ	O	surprising	_	0	SENT_27	[p3l503t917r965b1017],
6	,	,	O	,	_	0	SENT_27	[p3l503t917r965b1017],
7	since	IN	O	since	mark	13	SENT_27	[p3l1020t917r1235b995],
8	the	DT	O	the	det	10	SENT_27	[p3l1283t916r1416b995],
9	ﬁxed	JJ	O	ﬁxed	amod	10	SENT_27	[p3l1465t916r1681b995],
10	dose	NN	O	dose	nsubjpass	13	SENT_27	[p3l1730t916r1924b995],
11	presumably	RB	O	presumably	advmod	13	SENT_27	[p3l1971t942r2140b1017, p3l21t1044r381b1145],
12	was	VBD	O	be	auxpass	13	SENT_27	[p3l408t1071r571b1124],
13	derived	VBN	O	derive	advcl	5	SENT_27	[p3l611t1044r919b1123],
14	for	IN	O	for	_	0	SENT_27	[p3l955t1044r1078b1123],
15	the	DT	O	the	det	18	SENT_27	[p3l1113t1044r1246b1123],
16	“	JJ	O	“	amod	18	SENT_27	[p3l1286t1049r1644b1145],
17	average	JJ	O	average	amod	18	SENT_27	[p3l1286t1049r1644b1145],
18	patient	NN	O	patient	prep_for	13	SENT_27	[p3l1680t1045r2043b1145],
19	.	.	O	.	_	0	SENT_27	[p3l1680t1045r2043b1145],

1	”	RB	O	”	advmod	5	SENT_28	[p3l1680t1045r2043b1145],
2	It	PRP	O	it	nsubj	5	SENT_28	[p3l2082t1052r2148b1123],
3	was	VBD	O	be	cop	5	SENT_28	[p3l15t1199r177b1252],
4	the	DT	O	the	det	5	SENT_28	[p3l241t1172r374b1251],
5	outliers	NNS	O	outlier	_	0	SENT_28	[p3l436t1172r783b1268],
6	,	,	O	,	_	0	SENT_28	[p3l436t1172r783b1268],
7	those	DT	O	those	det	8	SENT_28	[p3l850t1172r1081b1251],
8	persons	NNS	O	person	appos	5	SENT_28	[p3l1141t1198r1476b1273],
9	who	WP	O	who	nsubj	10	SENT_28	[p3l1535t1172r1718b1252],
10	required	VBD	O	require	rcmod	8	SENT_28	[p3l1780t1172r2142b1273],
11	doses	NNS	O	dose	dobj	10	SENT_28	[p3l20t1300r256b1379],
12	higher	JJR	O	higher	advmod	10	SENT_28	[p3l296t1300r578b1401],
13	or	CC	O	or	_	0	SENT_28	[p3l613t1326r702b1379],
14	lower	JJR	O	lower	conj_or	12	SENT_28	[p3l735t1300r973b1380],
15	than	IN	O	than	_	0	SENT_28	[p3l1008t1300r1205b1379],
16	the	DT	O	the	det	17	SENT_28	[p3l1243t1300r1375b1379],
17	mean	NN	O	mean	prep_than	10	SENT_28	[p3l1414t1326r1674b1396],
18	,	,	O	,	_	0	SENT_28	[p3l1414t1326r1674b1396],
19	for	IN	O	for	_	0	SENT_28	[p3l1718t1300r1841b1379],
20	whom	WP	O	whom	rel	30	SENT_28	[p3l1872t1300r2143b1380],
21	determination	NN	O	determination	nsubj	30	SENT_28	[p3l20t1428r636b1507],
22	of	IN	O	of	_	0	SENT_28	[p3l684t1428r784b1507],
23	the	DT	O	the	det	24	SENT_28	[p3l814t1428r946b1507],
24	dose	NN	O	dose	prep_of	21	SENT_28	[p3l995t1428r1189b1507],
25	directed	VBN	O	direct	partmod	24	SENT_28	[p3l1238t1428r1586b1507],
26	by	IN	O	by	_	0	SENT_28	[p3l1634t1428r1731b1529],
27	pharmacogenetics	NNS	O	pharmacogenetic	agent	25	SENT_28	[p3l1773t1428r2140b1529, p3l20t1557r469b1657],
28	was	VBD	O	be	cop	30	SENT_28	[p3l505t1583r668b1635],
29	more	RBR	O	more	advmod	30	SENT_28	[p3l708t1582r927b1635],
30	predictive	JJ	O	predictive	rcmod	17	SENT_28	[p3l964t1556r1407b1657],
31	.	.	O	.	_	0	SENT_28	[p3l964t1556r1407b1657],

1	The	DT	O	the	det	3	SENT_29	[p3l145t1684r305b1763],
2	current	JJ	DATE	current	amod	3	SENT_29	[p3l348t1701r662b1763],
3	approach	NN	O	approach	nsubj	19	SENT_29	[p3l697t1684r1092b1785],
4	to	TO	O	to	_	0	SENT_29	[p3l1133t1701r1215b1763],
5	determining	VBG	O	determine	prepc_to	3	SENT_29	[p3l1258t1684r1797b1785],
6	the	DT	O	the	det	8	SENT_29	[p3l1834t1684r1967b1763],
7	appropriate	JJ	O	appropriate	amod	8	SENT_29	[p3l2008t1710r2140b1785, p3l18t1813r411b1913],
8	doses	NNS	O	dose	dobj	5	SENT_29	[p3l459t1812r700b1891],
9	of	IN	O	of	_	0	SENT_29	[p3l751t1812r852b1891],
10	drugs	NNS	O	drug	prep_of	8	SENT_29	[p3l882t1812r1130b1913],
11	that	WDT	O	that	nsubj	12	SENT_29	[p3l1180t1812r1356b1891],
12	have	VBP	O	have	rcmod	10	SENT_29	[p3l1398t1812r1592b1891],
13	large	JJ	O	large	amod	15	SENT_29	[p3l1638t1812r1856b1913],
14	interindividual	JJ	O	interindividual	amod	15	SENT_29	[p3l1904t1813r2140b1891, p3l19t1940r459b2019],
15	differences	NNS	O	difference	dobj	12	SENT_29	[p3l535t1940r1020b2019],
16	is	VBZ	O	be	cop	19	SENT_29	[p3l1095t1941r1162b2019],
17	a	DT	O	a	det	19	SENT_29	[p3l1238t1967r1282b2019],
18	Worl	JJ	O	worl	amod	19	SENT_29	[p3l1351t1940r1942b2020],
19	<	JJR	O	<	_	0	SENT_29	[p3l1351t1940r1942b2020],
20	.	.	O	.	_	0	SENT_29	[p3l1351t1940r1942b2020],

1	—	NN	O	—	_	0	SENT_30	[p3l1351t1940r1942b2020],
2	.	.	O	.	_	0	SENT_30	[p3l1351t1940r1942b2020],

1	around	IN	O	around	dep	3	SENT_31	[p3l1351t1940r1942b2020],
2	:	:	O	:	_	0	SENT_31	[p3l1351t1940r1942b2020],
3	for	IN	O	for	_	0	SENT_31	[p3l2020t1940r2145b2019],

1	Warfarin	NNP	O	Warfarin	nsubj	4	SENT_32	[p3l15t2068r420b2164],
2	,	,	O	,	_	0	SENT_32	[p3l15t2068r420b2164],
3	this	DT	O	this	nsubj	4	SENT_32	[p3l472t2068r634b2147],
4	involves	VBZ	O	involve	_	0	SENT_32	[p3l681t2068r1026b2148],
5	obtaining	VBG	O	obtain	ccomp	4	SENT_32	[p3l1074t2068r1504b2169],
6	repeated	VBN	O	repeat	amod	8	SENT_32	[p3l1546t2068r1921b2169],
7	INR	NN	O	inr	nn	8	SENT_32	[p3l1964t2075r2152b2152],
8	measurements	NNS	O	measurement	dobj	5	SENT_32	[p3l19t2213r658b2275],
9	and	CC	O	and	_	0	SENT_32	[p3l702t2196r862b2275],
10	making	VBG	O	make	conj_and	5	SENT_32	[p3l904t2196r1244b2297],
11	successive	JJ	O	successive	amod	13	SENT_32	[p3l1284t2197r1726b2275],
12	dose	NN	O	dose	nn	13	SENT_32	[p3l1770t2196r1967b2275],
13	adjustments	NNS	O	adjustment	dobj	10	SENT_32	[p3l2010t2196r2140b2275, p3l6t2325r472b2425],
14	.	.	O	.	_	0	SENT_32	[p3l2010t2196r2140b2275, p3l6t2325r472b2425],

1	The	DT	O	the	det	3	SENT_33	[p3l523t2324r684b2403],
2	clinical	JJ	O	clinical	amod	3	SENT_33	[p3l733t2324r1046b2403],
3	community	NN	O	community	nsubj	6	SENT_33	[p3l1095t2325r1592b2425],
4	is	VBZ	O	be	cop	6	SENT_33	[p3l1636t2325r1702b2403],
5	generally	RB	O	generally	advmod	6	SENT_33	[p3l1752t2324r2146b2425],
6	comfortable	JJ	O	comfortable	_	0	SENT_33	[p3l20t2453r531b2532],
7	With	IN	O	with	mark	11	SENT_33	[p3l562t2453r754b2532],
8	this	DT	O	this	det	10	SENT_33	[p3l790t2453r947b2532],
9	time	NN	O	time	nn	10	SENT_33	[p3l984t2453r1560b2532],
10	—	NN	O	—	nsubj	11	SENT_33	[p3l984t2453r1560b2532],
11	honored	VBD	O	honor	ccomp	6	SENT_33	[p3l984t2453r1560b2532],
12	method	NN	O	method	dobj	11	SENT_33	[p3l1595t2453r1921b2532],
13	even	RB	O	even	advmod	16	SENT_33	[p3l1957t2479r2143b2532],
14	though	IN	O	though	dep	16	SENT_33	[p3l20t2581r328b2682],
15	it	PRP	O	it	nsubj	16	SENT_33	[p3l370t2582r428b2660],
16	necessitates	VBZ	O	necessitate	dep	11	SENT_33	[p3l466t2582r975b2660],
17	additional	JJ	O	additional	amod	19	SENT_33	[p3l1020t2581r1456b2660],
18	blood	NN	O	blood	nn	19	SENT_33	[p3l1499t2581r1741b2660],
19	tests	NNS	O	test	dobj	16	SENT_33	[p3l1784t2598r1978b2660],
20	for	IN	O	for	_	0	SENT_33	[p3l2022t2581r2145b2660],
21	the	DT	O	the	det	22	SENT_33	[p3l20t2709r148b2788],
22	patient	NN	O	patient	prep_for	16	SENT_33	[p3l183t2710r472b2810],
23	and	CC	O	and	_	0	SENT_33	[p3l502t2709r655b2788],
24	more	JJR	O	more	amod	25	SENT_33	[p3l691t2735r904b2788],
25	data	NNS	O	datum	prep_for	16	SENT_33	[p3l941t2709r1118b2788],
26	for	IN	O	for	_	0	SENT_33	[p3l1152t2709r1271b2788],
27	the	DT	O	the	det	29	SENT_33	[p3l1304t2709r1433b2788],
28	health	NN	O	health	nn	29	SENT_33	[p3l1469t2709r1729b2788],
29	care	NN	O	care	prep_for	25	SENT_33	[p3l1766t2735r1934b2788],
30	professional	JJ	O	professional	amod	25	SENT_33	[p3l1968t2735r2140b2810, p3l19t2837r410b2916],
31	to	TO	O	to	aux	32	SENT_33	[p3l449t2854r531b2916],
32	interpret	VB	O	interpret	xcomp	16	SENT_33	[p3l572t2838r980b2938],
33	.	.	O	.	_	0	SENT_33	[p3l572t2838r980b2938],

1	Many	JJ	O	many	amod	4	SENT_34	[p3l1023t2845r1267b2938],
2	health	NN	O	health	nn	4	SENT_34	[p3l1301t2837r1578b2916],
3	care	NN	O	care	nn	4	SENT_34	[p3l1617t2863r1796b2916],
4	professionals	NNS	O	professional	nsubj	6	SENT_34	[p3l1834t2837r2140b2938, p3l21t2964r308b3042],
5	have	VBP	O	have	aux	6	SENT_34	[p3l344t2964r529b3043],
6	called	VBN	O	call	_	0	SENT_34	[p3l563t2964r807b3042],
7	for	IN	O	for	_	0	SENT_34	[p3l841t2964r961b3042],
8	randomized	VBN	O	randomize	prepc_for	6	SENT_34	[p3l992t2964r1520b3059],
9	,	,	O	,	_	0	SENT_34	[p3l992t2964r1520b3059],
10	controlled	VBN	O	control	dep	8	SENT_34	[p3l1559t2964r1983b3042],
11	trials	NNS	O	trial	dobj	10	SENT_34	[p3l2016t2965r2140b3042, p3l19t3093r131b3172],
12	to	TO	O	to	aux	13	SENT_34	[p3l172t3110r254b3172],
13	evaluate	VB	O	evaluate	xcomp	8	SENT_34	[p3l297t3093r642b3172],
14	whether	IN	O	whether	amod	16	SENT_34	[p3l680t3093r1035b3172],
15	clinical	JJ	O	clinical	amod	16	SENT_34	[p3l1074t3093r1388b3172],
16	outcomes	NNS	O	outcome	dobj	13	SENT_34	[p3l1429t3110r1841b3172],
17	in	IN	O	in	_	0	SENT_34	[p3l1883t3094r1967b3171],
18	the	DT	O	the	prep_in	16	SENT_34	[p3l2009t3093r2142b3172],

1	N	NN	O	n	nn	2	SENT_35	[p3l543t3257r557b3272],
2	ENGLJ	NN	O	englj	_	0	SENT_35	[p3l571t3257r649b3279],
3	MED	VBD	O	med	partmod	2	SENT_35	[p3l664t3257r716b3272],
4	36o	CD	NUMBER	36o	dobj	3	SENT_35	[p3l726t3251r795b3279],
5	;	:	O	;	_	0	SENT_35	[p3l726t3251r795b3279],
6	8	CD	NUMBER	8	num	8	SENT_35	[p3l726t3251r795b3279],
7	NEJM.ORG	NN	O	nejm.org	nn	8	SENT_35	[p3l830t3257r954b3279],
8	FEBRUARY19	NN	O	february19	dep	2	SENT_35	[p3l991t3257r1155b3278],
9	,	,	O	,	_	0	SENT_35	[p3l991t3257r1155b3278],
10	2009	CD	DATE	2009	num	11	SENT_35	[p3l1167t3257r1231b3278],
11	811	CD	NUMBER	811	appos	8	SENT_35	[p3l1959t3247r2016b3269],

1	The	DT	O	the	det	4	SENT_36	[p3l673t3478r718b3499],
2	NEW	NNP	O	NEW	nn	4	SENT_36	[p3l737t3480r822b3499],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_36	[p3l841t3480r1029b3499],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_36	[p3l1048t3480r1227b3506],
5	of	IN	O	of	_	0	SENT_36	[p3l1247t3478r1275b3505],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_36	[p3l1287t3480r1486b3499],

1	U	NNP	O	U	nn	3	SENT_37	[p4l136t431r176b462],
2	)	NNP	O	)	nn	3	SENT_37	[p4l136t431r176b462],
3	III	NNP	O	III	_	0	SENT_37	[p4l125t464r176b489],
4	’	CD	NUMBER	’	num	3	SENT_37	[p4l125t464r176b489],
5	:	:	O	:	_	0	SENT_37	[p4l136t494r175b528],
6	en	IN	O	en	_	0	SENT_37	[p4l136t534r176b569],
7	'	''	O	'	_	0	SENT_37	[p4l117t575r176b616],
8	5	CD	NUMBER	5	num	10	SENT_37	[p4l117t575r176b616],
9	cu	NN	O	cu	nn	10	SENT_37	[p4l136t618r176b652],
10	n.	NN	O	n.	prep_en	3	SENT_37	[p4l121t654r175b692],
11	Ho	NNP	O	Ho	dep	3	SENT_37	[p4l114t707r175b742, p4l136t744r176b782],
12	o	NN	O	o	nn	14	SENT_37	[p4l136t807r176b864],
13	'	''	O	'	_	0	SENT_37	[p4l136t807r176b864],
14	Z	NN	O	z	dep	11	SENT_37	[p4l121t873r176b920],

1	‘	NN	O	‘	nn	5	SENT_38	[p4l1393t1330r1456b1384],
2	,	,	O	,	_	0	SENT_38	[p4l1393t1330r1456b1384],
3	o	NN	O	o	dep	5	SENT_38	[p4l1393t1330r1456b1384],
4	‘	NN	O	‘	nn	5	SENT_38	[p4l1356t1373r1399b1422],
5	o	NN	O	o	_	0	SENT_38	[p4l1356t1373r1399b1422],
6	W	NNP	O	W	nn	7	SENT_38	[p4l1326t1416r1377b1458],
7	W	NNP	O	W	dep	5	SENT_38	[p4l1551t1416r1602b1458],

1	Warfarin	NNP	MISC	Warfarin	nn	2	SENT_39	[p4l848t1498r1131b1560],
2	Dose	NNP	MISC	Dose	_	0	SENT_39	[p4l1161t1505r1328b1560],
3	(	CD	NUMBER	(	num	5	SENT_39	[p4l1355t1499r1649b1579],
4	mg/day	JJ	O	mg/day	amod	5	SENT_39	[p4l1355t1499r1649b1579],
5	)	NN	O	)	dep	2	SENT_39	[p4l1355t1499r1649b1579],

1	Figure	NNP	O	Figure	_	0	SENT_40	[p4l84t1704r303b1787],
2	1	CD	NUMBER	1	dep	1	SENT_40	[p4l333t1708r390b1766],
3	.	.	O	.	_	0	SENT_40	[p4l333t1708r390b1766],

1	The	DT	O	the	det	2	SENT_41	[p4l417t1702r550b1766],
2	Range	NNP	O	Range	_	0	SENT_41	[p4l582t1708r798b1787],
3	of	IN	O	of	_	0	SENT_41	[p4l823t1701r905b1766],
4	Warfarin	NNP	O	Warfarin	nn	7	SENT_41	[p4l915t1701r1221b1767],
5	Maintenance	NNP	O	Maintenance	nn	7	SENT_41	[p4l1258t1704r1717b1766],
6	Doses	NNP	O	Doses	nn	7	SENT_41	[p4l1748t1708r1965b1766],
7	Required	NNP	O	Required	prep_of	2	SENT_41	[p4l84t1810r395b1894],
8	to	TO	O	to	aux	9	SENT_41	[p4l423t1820r493b1874],
9	Achieve	VB	O	achieve	infmod	2	SENT_41	[p4l519t1810r797b1874],
10	a	DT	O	a	det	18	SENT_41	[p4l824t1831r860b1874],
11	Stable	JJ	MISC	stable	amod	18	SENT_41	[p4l888t1810r1108b1875],
12	International	NNP	MISC	International	nn	18	SENT_41	[p4l1139t1810r1590b1874],
13	Normalized	NNP	MISC	Normalized	nn	18	SENT_41	[p4l1627t1810r2034b1874],
14	Ratio	NNP	MISC	Ratio	nn	18	SENT_41	[p4l84t1918r261b1982],
15	(	CD	NUMBER	(	num	18	SENT_41	[p4l293t1923r474b2002],
16	INR	NNP	O	INR	nn	18	SENT_41	[p4l293t1923r474b2002],
17	)	CD	NUMBER	)	num	18	SENT_41	[p4l293t1923r474b2002],
18	of2	NN	O	of2	dobj	9	SENT_41	[p4l505t1916r637b1982],
19	to	TO	O	to	_	0	SENT_41	[p4l663t1927r733b1982],
20	3	CD	NUMBER	3	prep_to	9	SENT_41	[p4l761t1922r819b1982],
21	.	.	O	.	_	0	SENT_41	[p4l761t1922r819b1982],

1	Data	NNS	O	datum	nsubj	2	SENT_42	[p4l86t2052r246b2111],
2	are	VBP	O	be	_	0	SENT_42	[p4l278t2069r381b2111],
3	from	IN	O	from	_	0	SENT_42	[p4l409t2045r576b2111],
4	Section	NN	O	section	prep_from	2	SENT_42	[p4l610t2051r873b2111],
5	5	CD	NUMBER	5	num	4	SENT_42	[p4l907t2052r939b2111],
6	in	IN	O	in	_	0	SENT_42	[p4l975t2052r1031b2109],
7	Supplementary	NNP	O	Supplementary	nn	8	SENT_42	[p4l1066t2046r1613b2131],
8	Appendix	NNP	O	Appendix	prep_in	4	SENT_42	[p4l1637t2046r1978b2130],
9	1	CD	NUMBER	1	num	8	SENT_42	[p4l2011t2052r2039b2109],
10	in	IN	O	in	_	0	SENT_42	[p4l83t2159r139b2217],
11	the	DT	O	the	det	12	SENT_42	[p4l169t2153r281b2218],
12	article	NN	O	article	prep_in	2	SENT_42	[p4l311t2153r530b2218],
13	by	IN	O	by	_	0	SENT_42	[p4l563t2153r636b2238],
14	the	DT	O	the	det	19	SENT_42	[p4l661t2154r773b2218],
15	International	NNP	ORGANIZATION	International	nn	19	SENT_42	[p4l808t2154r1259b2218],
16	Warfarin	NNP	ORGANIZATION	Warfarin	nn	19	SENT_42	[p4l1290t2153r1595b2218],
17	Pharmacogenetics	NNP	ORGANIZATION	Pharmacogenetics	nn	19	SENT_42	[p4l1634t2154r2014b2218, p4l81t2267r376b2347],
18	Consortium	NNP	ORGANIZATION	Consortium	nn	19	SENT_42	[p4l408t2261r887b2337],
19	}	NN	O	}	prep_by	2	SENT_42	[p4l408t2261r887b2337],
20	which	WDT	O	which	nsubj	24	SENT_42	[p4l915t2261r1121b2326],
21	is	VBZ	O	be	cop	24	SENT_42	[p4l1157t2267r1206b2326],
22	a	DT	O	a	det	24	SENT_42	[p4l1239t2284r1271b2326],
23	retrospective	JJ	O	retrospective	amod	24	SENT_42	[p4l1306t2267r1769b2345],
24	study	NN	O	study	rcmod	19	SENT_42	[p4l1800t2261r1992b2346],
25	of	IN	O	of	_	0	SENT_42	[p4l2019t2260r2097b2326],
26	5052	CD	DATE	5052	num	27	SENT_42	[p4l81t2372r246b2433],
27	patients	NNS	O	patient	prep_of	24	SENT_42	[p4l280t2374r563b2452],
28	who	WP	O	who	nsubj	30	SENT_42	[p4l592t2368r740b2433],
29	were	VBD	O	be	aux	30	SENT_42	[p4l768t2391r935b2433],
30	initiating	VBG	O	initiate	rcmod	27	SENT_42	[p4l968t2374r1280b2454],
31	warfarin	NN	O	warfarin	nn	32	SENT_42	[p4l1306t2367r1596b2433],
32	therapy	NN	O	therapy	dobj	30	SENT_42	[p4l1627t2368r1910b2453],
33	.	.	O	.	_	0	SENT_42	[p4l1627t2368r1910b2453],

1	treated	VBN	O	treat	csubjpass	4	SENT_43	[p4l12t2694r310b2773],
2	population	NN	O	population	dobj	1	SENT_43	[p4l349t2694r820b2795],
3	are	VBP	O	be	auxpass	4	SENT_43	[p4l859t2720r988b2773],
4	improved	VBN	O	improve	_	0	SENT_43	[p4l1028t2694r1432b2795],
5	by	IN	O	by	_	0	SENT_43	[p4l1472t2694r1569b2795],
6	the	DT	O	the	det	7	SENT_43	[p4l1605t2694r1738b2773],
7	addition	NN	O	addition	agent	4	SENT_43	[p4l1778t2694r2134b2773],
8	of	IN	O	of	_	0	SENT_43	[p4l12t2822r112b2901],
9	pharmacogenetic	JJ	O	pharmacogenetic	amod	10	SENT_43	[p4l122t2822r856b2923],
10	testing	NN	O	testing	prep_of	7	SENT_43	[p4l886t2823r1195b2923],
11	.	.	O	.	_	0	SENT_43	[p4l886t2823r1195b2923],

1	Others	NNS	O	other	nsubj	2	SENT_44	[p4l1231t2822r1514b2901],
2	feel	VBP	O	feel	_	0	SENT_44	[p4l1546t2822r1694b2901],
3	that	IN	O	that	complm	9	SENT_44	[p4l1724t2822r1893b2901],
4	more	JJR	O	more	amod	6	SENT_44	[p4l1918t2848r2134b2901],
5	limited	JJ	O	limited	amod	6	SENT_44	[p4l11t2950r319b3029],
6	data	NNS	O	datum	nsubj	9	SENT_44	[p4l360t2950r543b3029],
7	will	MD	O	will	aux	9	SENT_44	[p4l577t2950r741b3030],
8	be	VB	O	be	cop	9	SENT_44	[p4l781t2950r878b3029],
9	sufficient	JJ	O	sufficient	ccomp	2	SENT_44	[p4l919t2950r1331b3029],
10	for	IN	O	for	_	0	SENT_44	[p4l1365t2950r1489b3029],
11	drugs	NNS	O	drug	prep_for	9	SENT_44	[p4l1526t2950r1769b3051],
12	such	JJ	O	such	_	0	SENT_44	[p4l1813t2950r2007b3029],
13	as	IN	O	as	_	0	SENT_44	[p4l2046t2977r2132b3029],
14	warfarin	NN	O	warfarin	prep_such_as	11	SENT_44	[p4l7t3078r404b3174],
15	,	,	O	,	_	0	SENT_44	[p4l7t3078r404b3174],
16	since	IN	O	since	mark	28	SENT_44	[p4l449t3079r664b3157],
17	the	DT	O	the	det	20	SENT_44	[p4l702t3078r835b3157],
18	pharmacodynamic	JJ	O	pharmacodynamic	amod	20	SENT_44	[p4l871t3078r1683b3179],
19	end	NN	O	end	nn	20	SENT_44	[p4l1720t3078r1873b3157],
20	point	NN	O	point	nsubj	28	SENT_44	[p4l1909t3079r2139b3179],
21	is	VBZ	O	be	cop	28	SENT_44	[p4l11t3207r101b3302],
22	,	,	O	,	_	0	SENT_44	[p4l11t3207r101b3302],
23	after	IN	O	after	advmod	28	SENT_44	[p4l145t3206r346b3285],
24	all	DT	O	all	dep	23	SENT_44	[p4l381t3206r508b3302],
25	,	,	O	,	_	0	SENT_44	[p4l381t3206r508b3302],
26	the	DT	O	the	det	28	SENT_44	[p4l552t3206r684b3285],
27	entire	JJ	O	entire	amod	28	SENT_44	[p4l724t3207r969b3285],
28	basis	NN	O	basis	advcl	9	SENT_44	[p4l1009t3206r1220b3285],
29	of	IN	O	of	_	0	SENT_44	[p4l1260t3206r1360b3285],
30	warfarin	NN	O	warfarin	nn	31	SENT_44	[p4l1375t3206r1750b3286],
31	dosage	NN	O	dosage	prep_of	28	SENT_44	[p4l1788t3206r2108b3307],
32	.	.	O	.	_	0	SENT_44	[p4l1788t3206r2108b3307],

1	The	DT	O	the	det	3	SENT_45	[p4l137t3334r294b3413],
2	evidence	NN	O	evidence	nn	3	SENT_45	[p4l333t3334r683b3414],
3	base	NN	O	base	nsubjpass	9	SENT_45	[p4l723t3334r904b3413],
4	for	IN	O	for	_	0	SENT_45	[p4l943t3334r1062b3413],
5	pharmacogenetic	JJ	O	pharmacogenetic	amod	6	SENT_45	[p4l1096t3334r1815b3435],
6	testing	NN	O	testing	prep_for	3	SENT_45	[p4l1853t3335r2138b3435],
7	should	MD	O	should	aux	9	SENT_45	[p4l13t3462r300b3541],
8	be	VB	O	be	auxpass	9	SENT_45	[p4l342t3462r438b3541],
9	informed	VBN	O	inform	_	0	SENT_45	[p4l478t3462r880b3541],
10	by	IN	O	by	_	0	SENT_45	[p4l921t3462r1018b3563],
11	the	DT	O	the	det	13	SENT_45	[p4l1055t3462r1188b3541],
12	pharmacologic	JJ	O	pharmacologic	amod	13	SENT_45	[p4l1228t3462r1875b3563],
13	characteristics	NNS	O	characteristic	agent	9	SENT_45	[p4l1916t3462r2133b3541, p4l11t3591r441b3669],
14	of	IN	O	of	_	0	SENT_45	[p4l483t3590r584b3669],
15	the	DT	O	the	det	16	SENT_45	[p4l605t3590r737b3669],
16	drug	NN	O	drug	prep_of	13	SENT_45	[p4l778t3590r982b3691],
17	and	CC	O	and	_	0	SENT_45	[p4l1018t3590r1176b3669],
18	the	DT	O	the	det	19	SENT_45	[p4l1215t3590r1348b3669],
19	characteristics	NNS	O	characteristic	conj_and	13	SENT_45	[p4l1389t3590r2010b3669],
20	of	IN	O	of	_	0	SENT_45	[p4l2053t3590r2152b3669],
21	the	DT	O	the	det	22	SENT_45	[p5l12t20r145b99],
22	outliers	NNS	O	outlier	prep_of	19	SENT_45	[p5l181t20r528b99],
23	.	.	O	.	_	0	SENT_45	[p5l181t20r528b99],

1	What	WDT	O	what	det	2	SENT_46	[p5l564t20r800b99],
2	percentage	NN	O	percentage	dobj	10	SENT_46	[p5l828t37r1297b121],
3	of	IN	O	of	_	0	SENT_46	[p5l1333t20r1433b99],
4	the	DT	O	the	det	6	SENT_46	[p5l1449t20r1582b99],
5	overall	JJ	O	overall	amod	6	SENT_46	[p5l1618t20r1903b99],
6	population	NN	O	population	prep_of	2	SENT_46	[p5l1936t46r2133b121, p5l12t148r303b226],
7	do	VBP	O	do	aux	10	SENT_46	[p5l335t148r435b226],
8	the	DT	O	the	det	9	SENT_46	[p5l469t148r597b226],
9	outliers	NNS	O	outlier	nsubj	10	SENT_46	[p5l630t148r937b226],
10	represent	VB	O	represent	_	0	SENT_46	[p5l970t145r1389b248],
11	?	.	O	?	_	0	SENT_46	[p5l970t145r1389b248],

1	How	WRB	O	how	advmod	2	SENT_47	[p5l1420t155r1620b227],
2	extreme	JJ	O	extreme	dep	25	SENT_47	[p5l1648t164r1978b226],
3	are	VBP	O	be	auxpass	25	SENT_47	[p5l2009t174r2133b226],
4	their	PRP$	O	they	poss	5	SENT_47	[p5l12t276r216b355],
5	deviations	NNS	O	deviation	nsubjpass	25	SENT_47	[p5l272t276r708b355],
6	from	IN	O	from	_	0	SENT_47	[p5l768t276r978b355],
7	the	DT	O	the	det	9	SENT_47	[p5l1037t276r1169b355],
8	average	JJ	O	average	amod	9	SENT_47	[p5l1227t302r1545b377],
9	exposure	NN	O	exposure	prep_from	5	SENT_47	[p5l1604t302r1990b377],
10	or	CC	O	or	_	0	SENT_47	[p5l2049t302r2137b355],
11	pharmacodynamic	JJ	O	pharmacodynamic	amod	12	SENT_47	[p5l11t404r821b505],
12	effect	NN	O	effect	conj_or	9	SENT_47	[p5l859t404r1101b483],
13	and	CC	O	and	_	0	SENT_47	[p5l1133t404r1290b483],
14	what	WP	O	what	nsubj	19	SENT_47	[p5l1323t404r1538b483],
15	are	VBP	O	be	cop	19	SENT_47	[p5l1570t430r1699b483],
16	the	DT	O	the	det	19	SENT_47	[p5l1738t404r1870b483],
17	likely	JJ	O	likely	amod	19	SENT_47	[p5l1907t404r2138b505],
18	clinical	JJ	O	clinical	amod	19	SENT_47	[p5l12t532r326b611],
19	consequences	NNS	O	consequence	conj_and	9	SENT_47	[p5l365t558r954b633],
20	of	IN	O	of	_	0	SENT_47	[p5l996t532r1096b611],
21	these	DT	O	these	det	22	SENT_47	[p5l1117t532r1341b611],
22	deviations	NNS	O	deviation	prep_of	19	SENT_47	[p5l1381t532r1817b611],
23	(	RB	O	(	advmod	19	SENT_47	[p5l1863t539r1973b624],
24	as	IN	O	as	prep	19	SENT_47	[p5l1863t539r1973b624],
25	assessed	VBN	O	assess	_	0	SENT_47	[p5l2014t559r2133b611, p5l13t660r310b756],
26	,	,	O	,	_	0	SENT_47	[p5l2014t559r2133b611, p5l13t660r310b756],
27	for	IN	O	for	_	0	SENT_47	[p5l351t660r474b739],
28	example	NN	O	example	prep_for	25	SENT_47	[p5l506t660r884b761],
29	,	,	O	,	_	0	SENT_47	[p5l506t660r884b761],
30	by	IN	O	by	_	0	SENT_47	[p5l926t660r1023b761],
31	what	WP	O	what	nsubjpass	33	SENT_47	[p5l1049t660r1264b739],
32	is	VBZ	O	be	auxpass	33	SENT_47	[p5l1293t661r1359b739],
33	known	VBN	O	know	agent	25	SENT_47	[p5l1395t660r1693b740],
34	about	IN	O	about	_	0	SENT_47	[p5l1727t660r1971b739],
35	the	DT	O	the	det	39	SENT_47	[p5l2001t660r2134b739],
36	dose	NN	O	dose	nn	39	SENT_47	[p5l12t788r634b889],
37	—	NN	O	—	nn	39	SENT_47	[p5l12t788r634b889],
38	response	NN	O	response	nn	39	SENT_47	[p5l12t788r634b889],
39	relationships	NNS	O	relationship	prep_about	33	SENT_47	[p5l673t787r1281b889],
40	)	CD	NUMBER	)	dep	39	SENT_47	[p5l673t787r1281b889],
41	?	.	O	?	_	0	SENT_47	[p5l673t787r1281b889],

1	In	IN	O	in	_	0	SENT_48	[p5l1319t796r1407b866],
2	the	DT	O	the	det	3	SENT_48	[p5l1445t788r1576b867],
3	case	NN	O	case	prep_in	12	SENT_48	[p5l1615t815r1791b867],
4	of	IN	O	of	_	0	SENT_48	[p5l1831t788r1929b867],
5	warfarin	NN	O	warfarin	prep_of	3	SENT_48	[p5l1944t815r2133b867, p5l12t915r236b1010],
6	,	,	O	,	_	0	SENT_48	[p5l1944t815r2133b867, p5l12t915r236b1010],
7	randomized	VBN	O	randomize	partmod	3	SENT_48	[p5l280t915r824b1010],
8	,	,	O	,	_	0	SENT_48	[p5l280t915r824b1010],
9	controlled	VBN	O	control	amod	10	SENT_48	[p5l870t915r1307b993],
10	trials	NNS	O	trial	nsubj	12	SENT_48	[p5l1348t915r1568b993],
11	could	MD	O	could	aux	12	SENT_48	[p5l1611t915r1845b994],
12	investigate	VB	O	investigate	_	0	SENT_48	[p5l1885t916r2133b994, p5l12t1044r246b1144],
13	a	DT	O	a	det	14	SENT_48	[p5l276t1070r320b1122],
14	number	NN	O	number	dobj	12	SENT_48	[p5l350t1043r682b1122],
15	of	IN	O	of	_	0	SENT_48	[p5l711t1043r810b1122],
16	different	JJ	O	different	amod	17	SENT_48	[p5l823t1043r1191b1122],
17	hypotheses	NNS	O	hypothesis	prep_of	14	SENT_48	[p5l1217t1043r1712b1144],
18	:	:	O	:	_	0	SENT_48	[p5l1217t1043r1712b1144],
19	that	IN	O	that	complm	25	SENT_48	[p5l1748t1043r1916b1122],
20	dose	NN	O	dose	nn	21	SENT_48	[p5l1943t1043r2134b1122],
21	prediction	NN	O	prediction	nsubj	25	SENT_48	[p5l11t1171r443b1272],
22	directed	VBN	O	direct	partmod	21	SENT_48	[p5l484t1171r825b1250],
23	by	IN	O	by	_	0	SENT_48	[p5l866t1171r962b1272],
24	pharmacogenetics	NNS	O	pharmacogenetic	agent	22	SENT_48	[p5l996t1171r1771b1272],
25	hastens	VBZ	O	hasten	ccomp	12	SENT_48	[p5l1814t1171r2132b1250],
26	achievement	NN	O	achievement	dobj	25	SENT_48	[p5l11t1299r537b1378],
27	of	IN	O	of	_	0	SENT_48	[p5l568t1299r667b1378],
28	the	DT	O	the	det	29	SENT_48	[p5l683t1299r814b1378],
29	target	NN	O	target	prep_of	26	SENT_48	[p5l849t1316r1100b1400],
30	IN	IN	O	in	_	0	SENT_48	[p5l1128t1307r1236b1378],
31	R	NN	O	r	prep_in	29	SENT_48	[p5l1239t1306r1326b1395],
32	;	:	O	;	_	0	SENT_48	[p5l1239t1306r1326b1395],
33	that	IN	O	that	complm	35	SENT_48	[p5l1365t1299r1534b1378],
34	it	PRP	O	it	nsubj	35	SENT_48	[p5l1563t1300r1621b1378],
35	reduces	VBZ	O	reduce	dep	25	SENT_48	[p5l1650t1299r1966b1378],
36	the	DT	O	the	det	37	SENT_48	[p5l2004t1299r2134b1378],
37	consequences	NNS	O	consequence	dobj	35	SENT_48	[p5l12t1453r602b1528],
38	of	IN	O	of	_	0	SENT_48	[p5l646t1427r746b1506],
39	INRs	NNS	O	inr	prep_of	37	SENT_48	[p5l768t1434r987b1511],
40	that	WDT	O	that	nsubj	42	SENT_48	[p5l1031t1427r1204b1506],
41	are	VBP	O	be	cop	42	SENT_48	[p5l1239t1454r1368b1506],
42	out	IN	O	out	rcmod	39	SENT_48	[p5l1410t1444r1549b1506],
43	of	IN	O	of	_	0	SENT_48	[p5l1586t1427r1686b1506],
44	the	DT	O	the	det	46	SENT_48	[p5l1709t1427r1841b1506],
45	target	NN	O	target	nn	46	SENT_48	[p5l1884t1444r2139b1528],
46	range	NN	O	range	prep_of	42	SENT_48	[p5l12t1581r275b1656],
47	,	,	O	,	_	0	SENT_48	[p5l12t1581r275b1656],
48	or	CC	O	or	_	0	SENT_48	[p5l322t1581r410b1634],
49	that	IN	O	that	complm	51	SENT_48	[p5l448t1555r620b1634],
50	it	PRP	O	it	nsubj	51	SENT_48	[p5l654t1556r714b1634],
51	reduces	VBZ	O	reduce	conj_or	25	SENT_48	[p5l749t1555r1071b1634],
52	patient	NN	O	patient	nn	53	SENT_48	[p5l1112t1556r1414b1656],
53	visits	NNS	O	visit	dobj	51	SENT_48	[p5l1445t1556r1689b1634],
54	.	.	O	.	_	0	SENT_48	[p5l1445t1556r1689b1634],

1	However	RB	O	however	advmod	24	SENT_49	[p5l1734t1563r2128b1651],
2	,	,	O	,	_	0	SENT_49	[p5l1734t1563r2128b1651],
3	since	IN	O	since	mark	11	SENT_49	[p5l13t1684r224b1762],
4	a	DT	O	a	det	5	SENT_49	[p5l261t1710r306b1762],
5	majority	NN	O	majority	nsubj	11	SENT_49	[p5l342t1684r696b1784],
6	of	IN	O	of	_	0	SENT_49	[p5l730t1683r829b1762],
7	the	DT	O	the	det	8	SENT_49	[p5l849t1683r979b1762],
8	population	NN	O	population	prep_of	5	SENT_49	[p5l1016t1683r1478b1784],
9	is	VBZ	O	be	cop	11	SENT_49	[p5l1515t1684r1579b1762],
10	not	RB	O	not	neg	11	SENT_49	[p5l1619t1700r1760b1762],
11	likely	JJ	O	likely	advcl	24	SENT_49	[p5l1792t1683r2018b1784],
12	to	TO	O	to	aux	13	SENT_49	[p5l2052t1700r2133b1762],
13	benefit	VB	O	benefit	xcomp	11	SENT_49	[p5l12t1811r338b1907],
14	,	,	O	,	_	0	SENT_49	[p5l12t1811r338b1907],
15	trials	NNS	O	trial	nsubj	24	SENT_49	[p5l391t1811r610b1890],
16	that	WDT	O	that	nsubj	17	SENT_49	[p5l659t1811r831b1890],
17	investigate	VBP	O	investigate	rcmod	15	SENT_49	[p5l873t1812r1332b1912],
18	these	DT	O	these	det	19	SENT_49	[p5l1379t1811r1603b1890],
19	hypotheses	NNS	O	hypothesis	dobj	17	SENT_49	[p5l1650t1811r2132b1912],
20	only	RB	O	only	advmod	17	SENT_49	[p5l12t1939r190b2040],
21	in	IN	O	in	_	0	SENT_49	[p5l219t1940r300b2017],
22	outliers	NNS	O	outlier	prep_in	17	SENT_49	[p5l334t1939r642b2018],
23	would	MD	O	would	aux	24	SENT_49	[p5l674t1939r931b2019],
24	have	VB	O	have	_	0	SENT_49	[p5l964t1939r1147b2018],
25	improved	VBN	O	improve	amod	26	SENT_49	[p5l1181t1939r1570b2040],
26	power	NN	O	power	dobj	24	SENT_49	[p5l1602t1965r1861b2040],
27	to	TO	O	to	aux	28	SENT_49	[p5l1893t1956r1972b2018],
28	detect	VB	O	detect	infmod	26	SENT_49	[p5l2008t1939r2133b2018, p5l12t2084r170b2146],
29	any	DT	O	any	det	30	SENT_49	[p5l210t2093r360b2168],
30	benefit	NN	O	benefit	dobj	28	SENT_49	[p5l403t2067r708b2146],
31	to	TO	O	to	_	0	SENT_49	[p5l750t2084r831b2146],
32	them	PRP	O	they	prep_to	28	SENT_49	[p5l879t2067r1123b2146],
33	.	.	O	.	_	0	SENT_49	[p5l879t2067r1123b2146],

1	Of	IN	O	of	_	0	SENT_50	[p5l1175t2067r1296b2146],
2	course	NN	O	course	prep_of	12	SENT_50	[p5l1325t2093r1604b2146],
3	in	IN	O	in	_	0	SENT_50	[p5l1650t2068r1733b2145],
4	order	NN	O	order	prep_in	2	SENT_50	[p5l1780t2067r2008b2146],
5	to	TO	O	to	aux	6	SENT_50	[p5l2052t2084r2133b2146],
6	conduct	VB	O	conduct	infmod	2	SENT_50	[p5l12t2195r355b2274],
7	such	PDT	O	such	predet	9	SENT_50	[p5l393t2195r586b2274],
8	a	DT	O	a	det	9	SENT_50	[p5l627t2222r671b2274],
9	trial	NN	O	trial	dobj	6	SENT_50	[p5l711t2195r912b2291],
10	,	,	O	,	_	0	SENT_50	[p5l711t2195r912b2291],
11	there	EX	O	there	expl	12	SENT_50	[p5l960t2195r1176b2274],
12	needs	VBZ	O	need	_	0	SENT_50	[p5l1218t2195r1461b2274],
13	to	TO	O	to	aux	16	SENT_50	[p5l1505t2212r1586b2274],
14	be	VB	O	be	cop	16	SENT_50	[p5l1630t2195r1726b2274],
15	a	DT	O	a	det	16	SENT_50	[p5l1767t2222r1812b2274],
16	way	NN	O	way	xcomp	12	SENT_50	[p5l1847t2222r2014b2296],
17	to	TO	O	to	aux	18	SENT_50	[p5l2052t2212r2133b2274],
18	identify	VB	O	identify	infmod	16	SENT_50	[p5l11t2323r344b2424],
19	the	DT	O	the	det	20	SENT_50	[p5l378t2323r510b2402],
20	outliers	NNS	O	outlier	dobj	18	SENT_50	[p5l550t2323r896b2402],
21	.	.	O	.	_	0	SENT_50	[p5l550t2323r896b2402],

1	In	IN	O	in	_	0	SENT_51	[p5l140t2458r226b2527],
2	the	DT	O	the	det	3	SENT_51	[p5l260t2450r388b2528],
3	case	NN	O	case	prep_in	10	SENT_51	[p5l422t2477r595b2528],
4	of	IN	O	of	_	0	SENT_51	[p5l629t2450r727b2528],
5	other	JJ	O	other	amod	6	SENT_51	[p5l742t2450r960b2528],
6	treatments	NNS	O	treatment	prep_of	3	SENT_51	[p5l991t2467r1457b2545],
7	,	,	O	,	_	0	SENT_51	[p5l991t2467r1457b2545],
8	outliers	NNS	O	outlier	nsubj	10	SENT_51	[p5l1497t2450r1804b2529],
9	are	VBP	O	be	cop	10	SENT_51	[p5l1838t2476r1963b2528],
10	uncommon	JJ	O	uncommon	_	0	SENT_51	[p5l1996t2476r2133b2529, p5l12t2604r404b2657],
11	.	.	O	.	_	0	SENT_51	[p5l1996t2476r2133b2529, p5l12t2604r404b2657],

1	For	IN	O	for	_	0	SENT_52	[p5l439t2586r577b2657],
2	example	NN	O	example	prep_for	10	SENT_52	[p5l606t2578r969b2679],
3	,	,	O	,	_	0	SENT_52	[p5l606t2578r969b2679],
4	the	DT	O	the	det	8	SENT_52	[p5l1006t2578r1135b2657],
5	drug	NN	O	drug	nn	8	SENT_52	[p5l1167t2578r1364b2679],
6	6	CD	NUMBER	6	num	8	SENT_52	[p5l1392t2579r2134b2679],
7	—	NN	O	—	nn	8	SENT_52	[p5l1392t2579r2134b2679],
8	mercaptopurine	NN	O	mercaptopurine	nsubjpass	10	SENT_52	[p5l1392t2579r2134b2679],
9	is	VBZ	O	be	auxpass	10	SENT_52	[p5l11t2707r77b2785],
10	metabolized	VBN	O	metabolize	_	0	SENT_52	[p5l110t2706r643b2785],
11	by	IN	O	by	_	0	SENT_52	[p5l675t2706r772b2807],
12	the	DT	O	the	det	15	SENT_52	[p5l798t2706r931b2785],
13	enzyme	NN	O	enzyme	nn	15	SENT_52	[p5l962t2732r1292b2807],
14	thiopurine	NN	O	thiopurine	nn	15	SENT_52	[p5l1324t2706r1778b2807],
15	methyltransferase	NN	O	methyltransferase	agent	10	SENT_52	[p5l1809t2706r2133b2807, p5l12t2834r511b2913],
16	.	.	O	.	_	0	SENT_52	[p5l1809t2706r2133b2807, p5l12t2834r511b2913],

1	About	IN	O	about	_	0	SENT_53	[p5l559t2834r823b2913],
2	1	CD	NUMBER	1	prep_about	12	SENT_53	[p5l866t2840r910b2912],
3	of	IN	O	of	_	0	SENT_53	[p5l957t2834r1057b2913],
4	every	DT	O	every	quantmod	5	SENT_53	[p5l1084t2860r1306b2935],
5	300	CD	NUMBER	300	prep_of	2	SENT_53	[p5l1347t2840r1501b2913],
6	people	NNS	O	people	nsubj	12	SENT_53	[p5l1546t2834r1827b2935],
7	in	IN	O	in	_	0	SENT_53	[p5l1872t2835r1956b2912],
8	the	DT	O	the	det	10	SENT_53	[p5l2001t2834r2134b2913],
9	United	NNP	LOCATION	United	nn	10	SENT_53	[p5l9t2962r297b3041],
10	States	NNPS	LOCATION	States	prep_in	6	SENT_53	[p5l342t2968r590b3041],
11	is	VBZ	O	be	cop	12	SENT_53	[p5l635t2963r701b3041],
12	homozygous	JJ	O	homozygous	_	0	SENT_53	[p5l746t2962r1294b3063],
13	for	IN	O	for	_	0	SENT_53	[p5l1339t2962r1462b3041],
14	a	DT	O	a	det	16	SENT_53	[p5l1502t2989r1546b3041],
15	deficient	JJ	O	deficient	amod	16	SENT_53	[p5l1588t2962r1965b3041],
16	enzyme	NN	O	enzyme	prep_for	12	SENT_53	[p5l2004t2988r2134b3041, p5l9t3116r253b3191],
17	,	,	O	,	_	0	SENT_53	[p5l2004t2988r2134b3041, p5l9t3116r253b3191],
18	with	IN	O	with	_	0	SENT_53	[p5l291t3090r484b3169],
19	the	DT	O	the	det	20	SENT_53	[p5l521t3090r652b3169],
20	result	NN	O	result	prep_with	12	SENT_53	[p5l689t3090r927b3169],
21	that	IN	O	that	complm	40	SENT_53	[p5l960t3090r1149b3186],
22	,	,	O	,	_	0	SENT_53	[p5l960t3090r1149b3186],
23	in	IN	O	in	_	0	SENT_53	[p5l1191t3091r1273b3168],
24	these	DT	O	these	det	25	SENT_53	[p5l1311t3090r1530b3169],
25	people	NNS	O	people	prep_in	40	SENT_53	[p5l1566t3090r1865b3191],
26	,	,	O	,	_	0	SENT_53	[p5l1566t3090r1865b3191],
27	cellular	JJ	O	cellular	amod	28	SENT_53	[p5l1909t3090r2134b3169, p5l8t3218r122b3297],
28	exposure	NN	O	exposure	nsubjpass	40	SENT_53	[p5l156t3244r542b3319],
29	to	TO	O	to	_	0	SENT_53	[p5l581t3235r662b3297],
30	an	DT	O	a	det	32	SENT_53	[p5l701t3244r805b3297],
31	active	JJ	O	active	amod	32	SENT_53	[p5l842t3219r1083b3297],
32	metabolite	NN	O	metabolite	prep_to	28	SENT_53	[p5l1121t3218r1580b3297],
33	that	WDT	O	that	nsubj	35	SENT_53	[p5l1618t3218r1791b3297],
34	is	VBZ	O	be	cop	35	SENT_53	[p5l1823t3219r1889b3297],
35	toxic	JJ	O	toxic	rcmod	32	SENT_53	[p5l1930t3219r2136b3297],
36	to	TO	O	to	_	0	SENT_53	[p5l10t3363r91b3425],
37	bone	NN	O	bone	nn	38	SENT_53	[p5l130t3346r338b3425],
38	marrow	NN	O	marrow	prep_to	35	SENT_53	[p5l374t3372r718b3426],
39	is	VBZ	O	be	auxpass	40	SENT_53	[p5l750t3347r816b3425],
40	increased	VBN	O	increase	ccomp	12	SENT_53	[p5l853t3346r1263b3425],
41	by	IN	O	by	_	0	SENT_53	[p5l1300t3346r1397b3447],
42	a	DT	O	a	det	43	SENT_53	[p5l1428t3373r1473b3425],
43	factor	NN	O	factor	agent	40	SENT_53	[p5l1507t3346r1758b3425],
44	of	IN	O	of	_	0	SENT_53	[p5l1792t3346r1892b3425],
45	up	RB	O	up	quantmod	47	SENT_53	[p5l1910t3372r2014b3447],
46	to	TO	O	to	dep	47	SENT_53	[p5l2052t3363r2134b3425],
47	10	CD	NUMBER	10	prep_of	43	SENT_53	[p5l13t3480r129b3570],
48	,	,	O	,	_	0	SENT_53	[p5l13t3480r129b3570],
49	thereby	RB	O	thereby	advmod	50	SENT_53	[p5l183t3474r502b3575],
50	conferring	VBG	O	confer	xcomp	40	SENT_53	[p5l546t3474r1003b3575],
51	a	DT	O	a	det	54	SENT_53	[p5l1047t3501r1091b3553],
52	significantly	RB	O	significantly	advmod	54	SENT_53	[p5l1139t3474r1683b3575],
53	increased	VBN	O	increase	amod	54	SENT_53	[p5l1726t3474r2135b3553],
54	risk	NN	O	risk	dobj	50	SENT_53	[p5l10t3602r170b3682],
55	of	IN	O	of	_	0	SENT_53	[p5l200t3602r298b3681],
56	severe	JJ	O	severe	amod	58	SENT_53	[p5l315t3629r567b3682],
57	marrow	NN	O	marrow	nn	58	SENT_53	[p5l600t3628r939b3682],
58	suppression	NN	O	suppression	prep_of	54	SENT_53	[p5l970t3603r1533b3703],
59	?	.	O	?	_	0	SENT_53	[p5l970t3603r1533b3703],

1	Clinical	JJ	O	clinical	_	0	SENT_54	[p5l1566t3602r1892b3681],
2	practice	NN	O	practice	dep	1	SENT_54	[p5l1923t3628r2134b3703, p6l10t21r183b116],
3	,	,	O	,	_	0	SENT_54	[p5l1923t3628r2134b3703, p6l10t21r183b116],

1	in	IN	O	in	_	0	SENT_55	[p6l237t21r320b98],
2	the	DT	O	the	det	3	SENT_55	[p6l370t20r503b99],
3	setting	NN	O	setting	prep_in	9	SENT_55	[p6l555t21r853b121],
4	of	IN	O	of	_	0	SENT_55	[p6l900t20r1000b99],
5	childhood	NN	O	childhood	nn	6	SENT_55	[p6l1031t20r1469b99],
6	leukemia	NN	O	leukemia	prep_of	9	SENT_55	[p6l1516t20r1934b116],
7	,	,	O	,	_	0	SENT_55	[p6l1516t20r1934b116],
8	has	VBZ	O	have	aux	9	SENT_55	[p6l1989t20r2133b99],
9	been	VBN	O	be	_	0	SENT_55	[p6l11t148r205b227],
10	to	TO	O	to	aux	11	SENT_55	[p6l241t165r320b227],
11	monitor	VB	O	monitor	xcomp	9	SENT_55	[p6l356t149r695b227],
12	patients	NNS	O	patient	dobj	11	SENT_55	[p6l725t149r1052b249],
13	for	IN	O	for	_	0	SENT_55	[p6l1089t148r1208b227],
14	leukopenia	NN	O	leukopenia	prep_for	12	SENT_55	[p6l1239t148r1695b249],
15	and	CC	O	and	_	0	SENT_55	[p6l1728t148r1882b227],
16	modify	VB	O	modify	xcomp	9	SENT_55	[p6l1916t148r2134b227, p6l9t276r117b377],
17	the	DT	O	the	det	18	SENT_55	[p6l154t276r287b355],
18	dose	NN	O	dose	dobj	16	SENT_55	[p6l331t276r525b355],
19	of	IN	O	of	_	0	SENT_55	[p6l569t276r670b355],
20	6	CD	NUMBER	6	num	22	SENT_55	[p6l695t277r1470b377],
21	—	NN	O	—	nn	22	SENT_55	[p6l695t277r1470b377],
22	mercaptopurine	NN	O	mercaptopurine	prep_of	18	SENT_55	[p6l695t277r1470b377],
23	accordingly	RB	O	accordingly	advmod	16	SENT_55	[p6l1512t276r2027b377],
24	.	.	O	.	_	0	SENT_55	[p6l1512t276r2027b377],

1	A	DT	O	a	det	2	SENT_56	[p6l2073t284r2139b354],
2	case	NN	O	case	nsubjpass	5	SENT_56	[p6l11t431r190b483],
3	can	MD	O	can	aux	5	SENT_56	[p6l230t430r379b483],
4	be	VB	O	be	auxpass	5	SENT_56	[p6l418t404r515b483],
5	made	VBN	O	make	_	0	SENT_56	[p6l554t404r785b483],
6	for	IN	O	for	_	0	SENT_56	[p6l824t404r948b483],
7	identifying	VBG	O	identify	prepc_for	5	SENT_56	[p6l982t404r1458b505],
8	in	IN	O	in	_	0	SENT_56	[p6l1493t405r1576b482],
9	advance	NN	O	advance	nn	10	SENT_56	[p6l1614t404r1954b483],
10	homozygotes	NNS	O	homozygote	prep_in	7	SENT_56	[p6l1993t404r2134b483, p6l10t549r471b633],
11	who	WP	O	who	nsubj	12	SENT_56	[p6l515t532r698b612],
12	are	VBP	O	be	rcmod	10	SENT_56	[p6l745t558r874b611],
13	at	IN	O	at	_	0	SENT_56	[p6l919t549r998b611],
14	risk	NN	O	risk	prep_at	12	SENT_56	[p6l1039t532r1204b612],
15	on	IN	O	on	_	0	SENT_56	[p6l1246t558r1352b611],
16	the	DT	O	the	det	17	SENT_56	[p6l1398t532r1531b611],
17	basis	NN	O	basis	prep_on	14	SENT_56	[p6l1578t532r1790b611],
18	of	IN	O	of	_	0	SENT_56	[p6l1839t532r1939b611],
19	current	JJ	DATE	current	amod	20	SENT_56	[p6l1967t558r2134b611, p6l10t677r182b739],
20	evidence	NN	O	evidence	prep_of	17	SENT_56	[p6l211t660r600b739],
21	.	.	O	.	_	0	SENT_56	[p6l211t660r600b739],

1	In	IN	O	in	_	0	SENT_57	[p6l638t668r727b738],
2	fact	NN	O	fact	prep_in	17	SENT_57	[p6l760t660r940b756],
3	,	,	O	,	_	0	SENT_57	[p6l760t660r940b756],
4	in	IN	O	in	_	0	SENT_57	[p6l978t661r1062b738],
5	the	DT	O	the	det	6	SENT_57	[p6l1096t660r1228b739],
6	case	NN	O	case	prep_in	17	SENT_57	[p6l1263t687r1443b739],
7	of	IN	O	of	_	0	SENT_57	[p6l1477t660r1577b739],
8	many	JJ	O	many	amod	9	SENT_57	[p6l1592t686r1831b761],
9	drugs	NNS	O	drug	prep_of	6	SENT_57	[p6l1861t660r2130b761],
10	,	,	O	,	_	0	SENT_57	[p6l1861t660r2130b761],
11	known	JJ	O	known	amod	15	SENT_57	[p6l10t788r303b868],
12	exposure	NN	O	exposure	nn	15	SENT_57	[p6l335t814r1146b889],
13	—	NN	O	—	nn	15	SENT_57	[p6l335t814r1146b889],
14	response	NN	O	response	nn	15	SENT_57	[p6l335t814r1146b889],
15	relationships	NNS	O	relationship	nsubj	17	SENT_57	[p6l1177t788r1723b889],
16	may	MD	O	may	aux	17	SENT_57	[p6l1756t814r1933b889],
17	provide	VB	O	provide	_	0	SENT_57	[p6l1958t814r2134b889, p6l6t916r175b995],
18	adequate	JJ	O	adequate	amod	19	SENT_57	[p6l210t916r585b1017],
19	evidence	NN	O	evidence	dobj	17	SENT_57	[p6l622t916r980b995],
20	for	IN	O	for	_	0	SENT_57	[p6l1016t916r1137b995],
21	adjusting	VBG	O	adjust	prepc_for	17	SENT_57	[p6l1168t916r1560b1017],
22	doses	NNS	O	dose	dobj	21	SENT_57	[p6l1593t916r1825b995],
23	on	IN	O	on	_	0	SENT_57	[p6l1864t942r1969b995],
24	the	DT	O	the	det	25	SENT_57	[p6l2004t916r2135b995],
25	basis	NN	O	basis	prep_on	21	SENT_57	[p6l11t1044r218b1123],
26	of	IN	O	of	_	0	SENT_57	[p6l253t1044r351b1123],
27	pharmacogenetic	JJ	O	pharmacogenetic	amod	28	SENT_57	[p6l364t1044r1099b1145],
28	testing	NN	O	testing	prep_of	25	SENT_57	[p6l1131t1045r1422b1145],
29	in	IN	O	in	_	0	SENT_57	[p6l1450t1045r1532b1122],
30	the	DT	O	the	det	32	SENT_57	[p6l1565t1044r1695b1123],
31	same	JJ	O	same	amod	32	SENT_57	[p6l1729t1070r1946b1123],
32	way	NN	O	way	prep_in	28	SENT_57	[p6l1974t1071r2140b1145],
33	that	IN	O	that	complm	47	SENT_57	[p6l10t1172r183b1251],
34	doses	NNS	O	dose	nsubjpass	47	SENT_57	[p6l226t1172r462b1251],
35	of	IN	O	of	_	0	SENT_57	[p6l513t1172r613b1251],
36	drugs	NNS	O	drug	prep_of	34	SENT_57	[p6l643t1172r886b1273],
37	excreted	VBN	O	excrete	partmod	36	SENT_57	[p6l937t1172r1290b1251],
38	by	IN	O	by	_	0	SENT_57	[p6l1339t1172r1436b1273],
39	the	DT	O	the	det	40	SENT_57	[p6l1480t1172r1612b1251],
40	kidney	NN	O	kidney	agent	37	SENT_57	[p6l1659t1172r1962b1273],
41	,	,	O	,	_	0	SENT_57	[p6l1659t1172r1962b1273],
42	for	IN	O	for	_	0	SENT_57	[p6l2015t1172r2138b1251],
43	example	NN	O	example	prep_for	40	SENT_57	[p6l11t1300r390b1401],
44	,	,	O	,	_	0	SENT_57	[p6l11t1300r390b1401],
45	are	VBP	O	be	auxpass	47	SENT_57	[p6l442t1326r571b1379],
46	regularly	RB	O	regularly	advmod	47	SENT_57	[p6l619t1300r1007b1401],
47	adjusted	VBN	O	adjust	ccomp	17	SENT_57	[p6l1050t1300r1406b1401],
48	on	IN	O	on	_	0	SENT_57	[p6l1454t1326r1560b1379],
49	the	DT	O	the	det	50	SENT_57	[p6l1609t1300r1741b1379],
50	basis	NN	O	basis	prep_on	47	SENT_57	[p6l1791t1300r2002b1379],
51	of	IN	O	of	_	0	SENT_57	[p6l2053t1300r2153b1379],
52	pharmacokinetic	JJ	O	pharmacokinetic	amod	53	SENT_57	[p6l8t1428r744b1529],
53	findings	NNS	O	finding	prep_of	50	SENT_57	[p6l781t1428r1170b1529],
54	.	.	O	.	_	0	SENT_57	[p6l781t1428r1170b1529],

1	In	IN	O	in	_	0	SENT_58	[p6l138t1564r227b1634],
2	the	DT	O	the	det	3	SENT_58	[p6l266t1556r399b1635],
3	case	NN	O	case	prep_in	19	SENT_58	[p6l439t1583r618b1635],
4	of	IN	O	of	_	0	SENT_58	[p6l658t1556r758b1635],
5	drugs	NNS	O	drug	prep_of	3	SENT_58	[p6l780t1556r1023b1657],
6	that	WDT	O	that	nsubjpass	8	SENT_58	[p6l1065t1556r1237b1635],
7	are	VBP	O	be	auxpass	8	SENT_58	[p6l1271t1583r1400b1635],
8	administered	VBN	O	administer	rcmod	5	SENT_58	[p6l1438t1556r2009b1635],
9	as	IN	O	as	_	0	SENT_58	[p6l2047t1583r2132b1635],
10	prodrugs	NNS	O	prodrug	prep_as	8	SENT_58	[p6l8t1684r419b1785],
11	,	,	O	,	_	0	SENT_58	[p6l8t1684r419b1785],
12	metabolic	JJ	O	metabolic	amod	13	SENT_58	[p6l456t1684r873b1763],
13	conversion	NN	O	conversion	nsubj	19	SENT_58	[p6l904t1685r1355b1763],
14	to	TO	O	to	_	0	SENT_58	[p6l1387t1701r1467b1763],
15	the	DT	O	the	det	17	SENT_58	[p6l1500t1684r1631b1763],
16	active	JJ	O	active	amod	17	SENT_58	[p6l1662t1685r1897b1763],
17	form	NN	O	form	prep_to	13	SENT_58	[p6l1928t1684r2135b1763],
18	must	MD	O	must	aux	19	SENT_58	[p6l10t1829r219b1891],
19	take	VB	O	take	_	0	SENT_58	[p6l247t1812r420b1892],
20	place	NN	O	place	dobj	19	SENT_58	[p6l451t1812r662b1913],
21	within	IN	O	within	_	0	SENT_58	[p6l691t1812r965b1892],
22	the	DT	O	the	det	23	SENT_58	[p6l998t1812r1126b1891],
23	body	NN	O	body	prep_within	19	SENT_58	[p6l1159t1812r1373b1913],
24	.	.	O	.	_	0	SENT_58	[p6l1159t1812r1373b1913],

1	Persons	NNS	O	person	nsubj	11	SENT_59	[p6l1410t1819r1729b1891],
2	who	WP	O	who	nsubj	3	SENT_59	[p6l1759t1812r1938b1891],
3	lack	VBP	O	lack	rcmod	1	SENT_59	[p6l1970t1812r2140b1892],
4	the	DT	O	the	det	5	SENT_59	[p6l10t1940r138b2019],
5	enzyme	NN	O	enzyme	nsubj	6	SENT_59	[p6l170t1966r488b2041],
6	necessary	JJ	O	necessary	xcomp	3	SENT_59	[p6l519t1966r922b2041],
7	for	IN	O	for	_	0	SENT_59	[p6l948t1940r1067b2019],
8	this	DT	O	this	det	9	SENT_59	[p6l1093t1940r1247b2019],
9	conversion	NN	O	conversion	prep_for	6	SENT_59	[p6l1280t1941r1721b2019],
10	may	MD	O	may	aux	11	SENT_59	[p6l1751t1966r1926b2041],
11	have	VB	O	have	_	0	SENT_59	[p6l1951t1940r2135b2019],
12	little	JJ	O	little	amod	16	SENT_59	[p6l8t2068r205b2147],
13	or	CC	O	or	_	0	SENT_59	[p6l251t2094r341b2147],
14	no	DT	O	no	conj_or	12	SENT_59	[p6l382t2094r488b2147],
15	active	JJ	O	active	amod	16	SENT_59	[p6l533t2069r774b2147],
16	drug	NN	O	drug	dobj	11	SENT_59	[p6l820t2068r1024b2169],
17	circulating	VBG	O	circulate	partmod	16	SENT_59	[p6l1067t2068r1553b2169],
18	.	.	O	.	_	0	SENT_59	[p6l1067t2068r1553b2169],

1	Although	IN	O	although	mark	21	SENT_60	[p6l1600t2068r2008b2169],
2	in	IN	O	in	mark	5	SENT_60	[p6l2052t2069r2135b2146],
3	some	DT	O	some	det	4	SENT_60	[p6l11t2222r236b2275],
4	cases	NNS	O	case	nsubj	5	SENT_60	[p6l282t2223r505b2275],
5	(	VBP	O	(	advcl	21	SENT_60	[p6l557t2203r752b2297],
6	e.g.	FW	O	e.g.	dobj	5	SENT_60	[p6l557t2203r752b2297],
7	,	,	O	,	_	0	SENT_60	[p6l557t2203r752b2297],
8	codeine	NN	O	codeine	nn	9	SENT_60	[p6l803t2196r1183b2292],
9	)	NN	O	)	nsubj	21	SENT_60	[p6l803t2196r1183b2292],
10	,	,	O	,	_	0	SENT_60	[p6l803t2196r1183b2292],
11	the	DT	O	the	det	12	SENT_60	[p6l1235t2196r1368b2275],
12	consequences	NNS	O	consequence	appos	9	SENT_60	[p6l1415t2222r2005b2297],
13	of	IN	O	of	_	0	SENT_60	[p6l2053t2196r2153b2275],
14	the	DT	O	the	det	15	SENT_60	[p6l10t2324r143b2403],
15	lack	NN	O	lack	prep_of	12	SENT_60	[p6l188t2324r364b2404],
16	of	IN	O	of	_	0	SENT_60	[p6l407t2324r507b2403],
17	a	DT	O	a	det	19	SENT_60	[p6l534t2351r579b2403],
18	therapeutic	JJ	O	therapeutic	amod	19	SENT_60	[p6l624t2324r1110b2425],
19	response	NN	O	response	prep_of	15	SENT_60	[p6l1156t2350r1537b2425],
20	are	VBP	O	be	cop	21	SENT_60	[p6l1583t2350r1711b2403],
21	manageable	JJ	O	manageable	advcl	67	SENT_60	[p6l1759t2350r2134b2425, p6l9t2452r204b2548],
22	,	,	O	,	_	0	SENT_60	[p6l1759t2350r2134b2425, p6l9t2452r204b2548],
23	in	IN	O	in	_	0	SENT_60	[p6l245t2453r329b2530],
24	the	DT	O	the	det	25	SENT_60	[p6l366t2452r498b2531],
25	case	NN	O	case	prep_in	21	SENT_60	[p6l537t2479r717b2531],
26	of	IN	O	of	_	0	SENT_60	[p6l754t2452r855b2531],
27	drugs	NNS	O	drug	prep_of	25	SENT_60	[p6l874t2452r1117b2553],
28	that	WDT	O	that	nsubjpass	30	SENT_60	[p6l1157t2452r1330b2531],
29	are	VBP	O	be	auxpass	30	SENT_60	[p6l1361t2478r1490b2531],
30	prescribed	VBN	O	prescribe	rcmod	27	SENT_60	[p6l1526t2452r1978b2553],
31	for	IN	O	for	mark	34	SENT_60	[p6l2015t2452r2138b2531],
32	serious	JJ	O	serious	amod	33	SENT_60	[p6l11t2581r307b2659],
33	conditions	NNS	O	condition	nsubj	34	SENT_60	[p6l344t2580r788b2659],
34	(	VBP	O	(	advcl	30	SENT_60	[p6l830t2587r1019b2681],
35	e.g.	FW	O	e.g.	dobj	34	SENT_60	[p6l830t2587r1019b2681],
36	,	,	O	,	_	0	SENT_60	[p6l830t2587r1019b2681],
37	clopidogrel	NN	O	clopidogrel	dobj	34	SENT_60	[p6l1060t2580r1533b2681],
38	for	IN	O	for	_	0	SENT_60	[p6l1567t2580r1688b2659],
39	acute	JJ	O	acute	amod	41	SENT_60	[p6l1720t2597r1938b2659],
40	coronary	JJ	O	coronary	amod	41	SENT_60	[p6l1974t2606r2134b2659, p6l11t2734r254b2809],
41	syndrome	NN	O	syndrome	prep_for	37	SENT_60	[p6l287t2708r710b2809],
42	or	CC	O	or	_	0	SENT_60	[p6l748t2734r837b2787],
43	tamoxifen	NN	O	tamoxifen	dobj	34	SENT_60	[p6l871t2708r1311b2787],
44	for	IN	O	for	_	0	SENT_60	[p6l1347t2708r1471b2787],
45	breast	NN	O	breast	nn	47	SENT_60	[p6l1506t2708r1768b2787],
46	cancer	NN	O	cancer	nn	47	SENT_60	[p6l1801t2715r2130b2804],
47	)	NN	O	)	prep_for	43	SENT_60	[p6l1801t2715r2130b2804],
48	,	,	O	,	_	0	SENT_60	[p6l1801t2715r2130b2804],
49	if	IN	O	if	mark	56	SENT_60	[p6l9t2836r86b2914],
50	a	DT	O	a	det	51	SENT_60	[p6l110t2863r155b2915],
51	lack	NN	O	lack	nsubjpass	56	SENT_60	[p6l196t2836r371b2916],
52	of	IN	O	of	_	0	SENT_60	[p6l410t2836r510b2915],
53	activity	NN	O	activity	prep_of	51	SENT_60	[p6l534t2837r845b2937],
54	were	VBD	O	be	auxpass	56	SENT_60	[p6l879t2863r1081b2915],
55	definitively	RB	O	definitively	advmod	56	SENT_60	[p6l1125t2836r1608b2937],
56	shown	VBN	O	show	advcl	67	SENT_60	[p6l1648t2836r1953b2932],
57	,	,	O	,	_	0	SENT_60	[p6l1648t2836r1953b2932],
58	the	DT	O	the	det	59	SENT_60	[p6l2002t2836r2135b2915],
59	risks	NNS	O	risk	nsubjpass	67	SENT_60	[p6l10t2964r212b3044],
60	to	TO	O	to	_	0	SENT_60	[p6l262t2981r343b3043],
61	the	DT	O	the	det	63	SENT_60	[p6l393t2964r526b3043],
62	affected	VBN	O	affect	amod	63	SENT_60	[p6l573t2964r919b3043],
63	persons	NNS	O	person	prep_to	59	SENT_60	[p6l966t2990r1301b3065],
64	might	MD	O	might	aux	67	SENT_60	[p6l1351t2964r1612b3065],
65	well	RB	O	well	advmod	67	SENT_60	[p6l1649t2964r1827b3043],
66	be	VB	O	be	auxpass	67	SENT_60	[p6l1875t2964r1971b3043],
67	inferred	VBN	O	infer	_	0	SENT_60	[p6l2019t2965r2134b3042, p6l10t3092r265b3171],
68	without	IN	O	without	_	0	SENT_60	[p6l313t3092r653b3171],
69	demonstration	NN	O	demonstration	prep_without	67	SENT_60	[p6l701t3092r1335b3171],
70	in	IN	O	in	_	0	SENT_60	[p6l1387t3093r1471b3170],
71	a	DT	O	a	det	72	SENT_60	[p6l1523t3119r1567b3171],
72	prospective	JJ	O	prospective	prep_in	67	SENT_60	[p6l1617t3093r2130b3193],
73	,	,	O	,	_	0	SENT_60	[p6l1617t3093r2130b3193],
74	randomized	VBN	O	randomize	dep	67	SENT_60	[p6l10t3220r554b3316],
75	,	,	O	,	_	0	SENT_60	[p6l10t3220r554b3316],
76	controlled	VBN	O	control	aux	67	SENT_60	[p6l599t3220r1036b3299],
77	trial	NN	O	trial	nn	78	SENT_60	[p6l1074t3220r1314b3299],
78	.3	NN	NUMBER	.3	dobj	67	SENT_60	[p6l1074t3220r1314b3299],

1	Information	NN	O	information	nsubj	11	SENT_61	[p6l137t3349r667b3428],
2	on	IN	O	on	_	0	SENT_61	[p6l717t3375r823b3428],
3	genetic	JJ	O	genetic	amod	5	SENT_61	[p6l872t3350r1181b3450],
4	risk	NN	O	risk	nn	5	SENT_61	[p6l1230t3349r1394b3429],
5	factors	NNS	O	factor	prep_on	1	SENT_61	[p6l1438t3349r1729b3428],
6	for	IN	O	for	_	0	SENT_61	[p6l1781t3349r1904b3428],
7	serious	JJ	O	serious	amod	9	SENT_61	[p6l1951t3350r2134b3428, p6l10t3503r156b3556],
8	side	JJ	O	side	amod	9	SENT_61	[p6l205t3477r369b3556],
9	effects	NNS	O	effect	prep_for	5	SENT_61	[p6l414t3477r696b3556],
10	is	VBZ	O	be	aux	11	SENT_61	[p6l742t3478r808b3556],
11	beginning	VBG	O	begin	_	0	SENT_61	[p6l856t3477r1302b3578],
12	to	TO	O	to	aux	13	SENT_61	[p6l1344t3494r1426b3556],
13	appear	VB	O	appear	xcomp	11	SENT_61	[p6l1471t3503r1764b3578],
14	in	IN	O	in	_	0	SENT_61	[p6l1805t3478r1888b3555],
15	drug	NN	O	drug	nn	16	SENT_61	[p6l1934t3477r2138b3578],
16	labels	NNS	O	label	prep_in	13	SENT_61	[p6l8t3605r280b3684],
17	.	.	O	.	_	0	SENT_61	[p6l8t3605r280b3684],

1	For	IN	O	for	dep	4	SENT_62	[p6l324t3613r466b3684],
2	example	NN	O	example	pobj	1	SENT_62	[p6l504t3605r883b3706],
3	,	,	O	,	_	0	SENT_62	[p6l504t3605r883b3706],
4	testing	NN	O	testing	_	0	SENT_62	[p6l929t3606r1227b3706],
5	for	IN	O	for	_	0	SENT_62	[p6l1264t3605r1387b3684],
6	the	DT	O	the	det	7	SENT_62	[p6l1424t3605r1557b3684],
7	HLA	NN	O	hlum	prep_for	4	SENT_62	[p6l1597t3605r2135b3684],
8	.	.	O	.	_	0	SENT_62	[p6l1597t3605r2135b3684],

1	—	NN	O	—	_	0	SENT_63	[p6l1597t3605r2135b3684],
2	.	.	O	.	_	0	SENT_63	[p6l1597t3605r2135b3684],

1	B	NN	O	b	nsubj	23	SENT_64	[p6l1597t3605r2135b3684],
2	*	CD	NUMBER	*	num	1	SENT_64	[p6l1597t3605r2135b3684],
3	5701	CD	NUMBER	5701	num	4	SENT_64	[p6l1597t3605r2135b3684],
4	allele	NN	O	allele	nsubjpass	6	SENT_64	[p6l9t3734r232b3813],
5	is	VBZ	O	be	auxpass	6	SENT_64	[p6l287t3735r353b3813],
6	recommended	VBN	O	recommend	rcmod	1	SENT_64	[p6l411t3734r1028b3813],
7	before	IN	O	before	_	0	SENT_64	[p6l1084t3734r1353b3813],
8	the	DT	O	the	det	9	SENT_64	[p6l1409t3734r1542b3813],
9	initiation	NN	O	initiation	prep_before	6	SENT_64	[p6l1597t3735r1997b3813],
10	of	IN	O	of	_	0	SENT_64	[p6l2053t3734r2153b3813],
11	abacavir	NN	O	abacavir	nn	12	SENT_64	[p7l9t45r359b124],
12	therapy	NN	O	therapy	prep_of	9	SENT_64	[p7l393t45r709b146],
13	to	TO	O	to	aux	14	SENT_64	[p7l741t62r822b124],
14	reduce	VB	O	reduce	xcomp	6	SENT_64	[p7l860t45r1135b124],
15	the	DT	O	the	det	16	SENT_64	[p7l1173t45r1303b124],
16	risk	NN	O	risk	dobj	14	SENT_64	[p7l1341t45r1502b125],
17	of	IN	O	of	_	0	SENT_64	[p7l1535t45r1634b124],
18	hypersensitivity	NN	O	hypersensitivity	nn	19	SENT_64	[p7l1653t45r2134b146, p7l10t174r221b274],
19	reactions	NNS	O	reaction	prep_of	16	SENT_64	[p7l246t174r705b269],
20	,4	CD	NUMBER	,4	npadvmod	21	SENT_64	[p7l246t174r705b269],
21	as	IN	O	as	advmod	23	SENT_64	[p7l735t200r820b252],
22	is	VBZ	O	be	aux	23	SENT_64	[p7l853t174r918b252],
23	testing	VBG	O	test	_	0	SENT_64	[p7l953t174r1250b274],
24	for	IN	O	for	_	0	SENT_64	[p7l1278t173r1401b252],
25	the	DT	O	the	det	26	SENT_64	[p7l1430t173r1563b252],
26	HLA	NN	O	hlum	prep_for	23	SENT_64	[p7l1593t173r2134b252],
27	.	.	O	.	_	0	SENT_64	[p7l1593t173r2134b252],

1	—	NN	O	—	_	0	SENT_65	[p7l1593t173r2134b252],
2	.	.	O	.	_	0	SENT_65	[p7l1593t173r2134b252],

1	B	NN	O	b	_	0	SENT_66	[p7l1593t173r2134b252],
2	*	CD	NUMBER	*	number	3	SENT_66	[p7l1593t173r2134b252],
3	1502	CD	DATE	1502	num	4	SENT_66	[p7l1593t173r2134b252],
4	allele	NN	O	allele	dobj	1	SENT_66	[p7l9t301r227b380],
5	in	IN	O	in	_	0	SENT_66	[p7l260t302r342b379],
6	Asians	NNPS	MISC	Asians	prep_in	4	SENT_66	[p7l373t302r653b380],
7	to	TO	O	to	aux	8	SENT_66	[p7l690t318r771b380],
8	identify	VB	O	identify	xcomp	1	SENT_66	[p7l805t301r1131b402],
9	those	DT	O	those	dobj	8	SENT_66	[p7l1161t301r1387b380],
10	who	WP	O	who	nsubj	11	SENT_66	[p7l1418t301r1599b381],
11	are	VBP	O	be	rcmod	9	SENT_66	[p7l1633t327r1759b380],
12	at	IN	O	at	_	0	SENT_66	[p7l1793t318r1871b380],
13	much	RB	O	much	advmod	14	SENT_66	[p7l1900t301r2135b380],
14	higher	JJR	O	higher	amod	15	SENT_66	[p7l10t429r285b530],
15	risk	NN	O	risk	prep_at	11	SENT_66	[p7l321t429r482b509],
16	for	IN	O	for	_	0	SENT_66	[p7l516t429r637b508],
17	the	DT	O	the	det	18	SENT_66	[p7l673t429r804b508],
18	Stevens	NNP	PERSON	Stevens	prep_for	15	SENT_66	[p7l845t429r1555b521],
19	.	.	O	.	_	0	SENT_66	[p7l845t429r1555b521],

1	—	NN	O	—	_	0	SENT_67	[p7l845t429r1555b521],
2	.	.	O	.	_	0	SENT_67	[p7l845t429r1555b521],

1	Johnson	NNP	PERSON	Johnson	nn	2	SENT_68	[p7l845t429r1555b521],
2	syndrome	NN	O	syndrome	dep	12	SENT_68	[p7l1595t429r2011b530],
3	or	CC	O	or	_	0	SENT_68	[p7l2051t455r2138b508],
4	toxic	JJ	O	toxic	amod	6	SENT_68	[p7l10t558r216b636],
5	epidermal	JJ	O	epidermal	amod	6	SENT_68	[p7l268t557r700b658],
6	necrolysis	NN	O	necrolysis	dep	12	SENT_68	[p7l751t557r1173b658],
7	after	IN	O	after	_	0	SENT_68	[p7l1225t557r1428b636],
8	carbamazepine	NN	O	carbamazepine	prep_after	2	SENT_68	[p7l1477t557r2135b658],
9	therapy	NN	O	therapy	dep	12	SENT_68	[p7l10t685r382b786],
10	.5	CD	NUMBER	.5	num	9	SENT_68	[p7l10t685r382b786],
11	The	DT	O	the	det	12	SENT_68	[p7l424t685r586b764],
12	benefits	NNS	O	benefit	dep	33	SENT_68	[p7l629t685r973b764],
13	of	IN	O	of	_	0	SENT_68	[p7l1019t685r1118b764],
14	testing	NN	O	testing	prep_of	12	SENT_68	[p7l1143t686r1440b786],
15	for	IN	O	for	_	0	SENT_68	[p7l1480t685r1603b764],
16	hypersensitivity	NN	O	hypersensitivity	prep_for	14	SENT_68	[p7l1642t685r2134b786, p7l10t814r227b914],
17	to	TO	O	to	_	0	SENT_68	[p7l264t830r345b892],
18	abacavir	NN	O	abacavir	prep_to	16	SENT_68	[p7l387t813r762b909],
19	,	,	O	,	_	0	SENT_68	[p7l387t813r762b909],
20	the	DT	O	the	det	21	SENT_68	[p7l809t813r942b892],
21	incidence	NN	O	incidence	nsubjpass	33	SENT_68	[p7l983t813r1389b892],
22	of	IN	O	of	_	0	SENT_68	[p7l1431t813r1532b892],
23	which	WDT	O	which	nsubj	28	SENT_68	[p7l1550t813r1812b893],
24	is	VBZ	O	be	cop	28	SENT_68	[p7l1853t814r1919b892],
25	5	CD	NUMBER	5	number	27	SENT_68	[p7l1964t821r2007b892],
26	to	TO	O	to	dep	27	SENT_68	[p7l2052t830r2134b892],
27	8	CD	PERCENT	8	num	28	SENT_68	[p7l10t946r144b1020],
28	%	NN	PERCENT	%	prepc_of	21	SENT_68	[p7l10t946r144b1020],
29	among	IN	O	among	_	0	SENT_68	[p7l184t967r484b1042],
30	whites	NNS	O	whites	prep_among	28	SENT_68	[p7l519t941r825b1037],
31	,	,	O	,	_	0	SENT_68	[p7l519t941r825b1037],
32	were	VBD	O	be	auxpass	33	SENT_68	[p7l867t967r1069b1021],
33	evaluated	VBN	O	evaluate	_	0	SENT_68	[p7l1112t941r1515b1021],
34	in	IN	O	in	_	0	SENT_68	[p7l1555t942r1639b1019],
35	a	DT	O	a	prep_in	33	SENT_68	[p7l1680t968r1724b1020],
36	randomized	VBN	O	randomize	partmod	35	SENT_68	[p7l1764t941r2134b1020, p7l9t1069r201b1165],
37	,	,	O	,	_	0	SENT_68	[p7l1764t941r2134b1020, p7l9t1069r201b1165],
38	controlled	VBN	O	control	dep	36	SENT_68	[p7l235t1069r653b1148],
39	trial	NN	O	trial	dobj	36	SENT_68	[p7l681t1069r872b1165],
40	;	:	O	;	_	0	SENT_68	[p7l681t1069r872b1165],
41	the	DT	O	the	det	42	SENT_68	[p7l904t1069r1033b1148],
42	results	NNS	O	result	nsubj	46	SENT_68	[p7l1060t1069r1330b1149],
43	of	IN	O	of	_	0	SENT_68	[p7l1361t1069r1458b1148],
44	the	DT	O	the	det	45	SENT_68	[p7l1468t1069r1596b1148],
45	trial	NN	O	trial	prep_of	42	SENT_68	[p7l1625t1069r1794b1148],
46	showed	VBD	O	show	parataxis	33	SENT_68	[p7l1823t1069r2135b1149],
47	about	IN	O	about	_	0	SENT_68	[p7l9t1198r253b1277],
48	a	DT	O	a	det	51	SENT_68	[p7l288t1225r332b1277],
49	50	CD	PERCENT	50	number	50	SENT_68	[p7l373t1203r558b1277],
50	%	NN	PERCENT	%	amod	51	SENT_68	[p7l373t1203r558b1277],
51	reduction	NN	O	reduction	prep_about	46	SENT_68	[p7l598t1198r1007b1277],
52	in	IN	O	in	_	0	SENT_68	[p7l1047t1199r1130b1276],
53	risk	NN	O	risk	prep_in	51	SENT_68	[p7l1170t1198r1334b1278],
54	when	WRB	O	when	advmod	57	SENT_68	[p7l1366t1198r1599b1277],
55	testing	NN	O	testing	nsubjpass	57	SENT_68	[p7l1640t1199r1938b1299],
56	was	VBD	O	be	auxpass	57	SENT_68	[p7l1971t1225r2133b1278],
57	performed	VBN	O	perform	advcl	46	SENT_68	[p7l8t1326r489b1427],
58	.	.	O	.	_	0	SENT_68	[p7l8t1326r489b1427],

1	In	IN	O	in	_	0	SENT_69	[p7l533t1334r622b1404],
2	contrast	NN	O	contrast	prep_in	12	SENT_69	[p7l663t1343r1037b1422],
3	,	,	O	,	_	0	SENT_69	[p7l663t1343r1037b1422],
4	the	DT	O	the	det	5	SENT_69	[p7l1083t1326r1215b1405],
5	data	NNS	O	datum	nsubj	12	SENT_69	[p7l1256t1326r1440b1405],
6	for	IN	O	for	_	0	SENT_69	[p7l1479t1326r1602b1405],
7	the	DT	O	the	det	9	SENT_69	[p7l1640t1326r1772b1405],
8	rare	JJ	O	rare	amod	9	SENT_69	[p7l1813t1352r1980b1405],
9	reaction	NN	O	reaction	prep_for	5	SENT_69	[p7l2020t1353r2134b1405, p7l9t1455r267b1533],
10	to	TO	O	to	_	0	SENT_69	[p7l302t1471r382b1533],
11	carbamazepine	NN	O	carbamazepine	prep_to	9	SENT_69	[p7l418t1454r1064b1555],
12	came	VBD	O	come	_	0	SENT_69	[p7l1099t1480r1320b1533],
13	from	IN	O	from	_	0	SENT_69	[p7l1354t1454r1562b1533],
14	case	NN	O	case	nn	17	SENT_69	[p7l1597t1454r2135b1533],
15	—	CD	NUMBER	—	num	17	SENT_69	[p7l1597t1454r2135b1533],
16	control	NN	O	control	nn	17	SENT_69	[p7l1597t1454r2135b1533],
17	studies	NNS	O	study	prep_from	12	SENT_69	[p7l11t1582r336b1661],
18	.	.	O	.	_	0	SENT_69	[p7l11t1582r336b1661],

1	These	DT	O	these	det	2	SENT_70	[p7l382t1582r634b1661],
2	differences	NNS	O	difference	nsubj	6	SENT_70	[p7l679t1582r1154b1661],
3	in	IN	O	in	_	0	SENT_70	[p7l1200t1583r1284b1660],
4	evidence	NN	O	evidence	prep_in	2	SENT_70	[p7l1328t1582r1694b1662],
5	seem	VBP	O	seem	cop	6	SENT_70	[p7l1740t1608r1958b1661],
6	appropriate	JJ	O	appropriate	_	0	SENT_70	[p7l2001t1608r2134b1683, p7l8t1711r403b1811],
7	to	TO	O	to	_	0	SENT_70	[p7l441t1727r523b1789],
8	the	DT	O	the	det	9	SENT_70	[p7l563t1710r696b1789],
9	circumstances	NNS	O	circumstance	prep_to	6	SENT_70	[p7l734t1711r1353b1789],
10	of	IN	O	of	_	0	SENT_70	[p7l1394t1710r1494b1789],
11	the	DT	O	the	det	12	SENT_70	[p7l1514t1710r1647b1789],
12	risks	NNS	O	risk	prep_of	9	SENT_70	[p7l1685t1710r1912b1790],
13	.	.	O	.	_	0	SENT_70	[p7l1685t1710r1912b1790],

1	A	DT	O	a	det	3	SENT_71	[p7l135t1846r201b1916],
2	better	JJR	O	better	amod	3	SENT_71	[p7l234t1838r479b1917],
3	understanding	NN	O	understanding	_	0	SENT_71	[p7l511t1838r1129b1939],
4	of	IN	O	of	_	0	SENT_71	[p7l1162t1838r1260b1917],
5	individual	JJ	O	individual	amod	6	SENT_71	[p7l1277t1838r1694b1917],
6	differences	NNS	O	difference	prep_of	3	SENT_71	[p7l1730t1838r2134b1917, p7l10t1993r92b2045],
7	in	IN	O	in	_	0	SENT_71	[p7l127t1967r211b2044],
8	the	DT	O	the	det	9	SENT_71	[p7l247t1966r381b2045],
9	response	NN	O	response	prep_in	6	SENT_71	[p7l417t1992r821b2067],
10	,	,	O	,	_	0	SENT_71	[p7l417t1992r821b2067],
11	either	CC	O	either	dep	3	SENT_71	[p7l864t1966r1111b2045],
12	positive	JJ	O	positive	conj	3	SENT_71	[p7l1143t1967r1474b2067],
13	or	CC	O	or	_	0	SENT_71	[p7l1511t1992r1600b2045],
14	negative	JJ	O	negative	conj	3	SENT_71	[p7l1633t1967r2010b2067],
15	,	,	O	,	_	0	SENT_71	[p7l1633t1967r2010b2067],
16	to	TO	O	to	prep	14	SENT_71	[p7l2052t1983r2134b2045],

1	812	CD	NUMBER	812	num	3	SENT_72	[p7l149t2142r206b2163],
2	NENGLJ	NN	O	nenglj	nn	3	SENT_72	[p7l936t2152r1042b2174],
3	MED36o	NN	O	med36o	_	0	SENT_72	[p7l1057t2146r1188b2174],
4	;	:	O	;	_	0	SENT_72	[p7l1057t2146r1188b2174],
5	8	CD	NUMBER	8	num	6	SENT_72	[p7l1057t2146r1188b2174],
6	NEjM.oRG	NN	O	nejm.org	dep	3	SENT_72	[p7l1223t2152r1347b2174],
7	FEBRUARY	NN	DATE	february	dep	6	SENT_72	[p7l1384t2152r1623b2173],
8	'	''	O	'	_	0	SENT_72	[p7l1384t2152r1623b2173],
9	|	SYM	O	|	dep	10	SENT_72	[p7l1384t2152r1623b2173],
10	9,2009	CD	NUMBER	9,2009	dep	3	SENT_72	[p7l1384t2152r1623b2173],

1	EDITORIALS	NNS	O	editorial	_	0	SENT_73	[p7l983t2373r1177b2392],

1	medicines	NNS	O	medicine	nsubj	6	SENT_74	[p7l8t2586r426b2665],
2	should	MD	O	should	aux	6	SENT_74	[p7l463t2586r739b2665],
3	be	VB	O	be	cop	6	SENT_74	[p7l773t2586r866b2665],
4	an	DT	O	a	det	6	SENT_74	[p7l899t2612r1000b2665],
5	overarching	JJ	O	overarching	amod	6	SENT_74	[p7l1034t2586r1525b2687],
6	goal	NN	O	goal	_	0	SENT_74	[p7l1554t2586r1731b2687],
7	for	IN	O	for	_	0	SENT_74	[p7l1763t2586r1882b2665],
8	pharmacotherapy	NN	O	pharmacotherapy	prep_for	6	SENT_74	[p7l1911t2586r2132b2687, p7l8t2714r546b2815],
9	over	IN	O	over	_	0	SENT_74	[p7l583t2740r761b2793],
10	the	DT	DATE	the	det	12	SENT_74	[p7l801t2714r934b2793],
11	next	JJ	DATE	next	amod	12	SENT_74	[p7l978t2731r1163b2793],
12	decade	NN	DATE	decade	prep_over	8	SENT_74	[p7l1201t2714r1516b2793],
13	.	.	O	.	_	0	SENT_74	[p7l1201t2714r1516b2793],

1	Pharmacoge	NNP	O	Pharmacoge	nn	3	SENT_75	[p7l1563t2714r2132b2815],
2	—	CD	NUMBER	—	num	3	SENT_75	[p7l1563t2714r2132b2815],
3	netics	NNS	O	netic	nsubj	4	SENT_75	[p7l8t2843r258b2921],
4	has	VBZ	O	have	_	0	SENT_75	[p7l305t2842r449b2921],
5	the	DT	O	the	det	21	SENT_75	[p7l496t2842r630b2921],
6	potential	JJ	O	potential	amod	21	SENT_75	[p7l673t2842r1061b2943],
7	to	TO	O	to	aux	8	SENT_75	[p7l1106t2859r1187b2921],
8	increase	VB	O	increase	xcomp	6	SENT_75	[p7l1233t2843r1585b2921],
9	benefit	NN	O	benefit	dobj	8	SENT_75	[p7l1631t2842r1936b2921],
10	and	CC	O	and	_	0	SENT_75	[p7l1976t2842r2134b2921],
11	reduce	VB	O	reduce	conj_and	8	SENT_75	[p7l8t2970r283b3049],
12	harm	NN	O	harm	dobj	11	SENT_75	[p7l320t2970r548b3049],
13	in	IN	O	in	_	0	SENT_75	[p7l584t2971r667b3048],
14	people	NNS	O	people	prep_in	11	SENT_75	[p7l702t2970r978b3071],
15	whose	WP$	O	whose	poss	16	SENT_75	[p7l1011t2970r1281b3050],
16	drug	NN	O	drug	dobj	20	SENT_75	[p7l1319t2970r1519b3071],
17	responses	NNS	O	response	nsubj	20	SENT_75	[p7l1553t2996r1968b3071],
18	are	VBP	O	be	cop	20	SENT_75	[p7l2006t2997r2133b3049],
19	not	RB	O	not	neg	20	SENT_75	[p7l8t3115r151b3177],
20	“	JJ	O	“	rcmod	14	SENT_75	[p7l193t3103r614b3199],
21	average	NN	O	average	dobj	4	SENT_75	[p7l193t3103r614b3199],
22	.	.	O	.	_	0	SENT_75	[p7l193t3103r614b3199],

1	”	NN	O	”	npadvmod	12	SENT_76	[p7l193t3103r614b3199],
2	In	IN	O	in	_	0	SENT_76	[p7l659t3106r748b3176],
3	some	DT	O	some	det	4	SENT_76	[p7l793t3124r1017b3177],
4	cases	NNS	O	case	prep_in	12	SENT_76	[p7l1060t3125r1307b3194],
5	,	,	O	,	_	0	SENT_76	[p7l1060t3125r1307b3194],
6	randomized	VBN	O	randomize	partmod	4	SENT_76	[p7l1355t3098r1899b3194],
7	,	,	O	,	_	0	SENT_76	[p7l1355t3098r1899b3194],
8	controlled	VBN	O	control	amod	9	SENT_76	[p7l1948t3124r2132b3177, p7l9t3226r284b3305],
9	trials	NNS	O	trial	nsubjpass	12	SENT_76	[p7l317t3226r530b3305],
10	will	MD	O	will	aux	12	SENT_76	[p7l561t3226r723b3306],
11	be	VB	O	be	auxpass	12	SENT_76	[p7l755t3226r850b3305],
12	needed	VBN	O	need	_	0	SENT_76	[p7l883t3226r1181b3305],
13	to	TO	O	to	aux	14	SENT_76	[p7l1214t3243r1295b3305],
14	determine	VB	O	determine	xcomp	12	SENT_76	[p7l1329t3226r1759b3305],
15	whether	IN	O	whether	complm	19	SENT_76	[p7l1788t3226r2136b3306],
16	pharmacogenetic	JJ	O	pharmacogenetic	amod	17	SENT_76	[p7l7t3354r757b3455],
17	testing	NN	O	testing	nsubj	19	SENT_76	[p7l805t3355r1102b3455],
18	is	VBZ	O	be	cop	19	SENT_76	[p7l1146t3355r1211b3433],
19	worthwhile	JJ	O	worthwhile	ccomp	14	SENT_76	[p7l1257t3354r1776b3450],
20	;	:	O	;	_	0	SENT_76	[p7l1257t3354r1776b3450],
21	in	IN	O	in	_	0	SENT_76	[p7l1828t3355r1911b3432],
22	others	NNS	O	other	prep_in	28	SENT_76	[p7l1959t3354r2132b3433, p7l9t3508r154b3578],
23	,	,	O	,	_	0	SENT_76	[p7l1959t3354r2132b3433, p7l9t3508r154b3578],
24	less	JJR	O	less	amod	26	SENT_76	[p7l200t3482r356b3561],
25	rigorous	JJ	O	rigorous	amod	26	SENT_76	[p7l398t3483r757b3583],
26	approaches	NNS	O	approach	nsubj	28	SENT_76	[p7l800t3482r1283b3583],
27	will	MD	O	will	aux	28	SENT_76	[p7l1321t3482r1486b3562],
28	suffice	VB	O	suffice	parataxis	12	SENT_76	[p7l1528t3482r1842b3561],
29	.	.	O	.	_	0	SENT_76	[p7l1528t3482r1842b3561],

1	Given	VBN	O	give	prep	22	SENT_77	[p7l1889t3483r2133b3561],
2	the	DT	O	the	det	4	SENT_77	[p7l9t3610r141b3689],
3	expected	VBN	O	expect	amod	4	SENT_77	[p7l182t3610r559b3711],
4	volume	NN	O	volume	dep	1	SENT_77	[p7l593t3610r905b3689],
5	of	IN	O	of	_	0	SENT_77	[p7l946t3610r1045b3689],
6	genetic	JJ	O	genetic	amod	7	SENT_77	[p7l1066t3611r1375b3711],
7	information	NN	O	information	prep_of	4	SENT_77	[p7l1413t3610r1937b3689],
8	and	CC	O	and	_	0	SENT_77	[p7l1976t3610r2134b3689],
9	the	DT	O	the	det	11	SENT_77	[p8l9t20r140b99],
10	relative	JJ	O	relative	amod	11	SENT_77	[p8l176t20r477b99],
11	paucity	NN	O	paucity	conj_and	4	SENT_77	[p8l512t21r817b121],
12	of	IN	O	of	_	0	SENT_77	[p8l849t20r949b99],
13	randomized	VBN	O	randomize	prepc_of	11	SENT_77	[p8l966t20r1500b116],
14	,	,	O	,	_	0	SENT_77	[p8l966t20r1500b116],
15	controlled	VBN	O	control	dep	13	SENT_77	[p8l1542t20r1970b99],
16	trials	NNS	O	trial	dobj	15	SENT_77	[p8l2007t21r2132b99, p8l8t148r119b227],
17	involving	VBG	O	involve	xcomp	13	SENT_77	[p8l154t148r533b249],
18	marketed	VBN	O	market	dep	17	SENT_77	[p8l562t148r955b227],
19	drugs	NNS	O	drug	dobj	18	SENT_77	[p8l988t148r1246b249],
20	,	,	O	,	_	0	SENT_77	[p8l988t148r1246b249],
21	We	PRP	O	we	nsubj	22	SENT_77	[p8l1279t175r1395b227],
22	need	VBP	O	need	_	0	SENT_77	[p8l1428t148r1623b227],
23	clear	JJ	O	clear	acomp	22	SENT_77	[p8l1656t148r1853b227],
24	thinking	VBG	O	think	dep	23	SENT_77	[p8l1883t148r2132b228, p8l8t277r143b377],
25	about	IN	O	about	_	0	SENT_77	[p8l188t276r432b355],
26	what	WP	O	what	nsubjpass	28	SENT_77	[p8l473t276r689b355],
27	is	VBZ	O	be	auxpass	28	SENT_77	[p8l734t277r799b355],
28	required	VBN	O	require	prepc_about	24	SENT_77	[p8l852t276r1214b377],
29	for	IN	O	for	_	0	SENT_77	[p8l1264t276r1388b355],
30	the	DT	O	the	det	31	SENT_77	[p8l1435t276r1568b355],
31	adoption	NN	O	adoption	prep_for	28	SENT_77	[p8l1619t276r2001b377],
32	of	IN	O	of	_	0	SENT_77	[p8l2052t276r2152b355],
33	pharmacogenetic	JJ	O	pharmacogenetic	amod	34	SENT_77	[p8l7t404r757b505],
34	testing	NN	O	testing	prep_of	31	SENT_77	[p8l795t405r1111b505],
35	.	.	O	.	_	0	SENT_77	[p8l795t405r1111b505],

1	N	NN	O	n	nn	2	SENT_78	[p8l92t558r148b613],
2	o	NN	O	o	nn	4	SENT_78	[p8l152t572r188b612],
3	potential	JJ	O	potential	amod	4	SENT_78	[p8l215t553r503b628],
4	conﬂict	NN	O	conﬂict	nsubjpass	12	SENT_78	[p8l531t553r777b612],
5	of	IN	O	of	_	0	SENT_78	[p8l801t553r877b612],
6	interest	NN	O	interest	prep_of	4	SENT_78	[p8l890t554r1137b612],
7	relevant	JJ	O	relevant	amod	6	SENT_78	[p8l1160t553r1417b613],
8	to	TO	O	to	_	0	SENT_78	[p8l1440t566r1501b612],
9	this	DT	O	this	det	10	SENT_78	[p8l1529t553r1646b612],
10	article	NN	O	article	prep_to	7	SENT_78	[p8l1674t553r1872b612],
11	was	VBD	O	be	auxpass	12	SENT_78	[p8l1896t572r2019b613],
12	reported	VBN	O	report	_	0	SENT_78	[p8l2047t572r2133b612, p8l7t639r236b714],
13	.	.	O	.	_	0	SENT_78	[p8l2047t572r2133b612, p8l7t639r236b714],

1	From	IN	O	from	dep	6	SENT_79	[p8l14t740r181b796],
2	the	DT	O	the	det	3	SENT_79	[p8l214t735r320b796],
3	Center	NNP	ORGANIZATION	Center	pobj	1	SENT_79	[p8l352t740r575b796],
4	for	IN	ORGANIZATION	for	_	0	SENT_79	[p8l603t734r697b796],
5	Drug	NNP	ORGANIZATION	Drug	prep_for	3	SENT_79	[p8l732t740r897b816],
6	Evaluation	NN	ORGANIZATION	evaluation	_	0	SENT_79	[p8l932t735r1277b796],
7	and	CC	ORGANIZATION	and	_	0	SENT_79	[p8l1313t735r1431b796],
8	Research	NN	ORGANIZATION	research	conj_and	6	SENT_79	[p8l1472t735r1790b807],
9	,	,	ORGANIZATION	,	_	0	SENT_79	[p8l1472t735r1790b807],
10	Food	NNP	ORGANIZATION	Food	nn	13	SENT_79	[p8l1831t735r1992b796],
11	and	CC	ORGANIZATION	and	_	0	SENT_79	[p8l2028t735r2146b796],
12	Drug	NNP	ORGANIZATION	Drug	conj_and	10	SENT_79	[p8l14t838r179b914],
13	Administration	NNP	ORGANIZATION	Administration	appos	6	SENT_79	[p8l199t833r730b905],
14	,	,	O	,	_	0	SENT_79	[p8l199t833r730b905],
15	White	NNP	LOCATION	White	nn	16	SENT_79	[p8l756t833r954b894],
16	Oak	NNP	LOCATION	Oak	appos	6	SENT_79	[p8l979t833r1131b905],
17	,	,	O	,	_	0	SENT_79	[p8l979t833r1131b905],
18	MD.	NNP	LOCATION	MD.	appos	6	SENT_79	[p8l1163t838r1299b894],
19	.	.	O	.	_	0	SENT_79	[p8l1163t838r1299b894],

1	1	LS	NUMBER	1	_	0	SENT_80	[p8l11t1070r60b1122],
2	.	.	O	.	_	0	SENT_80	[p8l11t1070r60b1122],

1	The	DT	O	the	det	3	SENT_81	[p8l135t1062r259b1121],
2	International	NNP	O	International	nn	3	SENT_81	[p8l289t1062r730b1122],
3	Warfarin	NNP	O	Warfarin	_	0	SENT_81	[p8l757t1062r1058b1121],
4	Pharmacogenetics	NNP	O	Pharmacogenetics	nn	5	SENT_81	[p8l1088t1062r1697b1139],
5	Consortium	NNP	O	Consortium	dep	3	SENT_81	[p8l1730t1063r2148b1122],
6	.	.	O	.	_	0	SENT_81	[p8l1730t1063r2148b1122],

1	Estimation	NN	O	estimation	_	0	SENT_82	[p8l7t1160r372b1219],
2	of	IN	O	of	_	0	SENT_82	[p8l401t1159r477b1219],
3	the	DT	O	the	det	5	SENT_82	[p8l493t1159r595b1218],
4	warfarin	NN	O	warfarin	nn	5	SENT_82	[p8l619t1159r908b1219],
5	dose	NN	O	dose	prep_of	1	SENT_82	[p8l938t1159r1087b1219],
6	with	IN	O	with	_	0	SENT_82	[p8l1112t1159r1262b1219],
7	clinical	JJ	O	clinical	amod	12	SENT_82	[p8l1291t1159r1534b1218],
8	and	CC	O	and	_	0	SENT_82	[p8l1561t1159r1683b1219],
9	pharmacoge	JJ	O	pharmacoge	amod	12	SENT_82	[p8l1710t1159r2150b1236],
10	—	NN	O	—	nn	12	SENT_82	[p8l1710t1159r2150b1236],
11	netic	JJ	O	netic	amod	12	SENT_82	[p8l8t1257r169b1315],
12	data	NNS	O	datum	prep_with	1	SENT_82	[p8l195t1256r353b1316],
13	.	.	O	.	_	0	SENT_82	[p8l195t1256r353b1316],

1	N	NN	O	n	nn	3	SENT_83	[p8l382t1261r438b1316],
2	Engl	NNP	O	Engl	nn	3	SENT_83	[p8l463t1256r658b1333],
3	]	NNP	O	]	nsubj	4	SENT_83	[p8l463t1256r658b1333],
4	Med	VBD	O	med	_	0	SENT_83	[p8l681t1256r824b1316],
5	2009	CD	DATE	2009	dobj	4	SENT_83	[p8l850t1260r1420b1328],
6	;	:	O	;	_	0	SENT_83	[p8l850t1260r1420b1328],
7	360:753	CD	NUMBER	360:753	number	8	SENT_83	[p8l850t1260r1420b1328],
8	—	CD	NUMBER	—	dep	5	SENT_83	[p8l850t1260r1420b1328],
9	64	CD	NUMBER	64	dep	8	SENT_83	[p8l850t1260r1420b1328],
10	.	.	O	.	_	0	SENT_83	[p8l850t1260r1420b1328],

1	2	LS	NUMBER	2	_	0	SENT_84	[p8l7t1361r61b1412],
2	.	.	O	.	_	0	SENT_84	[p8l7t1361r61b1412],

1	Relling	VBG	ORGANIZATION	rell	_	0	SENT_85	[p8l137t1353r375b1430],
2	MV	NN	ORGANIZATION	mv	dobj	1	SENT_85	[p8l402t1358r524b1425],
3	,	,	O	,	_	0	SENT_85	[p8l402t1358r524b1425],
4	Hancock	NNP	PERSON	Hancock	nn	5	SENT_85	[p8l560t1353r852b1413],
5	ML	NNP	O	ML	appos	2	SENT_85	[p8l879t1358r1004b1425],
6	,	,	O	,	_	0	SENT_85	[p8l879t1358r1004b1425],
7	Rivera	NNP	PERSON	Rivera	nn	8	SENT_85	[p8l1040t1354r1244b1416],
8	GK	NNP	PERSON	GK	appos	2	SENT_85	[p8l1275t1357r1396b1425],
9	,	,	O	,	_	0	SENT_85	[p8l1275t1357r1396b1425],
10	et	FW	O	et	nn	11	SENT_85	[p8l1434t1366r1492b1412],
11	al.	FW	O	al.	appos	2	SENT_85	[p8l1520t1353r1594b1413],
12	.	.	O	.	_	0	SENT_85	[p8l1520t1353r1594b1413],

1	Mercaptopurine	JJ	O	mercaptopurine	amod	2	SENT_86	[p8l1628t1354r2152b1429],
2	therapy	NN	O	therapy	_	0	SENT_86	[p8l8t1450r252b1526],
3	intolerance	NN	O	intolerance	dep	2	SENT_86	[p8l275t1450r639b1510],
4	and	CC	O	and	_	0	SENT_86	[p8l666t1450r786b1510],
5	heterozygosity	NN	O	heterozygosity	dep	2	SENT_86	[p8l812t1450r1289b1527],
6	at	IN	O	at	_	0	SENT_86	[p8l1312t1463r1372b1509],
7	the	DT	O	the	det	9	SENT_86	[p8l1395t1450r1495b1509],
8	thiopurine	NN	O	thiopurine	nn	9	SENT_86	[p8l1523t1450r1868b1526],
9	S	NN	O	s	prep_at	3	SENT_86	[p8l1897t1450r2150b1510],
10	—	CD	NUMBER	—	num	12	SENT_86	[p8l1897t1450r2150b1510],
11	meth	NN	O	meth	nn	12	SENT_86	[p8l1897t1450r2150b1510],
12	—	NN	O	—	dep	2	SENT_86	[p8l1897t1450r2150b1510],
13	lytransferase	NN	O	lytransferase	nn	15	SENT_86	[p8l7t1546r425b1622],
14	gene	NN	O	gene	nn	15	SENT_86	[p8l451t1566r604b1623],
15	locus	NN	O	locus	dep	12	SENT_86	[p8l629t1546r821b1606],
16	.	.	O	.	_	0	SENT_86	[p8l629t1546r821b1606],

1	J	NNP	O	J	nn	4	SENT_87	[p8l844t1552r872b1615],
2	Natl	NNP	O	Natl	nn	4	SENT_87	[p8l895t1546r1036b1606],
3	Cancer	NNP	O	Cancer	nn	4	SENT_87	[p8l1062t1551r1292b1606],
4	Inst	NNP	O	Inst	_	0	SENT_87	[p8l1315t1552r1446b1605],
5	1999	CD	DATE	1999	num	4	SENT_87	[p8l1470t1550r1992b1618],
6	;	:	O	;	_	0	SENT_87	[p8l1470t1550r1992b1618],
7	91:2001	CD	NUMBER	91:2001	number	8	SENT_87	[p8l1470t1550r1992b1618],
8	—	CD	NUMBER	—	dep	4	SENT_87	[p8l1470t1550r1992b1618],
9	8	CD	NUMBER	8	dep	8	SENT_87	[p8l1470t1550r1992b1618],
10	.	.	O	.	_	0	SENT_87	[p8l1470t1550r1992b1618],

1	3	LS	NUMBER	3	_	0	SENT_88	[p8l8t1651r58b1704],
2	.	.	O	.	_	0	SENT_88	[p8l8t1651r58b1704],

1	Mega	JJ	O	mega	amod	2	SENT_89	[p8l136t1649r316b1721],
2	JL	NN	O	jl	_	0	SENT_89	[p8l331t1649r420b1717],
3	,	,	O	,	_	0	SENT_89	[p8l331t1649r420b1717],
4	Close	NNP	O	Close	nn	5	SENT_89	[p8l447t1644r626b1704],
5	SL	NNP	O	SL	appos	2	SENT_89	[p8l652t1648r746b1716],
6	,	,	O	,	_	0	SENT_89	[p8l652t1648r746b1716],
7	Wiviott	NNP	PERSON	Wiviott	nn	8	SENT_89	[p8l770t1645r1018b1704],
8	SD	NN	O	sd	appos	2	SENT_89	[p8l1039t1648r1144b1717],
9	,	,	O	,	_	0	SENT_89	[p8l1039t1648r1144b1717],
10	et	FW	O	et	nn	11	SENT_89	[p8l1172t1657r1231b1703],
11	al.	FW	O	al.	appos	2	SENT_89	[p8l1250t1644r1326b1704],
12	.	.	O	.	_	0	SENT_89	[p8l1250t1644r1326b1704],

1	Cytochrome	NN	O	cytochrome	nn	2	SENT_90	[p8l1353t1644r1759b1720],
2	P	NN	O	p	_	0	SENT_90	[p8l1781t1648r1965b1704],
3	—	CD	NUMBER	—	number	4	SENT_90	[p8l1781t1648r1965b1704],
4	450	CD	NUMBER	450	num	5	SENT_90	[p8l1781t1648r1965b1704],
5	polymorphisms	NNS	O	polymorphism	dep	2	SENT_90	[p8l1988t1644r2150b1720, p8l8t1741r387b1817],
6	and	CC	O	and	_	0	SENT_90	[p8l426t1741r547b1801],
7	response	NN	O	response	conj_and	5	SENT_90	[p8l585t1760r880b1817],
8	to	TO	O	to	_	0	SENT_90	[p8l918t1754r981b1801],
9	clopidogrel	NN	O	clopidogrel	prep_to	7	SENT_90	[p8l1021t1741r1412b1818],
10	.	.	O	.	_	0	SENT_90	[p8l1021t1741r1412b1818],

1	N	NN	O	n	nn	3	SENT_91	[p8l1453t1746r1510b1801],
2	Engl	NNP	O	Engl	nn	3	SENT_91	[p8l1546t1741r1696b1818],
3	J	NNP	O	J	nsubj	4	SENT_91	[p8l1726t1746r1754b1810],
4	Med	VBD	O	med	_	0	SENT_91	[p8l1788t1741r1932b1801],
5	2009	CD	DATE	2009	dobj	4	SENT_91	[p8l1969t1745r2148b1813],
6	;	:	O	;	_	0	SENT_91	[p8l1969t1745r2148b1813],
7	360:354	CD	NUMBER	360:354	number	8	SENT_91	[p8l8t1842r395b1898],
8	—	CD	NUMBER	—	dep	5	SENT_91	[p8l8t1842r395b1898],
9	62	CD	NUMBER	62	dep	8	SENT_91	[p8l8t1842r395b1898],
10	.	.	O	.	_	0	SENT_91	[p8l8t1842r395b1898],

1	4	LS	NUMBER	4	_	0	SENT_92	[p8l6t1943r60b1995],
2	.	.	O	.	_	0	SENT_92	[p8l6t1943r60b1995],

1	Mallal	JJ	O	mallal	amod	2	SENT_93	[p8l136t1935r348b1994],
2	S	NN	O	s	_	0	SENT_93	[p8l380t1939r432b2008],
3	,	,	O	,	_	0	SENT_93	[p8l380t1939r432b2008],
4	Phillips	NNP	PERSON	Phillips	nn	5	SENT_93	[p8l465t1935r717b2011],
5	E	NNP	O	E	appos	2	SENT_93	[p8l748t1940r807b2007],
6	,	,	O	,	_	0	SENT_93	[p8l748t1940r807b2007],
7	Carosi	NNP	PERSON	Carosi	nn	8	SENT_93	[p8l842t1936r1054b1995],
8	G	NNP	PERSON	G	appos	2	SENT_93	[p8l1084t1939r1154b2008],
9	,	,	O	,	_	0	SENT_93	[p8l1084t1939r1154b2008],
10	et	FW	O	et	nn	11	SENT_93	[p8l1190t1948r1249b1994],
11	al.	FW	O	al.	appos	2	SENT_93	[p8l1275t1935r1351b1995],
12	.	.	O	.	_	0	SENT_93	[p8l1275t1935r1351b1995],

1	HLA	NN	O	hlum	_	0	SENT_94	[p8l1385t1935r1800b1995],
2	.	.	O	.	_	0	SENT_94	[p8l1385t1935r1800b1995],

1	—	NN	O	—	_	0	SENT_95	[p8l1385t1935r1800b1995],
2	.	.	O	.	_	0	SENT_95	[p8l1385t1935r1800b1995],

1	B	NN	O	b	_	0	SENT_96	[p8l1385t1935r1800b1995],
2	*	CD	NUMBER	*	number	3	SENT_96	[p8l1385t1935r1800b1995],
3	5701	CD	NUMBER	5701	num	4	SENT_96	[p8l1385t1935r1800b1995],
4	screening	NN	O	screening	dep	1	SENT_96	[p8l1831t1936r2154b2012],
5	for	IN	O	for	_	0	SENT_96	[p8l8t2031r103b2091],
6	hypersensitivity	NN	O	hypersensitivity	prep_for	4	SENT_96	[p8l127t2031r654b2107],
7	to	TO	O	to	_	0	SENT_96	[p8l677t2044r739b2091],
8	abacavir	NN	O	abacavir	prep_to	6	SENT_96	[p8l766t2031r1057b2091],
9	.	.	O	.	_	0	SENT_96	[p8l766t2031r1057b2091],

1	N	NN	O	n	nn	3	SENT_97	[p8l1085t2037r1142b2091],
2	Engl	NNP	O	Engl	nn	3	SENT_97	[p8l1166t2031r1362b2108],
3	]	NNP	O	]	nsubj	4	SENT_97	[p8l1166t2031r1362b2108],
4	Med	VBD	O	med	_	0	SENT_97	[p8l1384t2031r1527b2091],
5	2008	CD	DATE	2008	dobj	4	SENT_97	[p8l1553t2036r2111b2103],
6	;	:	O	;	_	0	SENT_97	[p8l1553t2036r2111b2103],
7	358:568	CD	NUMBER	358:568	number	8	SENT_97	[p8l1553t2036r2111b2103],
8	—	CD	NUMBER	—	dep	5	SENT_97	[p8l1553t2036r2111b2103],
9	79	CD	NUMBER	79	dep	8	SENT_97	[p8l1553t2036r2111b2103],
10	.	.	O	.	_	0	SENT_97	[p8l1553t2036r2111b2103],

1	5	CD	NUMBER	5	_	0	SENT_98	[p8l9t2137r59b2189],
2	.	.	O	.	_	0	SENT_98	[p8l9t2137r59b2189],

1	Food	NNP	O	Food	nn	4	SENT_99	[p8l137t2129r302b2189],
2	and	CC	O	and	_	0	SENT_99	[p8l326t2129r447b2189],
3	Drug	NNP	O	Drug	nn	4	SENT_99	[p8l471t2134r641b2206],
4	Administration	NNP	O	Administration	_	0	SENT_99	[p8l661t2129r1193b2189],
5	.	.	O	.	_	0	SENT_99	[p8l661t2129r1193b2189],

1	Information	NN	O	information	nsubj	5	SENT_100	[p8l1222t2129r1631b2189],
2	on	IN	O	on	_	0	SENT_100	[p8l1656t2148r1737b2189],
3	carbamaze	NN	O	carbamaze	prep_on	1	SENT_100	[p8l1762t2129r2150b2189],
4	—	CD	NUMBER	—	num	3	SENT_100	[p8l1762t2129r2150b2189],
5	pine	VBP	O	pine	_	0	SENT_100	[p8l7t2227r149b2302],
6	(	NN	O	(	dobj	5	SENT_100	[p8l188t2226r523b2295],
7	marketed	VBN	O	market	partmod	6	SENT_100	[p8l188t2226r523b2295],
8	as	IN	O	as	_	0	SENT_100	[p8l558t2246r623b2285],
9	Carbatrol	NNP	O	Carbatrol	nn	13	SENT_100	[p8l660t2226r992b2298],
10	,	,	O	,	_	0	SENT_100	[p8l660t2226r992b2298],
11	Equetro	NNP	PERSON	Equetro	appos	13	SENT_100	[p8l1030t2231r1307b2302],
12	,	,	O	,	_	0	SENT_100	[p8l1030t2231r1307b2302],
13	Tegretol	NNP	O	Tegretol	prep_as	7	SENT_100	[p8l1344t2226r1637b2303],
14	,	,	O	,	_	0	SENT_100	[p8l1344t2226r1637b2303],
15	and	CC	O	and	_	0	SENT_100	[p8l1676t2226r1797b2286],
16	generics	NNS	O	generic	conj_and	13	SENT_100	[p8l1832t2227r2147b2303],
17	)	CD	NUMBER	)	num	16	SENT_100	[p8l1832t2227r2147b2303],
18	.	.	O	.	_	0	SENT_100	[p8l1832t2227r2147b2303],

1	(	NN	O	(	nsubj	2	SENT_101	[p8l11t2323r333b2392],
2	Accessed	VBD	O	access	_	0	SENT_101	[p8l11t2323r333b2392],
3	January	NNP	DATE	January	tmod	2	SENT_101	[p8l370t2328r630b2399],
4	30	CD	DATE	30	num	3	SENT_101	[p8l673t2328r766b2396],
5	,	,	DATE	,	_	0	SENT_101	[p8l673t2328r766b2396],
6	2009	CD	DATE	2009	num	3	SENT_101	[p8l817t2327r992b2395],
7	,	,	O	,	_	0	SENT_101	[p8l817t2327r992b2395],
8	at	IN	O	at	_	0	SENT_101	[p8l1041t2336r1102b2382],
9	http://WWW.fda.gov/cder/drug/	NN	O	http://www.fda.gov/cder/drug/	nn	10	SENT_101	[p8l1144t2323r2150b2400],
10	infopage/carbamazepine/default	NN	O	infopage/carbamazepine/default	prep_at	2	SENT_101	[p8l7t2420r1287b2497],
11	.	.	O	.	_	0	SENT_101	[p8l7t2420r1287b2497],

1	htm	NN	O	htm	_	0	SENT_102	[p8l7t2420r1287b2497],
2	.	.	O	.	_	0	SENT_102	[p8l7t2420r1287b2497],
3	)	SYM	O	)	dep	1	SENT_102	[p8l7t2420r1287b2497],

1	Copyright	NN	O	copyright	_	0	SENT_103	[p8l10t2544r265b2609],
2	©	CD	NUMBER	©	num	6	SENT_103	[p8l290t2549r343b2604],
3	2009	CD	DATE	2009	num	6	SENT_103	[p8l370t2548r506b2594],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_103	[p8l528t2544r912b2593],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_103	[p8l936t2544r1146b2594],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_103	[p8l1167t2546r1365b2608],
7	.	.	O	.	_	0	SENT_103	[p8l1167t2546r1365b2608],

1	Metabolic	JJ	O	metabolic	amod	2	SENT_104	[p8l336t2756r591b2805],
2	Enzymes	NNS	O	enzyme	_	0	SENT_104	[p8l612t2760r840b2820],
3	as	IN	O	as	_	0	SENT_104	[p8l860t2772r914b2805],
4	Oncogenes	NNS	O	oncogene	prep_as	2	SENT_104	[p8l933t2760r1230b2819],
5	or	CC	O	or	_	0	SENT_104	[p8l1249t2772r1302b2805],
6	Tumor	NN	O	tumor	nn	7	SENT_104	[p8l1317t2760r1489b2805],
7	Suppressors	NNS	O	suppressor	prep_as	2	SENT_104	[p8l1505t2760r1828b2819],

1	Craig	NNP	PERSON	Craig	nn	3	SENT_105	[p8l859t2840r947b2879],
2	B.	NNP	PERSON	B.	nn	3	SENT_105	[p8l963t2841r991b2869],
3	Thompson	NNP	PERSON	Thompson	_	0	SENT_105	[p8l1006t2838r1201b2879],
4	,	,	O	,	_	0	SENT_105	[p8l1006t2838r1201b2879],
5	M.D.	NNP	O	M.D.	appos	3	SENT_105	[p8l1220t2841r1300b2869],

1	Whether	IN	O	whether	complm	6	SENT_106	[p8l6t3005r385b3084],
2	mutations	NNS	O	mutation	nsubj	6	SENT_106	[p8l427t3006r866b3084],
3	in	IN	O	in	_	0	SENT_106	[p8l912t3006r996b3083],
4	metabolic	JJ	O	metabolic	amod	5	SENT_106	[p8l1042t3005r1470b3084],
5	pathways	NNS	O	pathway	prep_in	2	SENT_106	[p8l1514t3005r1915b3106],
6	contribute	VBP	O	contribute	csubj	13	SENT_106	[p8l1964t3031r2148b3084, p8l11t3133r298b3212],
7	to	TO	O	to	_	0	SENT_106	[p8l344t3150r426b3212],
8	the	DT	O	the	det	9	SENT_106	[p8l473t3133r607b3212],
9	pathogenesis	NN	O	pathogenesis	prep_to	6	SENT_106	[p8l651t3133r1219b3234],
10	of	IN	O	of	_	0	SENT_106	[p8l1267t3133r1367b3212],
11	cancer	NN	O	cancer	prep_of	9	SENT_106	[p8l1395t3159r1678b3212],
12	is	VBZ	O	be	cop	13	SENT_106	[p8l1718t3134r1785b3212],
13	controversial	JJ	O	controversial	_	0	SENT_106	[p8l1833t3150r2148b3212, p8l6t3261r408b3340],
14	.	.	O	.	_	0	SENT_106	[p8l1833t3150r2148b3212, p8l6t3261r408b3340],

1	”	NN	O	”	nn	3	SENT_107	[p8l1833t3150r2148b3212, p8l6t3261r408b3340],
2	Cancer	NN	O	cancer	nn	3	SENT_107	[p8l457t3267r758b3340],
3	cells	NNS	O	cell	nsubjpass	7	SENT_107	[p8l804t3261r993b3340],
4	have	VBP	O	have	aux	7	SENT_107	[p8l1044t3261r1235b3340],
5	long	RB	O	long	advmod	7	SENT_107	[p8l1283t3261r1476b3362],
6	been	VBN	O	be	auxpass	7	SENT_107	[p8l1522t3261r1724b3340],
7	noted	VBN	O	note	dep	10	SENT_107	[p8l1773t3261r2017b3340],
8	to	TO	O	to	xcomp	7	SENT_107	[p8l2066t3278r2148b3340],
9	preferentially	RB	O	preferentially	advmod	10	SENT_107	[p8l9t3389r578b3490],
10	metabolize	VBZ	O	metabolize	_	0	SENT_107	[p8l614t3389r1085b3468],
11	glucose	NN	O	glucose	dobj	10	SENT_107	[p8l1126t3389r1445b3490],
12	through	IN	O	through	_	0	SENT_107	[p8l1487t3389r1831b3490],
13	glycol	NN	O	glycol	nn	15	SENT_107	[p8l1872t3389r2148b3490],
14	—	CD	NUMBER	—	num	15	SENT_107	[p8l1872t3389r2148b3490],
15	ysis	NN	O	ysis	prep_through	10	SENT_107	[p8l6t3518r183b3618],
16	,	,	O	,	_	0	SENT_107	[p8l6t3518r183b3618],
17	a	DT	O	a	det	18	SENT_107	[p8l230t3544r275b3596],
18	discovery	NN	O	discovery	appos	15	SENT_107	[p8l317t3517r724b3618],
19	that	WDT	O	that	nsubjpass	22	SENT_107	[p8l762t3517r936b3596],
20	has	VBZ	O	have	aux	22	SENT_107	[p8l973t3517r1119b3596],
21	been	VBN	O	be	auxpass	22	SENT_107	[p8l1164t3517r1367b3596],
22	translated	VBN	O	translate	rcmod	18	SENT_107	[p8l1410t3517r1846b3596],
23	to	TO	O	to	_	0	SENT_107	[p8l1889t3534r1971b3596],
24	the	DT	O	the	det	25	SENT_107	[p8l2015t3517r2149b3596],
25	clinic	NN	O	clinic	prep_to	22	SENT_107	[p8l11t3645r240b3724],
26	through	IN	O	through	_	0	SENT_107	[p8l272t3645r617b3746],
27	positron	NN	O	positron	nn	31	SENT_107	[p8l648t3645r1977b3746],
28	—	CD	NUMBER	—	num	31	SENT_107	[p8l648t3645r1977b3746],
29	emission	NN	O	emission	nn	31	SENT_107	[p8l648t3645r1977b3746],
30	—	NN	O	—	nn	31	SENT_107	[p8l648t3645r1977b3746],
31	tomography	NN	O	tomography	prep_through	22	SENT_107	[p8l648t3645r1977b3746],
32	imaging	NN	O	imaging	nsubj	10	SENT_107	[p8l2004t3646r2148b3723, p9l10t21r246b121],

1	of	IN	O	of	_	0	SENT_108	[p9l273t20r372b99],
2	18F	NN	O	18f	nn	5	SENT_108	[p9l384t20r1092b121],
3	—	CD	NUMBER	—	num	5	SENT_108	[p9l384t20r1092b121],
4	deoXyglucose	NN	O	deoxyglucose	nn	5	SENT_108	[p9l384t20r1092b121],
5	uptake	NN	O	uptake	pobj	1	SENT_108	[p9l1123t20r1403b121],
6	in	IN	O	in	_	0	SENT_108	[p9l1432t21r1514b98],
7	tumors	NNS	O	tumor	prep_in	5	SENT_108	[p9l1544t37r1867b99],
8	.	.	O	.	_	0	SENT_108	[p9l1544t37r1867b99],

1	Moreover	RB	O	moreover	advmod	6	SENT_109	[p9l1899t28r2148b99, p9l11t174r201b244],
2	,	,	O	,	_	0	SENT_109	[p9l1899t28r2148b99, p9l11t174r201b244],
3	recent	JJ	O	recent	amod	4	SENT_109	[p9l252t165r511b227],
4	studies	NNS	O	study	nsubj	6	SENT_109	[p9l551t148r843b227],
5	have	VBP	O	have	aux	6	SENT_109	[p9l890t148r1076b227],
6	uncovered	VBN	O	uncover	_	0	SENT_109	[p9l1120t148r1550b228],
7	recurrent	JJ	O	recurrent	amod	9	SENT_109	[p9l1593t165r1983b228],
8	somatic	JJ	O	somatic	amod	9	SENT_109	[p9l2024t174r2148b227, p9l10t278r245b356],
9	mutations	NNS	O	mutation	dobj	6	SENT_109	[p9l297t278r734b356],
10	in	IN	O	in	_	0	SENT_109	[p9l792t278r876b355],
11	four	CD	NUMBER	four	num	12	SENT_109	[p9l932t277r1113b356],
12	genes	NNS	O	gene	prep_in	6	SENT_109	[p9l1166t303r1409b378],
13	involved	VBN	O	involve	partmod	12	SENT_109	[p9l1466t277r1821b357],
14	in	IN	O	in	_	0	SENT_109	[p9l1876t278r1959b355],
15	the	DT	O	the	det	16	SENT_109	[p9l2016t277r2149b356],
16	metabolism	NN	O	metabolism	prep_in	13	SENT_109	[p9l10t406r525b485],
17	of	IN	O	of	_	0	SENT_109	[p9l572t406r673b485],
18	mitochondrial	JJ	O	mitochondrial	amod	19	SENT_109	[p9l701t406r1325b485],
19	citrate	NN	O	citrate	prep_of	16	SENT_109	[p9l1371t407r1640b485],
20	that	WDT	O	that	dep	21	SENT_109	[p9l1688t406r1862b485],
21	either	CC	O	either	rcmod	16	SENT_109	[p9l1904t406r2153b485],
22	cause	NN	O	cause	dep	21	SENT_109	[p9l11t561r245b613],
23	or	CC	O	or	_	0	SENT_109	[p9l285t560r374b613],
24	predispose	VB	O	predispose	conj_or	21	SENT_109	[p9l408t534r878b635],
25	cells	NNS	O	cell	nsubj	28	SENT_109	[p9l917t534r1106b613],
26	to	TO	O	to	aux	28	SENT_109	[p9l1146t551r1229b613],
27	become	VB	O	become	cop	28	SENT_109	[p9l1269t534r1602b613],
28	malignant	JJ	O	malignant	xcomp	24	SENT_109	[p9l1640t534r2114b635],
29	.	.	O	.	_	0	SENT_109	[p9l1640t534r2114b635],

1	In	IN	O	in	_	0	SENT_110	[p9l138t670r227b740],
2	this	DT	O	this	det	3	SENT_110	[p9l261t662r417b741],
3	issue	NN	O	issue	prep_in	11	SENT_110	[p9l452t663r659b741],
4	of	IN	O	of	_	0	SENT_110	[p9l695t662r793b741],
5	the	DT	O	the	det	6	SENT_110	[p9l809t662r940b741],
6	journal	NN	O	journal	prep_of	3	SENT_110	[p9l958t662r1261b763],
7	,	,	O	,	_	0	SENT_110	[p9l958t662r1261b763],
8	Yan	NNP	PERSON	Yan	nsubj	11	SENT_110	[p9l1297t670r1452b741],
9	and	CC	O	and	_	0	SENT_110	[p9l1486t662r1642b741],
10	colleagues3	NN	O	colleagues3	conj_and	8	SENT_110	[p9l1676t662r2148b763],
11	report	NN	O	report	_	0	SENT_110	[p9l10t807r279b891],
12	that	WDT	O	that	dobj	22	SENT_110	[p9l324t790r499b869],
13	70	CD	PERCENT	70	number	14	SENT_110	[p9l545t796r730b869],
14	%	NN	PERCENT	%	nsubj	22	SENT_110	[p9l545t796r730b869],
15	or	CC	O	or	_	0	SENT_110	[p9l781t816r870b869],
16	more	JJR	O	more	conj_or	14	SENT_110	[p9l917t816r1138b869],
17	of	IN	O	of	_	0	SENT_110	[p9l1190t790r1291b869],
18	low	JJ	O	low	amod	21	SENT_110	[p9l1321t790r1752b891],
19	—	NN	O	—	nn	21	SENT_110	[p9l1321t790r1752b891],
20	grade	NN	O	grade	nn	21	SENT_110	[p9l1321t790r1752b891],
21	gliomas	NNS	O	glioma	prep_of	14	SENT_110	[p9l1803t790r2147b891],
22	bear	VBP	O	bear	ccomp	11	SENT_110	[p9l11t918r201b997],
23	mutations	NNS	O	mutation	nsubj	29	SENT_110	[p9l238t919r676b997],
24	in	IN	O	in	_	0	SENT_110	[p9l717t919r801b996],
25	one	CD	TIME	one	prep_in	23	SENT_110	[p9l842t944r994b997],
26	of	IN	TIME	of	_	0	SENT_110	[p9l1035t918r1136b997],
27	two	CD	TIME	two	num	28	SENT_110	[p9l1158t935r1316b998],
28	NADP	NN	O	nadp	prep_of	25	SENT_110	[p9l1355t918r2154b1019],
29	+	CC	O	+	xcomp	22	SENT_110	[p9l1355t918r2154b1019],
30	.	.	O	.	_	0	SENT_110	[p9l1355t918r2154b1019],

1	—	NN	O	—	_	0	SENT_111	[p9l1355t918r2154b1019],
2	.	.	O	.	_	0	SENT_111	[p9l1355t918r2154b1019],

1	dependent	JJ	O	dependent	amod	4	SENT_112	[p9l1355t918r2154b1019],
2	isocitrate	NN	O	isocitrate	nn	4	SENT_112	[p9l10t1047r408b1125],
3	dehydrogenase	NN	O	dehydrogenase	nn	4	SENT_112	[p9l482t1046r1128b1147],
4	enzymes	NNS	O	enzyme	nsubj	5	SENT_112	[p9l1202t1072r1577b1147],
5	(	VBP	O	(	_	0	SENT_112	[p9l1656t1052r1919b1138],
6	IDH1	NN	O	idh1	nn	9	SENT_112	[p9l1656t1052r1919b1138],
7	and	CC	O	and	_	0	SENT_112	[p9l1990t1046r2149b1125],
8	IDH2	NN	O	idh2	nn	9	SENT_112	[p9l8t1180r296b1266],
9	)	NN	O	)	dobj	5	SENT_112	[p9l8t1180r296b1266],
10	.	.	O	.	_	0	SENT_112	[p9l8t1180r296b1266],

1	A	DT	O	a	det	3	SENT_113	[p9l358t1182r425b1252],
2	similar	JJ	O	similar	amod	3	SENT_113	[p9l485t1174r793b1253],
3	result	NN	O	result	nsubjpass	6	SENT_113	[p9l851t1174r1096b1253],
4	has	VBZ	O	have	aux	6	SENT_113	[p9l1152t1174r1297b1253],
5	been	VBN	O	be	auxpass	6	SENT_113	[p9l1361t1174r1564b1253],
6	reported	VBN	O	report	_	0	SENT_113	[p9l1625t1174r1994b1275],
7	by	IN	O	by	_	0	SENT_113	[p9l2056t1174r2154b1275],
8	Balss	NNP	O	Balss	agent	6	SENT_113	[p9l8t1303r232b1382],
9	et	FW	O	et	nn	10	SENT_113	[p9l273t1320r351b1382],
10	al.	FW	O	al.	dep	8	SENT_113	[p9l383t1303r525b1382],
11	4	CD	NUMBER	4	dep	10	SENT_113	[p9l383t1303r525b1382],
12	These	DT	O	these	det	13	SENT_113	[p9l559t1303r812b1382],
13	studies	NNS	O	study	nsubj	14	SENT_113	[p9l851t1303r1153b1382],
14	follow	VBP	O	follow	ccomp	6	SENT_113	[p9l1193t1303r1468b1382],
15	the	DT	O	the	det	16	SENT_113	[p9l1502t1303r1636b1382],
16	discoveries	NNS	O	discovery	dobj	14	SENT_113	[p9l1674t1303r2147b1382],
17	that	WDT	O	that	dobj	23	SENT_113	[p9l11t1431r184b1510],
18	mutations	NNS	O	mutation	nsubjpass	23	SENT_113	[p9l232t1432r670b1510],
19	in	IN	O	in	_	0	SENT_113	[p9l725t1432r809b1509],
20	succinate	NN	O	succinate	nn	21	SENT_113	[p9l864t1432r1265b1510],
21	dehydrogenase	NN	O	dehydrogenase	prep_in	18	SENT_113	[p9l1319t1431r1966b1532],
22	are	VBP	O	be	auxpass	23	SENT_113	[p9l2019t1457r2149b1510],
23	linked	VBN	O	link	rcmod	16	SENT_113	[p9l9t1559r282b1639],
24	to	TO	O	to	_	0	SENT_113	[p9l328t1576r411b1638],
25	paraganglioma	NN	O	paraganglioma	prep_to	23	SENT_113	[p9l457t1559r1117b1660],
26	and	CC	O	and	_	0	SENT_113	[p9l1161t1559r1319b1638],
27	that	IN	O	that	complm	53	SENT_113	[p9l1366t1559r1539b1638],
28	mutations	NNS	O	mutation	nsubj	53	SENT_113	[p9l1580t1560r2018b1638],
29	in	IN	O	in	_	0	SENT_113	[p9l2065t1560r2149b1637],
30	fumarate	JJ	O	fumarate	amod	35	SENT_113	[p9l10t1687r391b1766],
31	hydratase	NN	O	hydratase	nn	35	SENT_113	[p9l432t1687r829b1788],
32	(	NN	O	(	nn	35	SENT_113	[p9l876t1687r1314b1779],
33	fumarase	NN	O	fumarase	nn	35	SENT_113	[p9l876t1687r1314b1779],
34	)	CD	NUMBER	)	num	35	SENT_113	[p9l876t1687r1314b1779],
35	lead	NN	O	lead	prep_in	28	SENT_113	[p9l1361t1687r1529b1766],
36	to	TO	O	to	_	0	SENT_113	[p9l1570t1704r1651b1766],
37	leiomyoma	NN	O	leiomyoma	nn	42	SENT_113	[p9l1692t1687r2150b1788],
38	and	CC	O	and	_	0	SENT_113	[p9l10t1815r165b1894],
39	leiomyosarcoma	NN	O	leiomyosarcoma	conj_and	37	SENT_113	[p9l201t1815r947b1916],
40	.5	CD	NUMBER	.5	num	42	SENT_113	[p9l201t1815r947b1916],
41	Recurrent	JJ	O	recurrent	amod	42	SENT_113	[p9l985t1822r1405b1899],
42	mutations	NNS	O	mutation	prep_to	28	SENT_113	[p9l1436t1816r1862b1894],
43	in	IN	O	in	_	0	SENT_113	[p9l1899t1816r1982b1893],
44	the	DT	O	the	det	47	SENT_113	[p9l2019t1815r2149b1894],
45	metabolic	JJ	O	metabolic	amod	47	SENT_113	[p9l10t1943r430b2022],
46	regulatory	JJ	O	regulatory	amod	47	SENT_113	[p9l465t1943r907b2044],
47	genes	NNS	O	gene	prep_in	28	SENT_113	[p9l938t1969r1178b2044],
48	of	IN	O	of	_	0	SENT_113	[p9l1217t1943r1317b2022],
49	these	DT	O	these	det	50	SENT_113	[p9l1334t1943r1555b2022],
50	types	NNS	O	type	prep_of	28	SENT_113	[p9l1592t1960r1812b2044],
51	of	IN	O	of	_	0	SENT_113	[p9l1852t1943r1951b2022],
52	cancer	NN	O	cancer	prep_of	50	SENT_113	[p9l1969t1969r2148b2022, p9l11t2098r136b2151],
53	constitute	VBP	O	constitute	ccomp	6	SENT_113	[p9l178t2073r608b2151],
54	the	DT	O	the	det	56	SENT_113	[p9l655t2072r789b2151],
55	best	JJS	O	best	amod	56	SENT_113	[p9l836t2072r1014b2151],
56	evidence	NN	O	evidence	dobj	53	SENT_113	[p9l1056t2072r1425b2151],
57	to	TO	O	to	_	0	SENT_113	[p9l1471t2089r1554b2151],
58	date	NN	O	date	prep_to	53	SENT_113	[p9l1602t2072r1781b2151],
59	that	WDT	O	that	dep	60	SENT_113	[p9l1828t2072r2002b2151],
60	alterations	NNS	O	alteration	rcmod	58	SENT_113	[p9l2042t2072r2148b2151, p9l11t2202r381b2280],

1	in	IN	O	in	_	0	SENT_114	[p9l418t2202r502b2279],
2	cellular	JJ	O	cellular	prep_in	4	SENT_114	[p9l538t2201r854b2280],
3	metabolism	NN	O	metabolism	nsubj	4	SENT_114	[p9l886t2201r1391b2280],
4	contribute	VBP	O	contribute	_	0	SENT_114	[p9l1427t2201r1863b2280],
5	to	TO	O	to	_	0	SENT_114	[p9l1899t2218r1980b2280],
6	the	DT	O	the	det	7	SENT_114	[p9l2018t2201r2149b2280],
7	pathogenesis	NN	O	pathogenesis	prep_to	4	SENT_114	[p9l9t2329r577b2430],
8	of	IN	O	of	_	0	SENT_114	[p9l618t2329r719b2408],
9	human	JJ	O	human	amod	10	SENT_114	[p9l738t2329r1045b2408],
10	cancer	NN	O	cancer	prep_of	7	SENT_114	[p9l1084t2355r1385b2408],
11	.	.	O	.	_	0	SENT_114	[p9l1084t2355r1385b2408],

1	Mutations	NNS	O	mutation	nsubjpass	5	SENT_115	[p9l137t2458r577b2536],
2	in	IN	O	in	_	0	SENT_115	[p9l613t2458r697b2535],
3	IDH1	NN	O	idh1	prep_in	1	SENT_115	[p9l729t2464r933b2535],
4	were	VBD	O	be	auxpass	5	SENT_115	[p9l966t2483r1170b2536],
5	found	VBN	O	find	_	0	SENT_115	[p9l1203t2457r1457b2536],
6	in	IN	O	in	_	0	SENT_115	[p9l1491t2458r1575b2535],
7	12	CD	PERCENT	12	num	8	SENT_115	[p9l1612t2463r1799b2536],
8	%	NN	PERCENT	%	prep_in	5	SENT_115	[p9l1612t2463r1799b2536],
9	of	IN	O	of	_	0	SENT_115	[p9l1833t2457r1933b2536],
10	glioblastomas	NNS	O	glioblastoma	prep_of	8	SENT_115	[p9l1948t2457r2148b2558, p9l11t2585r451b2664],
11	as	IN	O	as	_	0	SENT_115	[p9l499t2612r585b2664],
12	part	NN	O	part	prep_as	5	SENT_115	[p9l634t2602r814b2686],
13	of	IN	O	of	_	0	SENT_115	[p9l857t2585r958b2664],
14	a	DT	O	a	det	17	SENT_115	[p9l985t2612r1030b2664],
15	genomewide	JJ	O	genomewide	amod	17	SENT_115	[p9l1076t2585r1626b2686],
16	mutational	JJ	O	mutational	amod	17	SENT_115	[p9l1674t2585r2150b2664],
17	analysis	NN	O	analysis	prep_of	12	SENT_115	[p9l10t2713r352b2814],
18	of	IN	O	of	_	0	SENT_115	[p9l406t2713r507b2792],
19	glioblastoma	NN	O	glioblastoma	prep_of	17	SENT_115	[p9l539t2713r1108b2814],
20	multiforme	JJ	O	multiforme	amod	19	SENT_115	[p9l1158t2713r1718b2792],
21	.6	CD	NUMBER	.6	tmod	20	SENT_115	[p9l1158t2713r1718b2792],
22	The	DT	O	the	det	23	SENT_115	[p9l1766t2713r1928b2792],
23	mutation	NN	O	mutation	nsubjpass	34	SENT_115	[p9l1980t2739r2148b2792, p9l11t2842r265b2920],
24	Was	VBD	O	be	auxpass	25	SENT_115	[p9l333t2868r497b2921],
25	associated	VBN	O	associate	rcmod	19	SENT_115	[p9l573t2841r1020b2920],
26	with	IN	O	with	_	0	SENT_115	[p9l1089t2841r1286b2920],
27	a	DT	O	a	det	30	SENT_115	[p9l1359t2868r1404b2920],
28	relatively	RB	O	relatively	advmod	29	SENT_115	[p9l1475t2841r1863b2942],
29	good	JJ	O	good	amod	30	SENT_115	[p9l1932t2841r2150b2942],
30	prognosis	NN	O	prognosis	prep_with	25	SENT_115	[p9l9t2970r438b3070],
31	and	CC	O	and	_	0	SENT_115	[p9l474t2969r633b3048],
32	was	VBD	O	be	auxpass	34	SENT_115	[p9l662t2996r826b3049],
33	also	RB	O	also	advmod	34	SENT_115	[p9l862t2969r1035b3048],
34	found	VBN	O	find	conj_and	25	SENT_115	[p9l1071t2969r1325b3048],
35	in	IN	O	in	_	0	SENT_115	[p9l1358t2970r1442b3047],
36	secondary	JJ	O	secondary	amod	37	SENT_115	[p9l1478t2969r1919b3070],
37	glioblastomas	NNS	O	glioblastoma	prep_in	34	SENT_115	[p9l1948t2969r2148b3070, p9l11t3097r476b3193],
38	,	,	O	,	_	0	SENT_115	[p9l1948t2969r2148b3070, p9l11t3097r476b3193],
39	which	WDT	O	which	nsubj	41	SENT_115	[p9l514t3097r780b3176],
40	probably	RB	O	probably	advmod	41	SENT_115	[p9l816t3097r1196b3198],
41	arise	VBP	O	arise	rcmod	37	SENT_115	[p9l1228t3098r1433b3176],
42	from	IN	O	from	_	0	SENT_115	[p9l1471t3097r1683b3176],
43	the	DT	O	the	det	44	SENT_115	[p9l1722t3097r1855b3176],
44	transformation	NN	O	transformation	prep_from	41	SENT_115	[p9l1894t3114r2148b3176, p9l7t3225r442b3304],
45	of	IN	O	of	_	0	SENT_115	[p9l486t3225r586b3304],
46	lower	JJR	O	lower	amod	49	SENT_115	[p9l610t3225r1121b3326],
47	—	NN	O	—	nn	49	SENT_115	[p9l610t3225r1121b3326],
48	grade	NN	O	grade	nn	49	SENT_115	[p9l610t3225r1121b3326],
49	gliomas	NNS	O	glioma	prep_of	44	SENT_115	[p9l1165t3225r1532b3326],
50	.	.	O	.	_	0	SENT_115	[p9l1165t3225r1532b3326],

1	Moreover	RB	O	moreover	advmod	18	SENT_116	[p9l1579t3233r2004b3321],
2	,	,	O	,	_	0	SENT_116	[p9l1579t3233r2004b3321],
3	in	IN	O	in	_	0	SENT_116	[p9l2052t3226r2136b3303],
4	stage	NN	O	stage	prep_in	18	SENT_116	[p9l9t3370r221b3454],
5	II	CD	NUMBER	ii	num	4	SENT_116	[p9l248t3361r312b3431],
6	or	CC	O	or	_	0	SENT_116	[p9l341t3379r427b3432],
7	III	CD	NUMBER	iii	num	8	SENT_116	[p9l451t3361r548b3431],
8	astrocytomas	NNS	O	astrocytoma	conj_or	4	SENT_116	[p9l575t3370r1129b3454],
9	or	CC	O	or	_	0	SENT_116	[p9l1160t3379r1247b3432],
10	oligodendrogliomas	NNS	O	oligodendroglioma	conj_or	4	SENT_116	[p9l1273t3353r2130b3454],
11	,	,	O	,	_	0	SENT_116	[p9l1273t3353r2130b3454],
12	more	JJR	O	more	mwe	13	SENT_116	[p9l7t3508r222b3561],
13	than	IN	O	than	quantmod	14	SENT_116	[p9l255t3482r447b3561],
14	70	CD	PERCENT	70	num	15	SENT_116	[p9l481t3487r662b3561],
15	%	NN	PERCENT	%	nsubj	18	SENT_116	[p9l481t3487r662b3561],
16	of	IN	O	of	_	0	SENT_116	[p9l695t3482r793b3561],
17	tumors	NNS	O	tumor	prep_of	15	SENT_116	[p9l808t3499r1108b3561],
18	had	VBD	O	have	_	0	SENT_116	[p9l1143t3482r1296b3561],
19	mutations	NNS	O	mutation	dobj	18	SENT_116	[p9l1328t3483r1751b3561],
20	in	IN	O	in	prep	18	SENT_116	[p9l1784t3483r1866b3560],
21	either	CC	O	either	advmod	18	SENT_116	[p9l1899t3482r2139b3561],

1	IDH1	NN	O	idh1	_	0	SENT_117	[p9l6t3617r227b3706],
2	,	,	O	,	_	0	SENT_117	[p9l6t3617r227b3706],
3	the	DT	O	the	det	4	SENT_117	[p9l273t3610r402b3689],
4	gene	NN	O	gene	appos	1	SENT_117	[p9l442t3636r637b3711],
5	for	IN	O	for	_	0	SENT_117	[p9l677t3610r798b3689],
6	the	DT	O	the	det	7	SENT_117	[p9l835t3610r964b3689],
7	form	NN	O	form	prep_for	4	SENT_117	[p9l1004t3610r1210b3689],
8	of	IN	O	of	_	0	SENT_117	[p9l1250t3610r1349b3689],
9	NADP	NN	O	nadp	prep_of	7	SENT_117	[p9l1368t3610r2140b3711],
10	+	CC	O	+	rcmod	9	SENT_117	[p9l1368t3610r2140b3711],
11	.	.	O	.	_	0	SENT_117	[p9l1368t3610r2140b3711],

1	—	NN	O	—	_	0	SENT_118	[p9l1368t3610r2140b3711],
2	.	.	O	.	_	0	SENT_118	[p9l1368t3610r2140b3711],

1	dependent	JJ	O	dependent	amod	3	SENT_119	[p9l1368t3610r2140b3711],
2	isocitrate	NN	O	isocitrate	nn	3	SENT_119	[p10l7t21r404b99],
3	dehydrogenase	NN	O	dehydrogenase	nsubj	18	SENT_119	[p10l442t20r1085b121],
4	associated	VBN	O	associate	partmod	3	SENT_119	[p10l1121t20r1567b99],
5	with	IN	O	with	_	0	SENT_119	[p10l1599t20r1795b99],
6	cytosol	NN	O	cytosol	prep_with	4	SENT_119	[p10l1832t20r2135b121],
7	or	CC	O	or	_	0	SENT_119	[p10l8t174r96b227],
8	peroxisomes	NNS	O	peroxisome	prep_with	4	SENT_119	[p10l133t149r690b249],
9	,	,	O	,	_	0	SENT_119	[p10l133t149r690b249],
10	or	CC	O	or	_	0	SENT_119	[p10l738t174r826b227],
11	IDH2	NN	O	idh2	conj_or	6	SENT_119	[p10l862t155r1086b244],
12	,	,	O	,	_	0	SENT_119	[p10l862t155r1086b244],
13	the	DT	O	the	det	17	SENT_119	[p10l1134t148r1265b227],
14	mitochondria	NN	O	mitochondrium	nn	17	SENT_119	[p10l1306t148r2134b227],
15	—	CD	NUMBER	—	num	17	SENT_119	[p10l1306t148r2134b227],
16	asso	NN	O	asso	nn	17	SENT_119	[p10l1306t148r2134b227],
17	—	NN	O	—	appos	11	SENT_119	[p10l1306t148r2134b227],
18	ciated	VBD	O	ciate	_	0	SENT_119	[p10l8t276r256b355],
19	form	NN	O	form	dobj	18	SENT_119	[p10l300t276r511b355],
20	of	IN	O	of	_	0	SENT_119	[p10l556t276r656b355],
21	the	DT	O	the	det	22	SENT_119	[p10l682t276r816b355],
22	enzyme	NN	O	enzyme	prep_of	19	SENT_119	[p10l861t302r1215b377],
23	.	.	O	.	_	0	SENT_119	[p10l861t302r1215b377],

1	On	IN	O	on	_	0	SENT_120	[p10l1266t282r1392b355],
2	the	DT	O	the	det	3	SENT_120	[p10l1438t276r1570b355],
3	basis	NN	O	basis	prep_on	23	SENT_120	[p10l1616t276r1828b355],
4	of	IN	O	of	_	0	SENT_120	[p10l1875t276r1976b355],
5	the	DT	O	the	det	6	SENT_120	[p10l2002t276r2135b355],
6	analysis	NN	O	analysis	prep_of	3	SENT_120	[p10l7t404r348b505],
7	of	IN	O	of	_	0	SENT_120	[p10l391t404r491b483],
8	the	DT	O	the	det	10	SENT_120	[p10l514t404r648b483],
9	mutational	JJ	O	mutational	amod	10	SENT_120	[p10l689t404r1163b483],
10	status	NN	O	status	prep_of	6	SENT_120	[p10l1205t421r1457b483],
11	of	IN	O	of	_	0	SENT_120	[p10l1501t404r1602b483],
12	other	JJ	O	other	amod	13	SENT_120	[p10l1625t404r1853b483],
13	genes	NNS	O	gene	prep_of	10	SENT_120	[p10l1891t430r2134b505],
14	implicated	VBN	O	implicate	partmod	13	SENT_120	[p10l7t532r463b633],
15	in	IN	O	in	_	0	SENT_120	[p10l497t533r580b610],
16	the	DT	O	the	det	17	SENT_120	[p10l616t532r749b611],
17	pathogenesis	NN	O	pathogenesis	prep_in	14	SENT_120	[p10l783t532r1348b633],
18	of	IN	O	of	_	0	SENT_120	[p10l1386t532r1486b611],
19	gliomas	NNS	O	glioma	prep_of	17	SENT_120	[p10l1502t532r1870b633],
20	,	,	O	,	_	0	SENT_120	[p10l1502t532r1870b633],
21	these	DT	O	these	det	22	SENT_120	[p10l1911t532r2135b611],
22	studies	NNS	O	study	nsubj	23	SENT_120	[p10l9t660r296b739],
23	provide	VBP	O	provide	_	0	SENT_120	[p10l329t660r635b761],
24	compelling	JJ	O	compelling	amod	25	SENT_120	[p10l667t660r1137b761],
25	evidence	NN	O	evidence	dobj	23	SENT_120	[p10l1165t660r1517b739],
26	that	IN	O	that	complm	29	SENT_120	[p10l1549t660r1715b739],
27	IDHI	NN	O	idhus	nn	28	SENT_120	[p10l1739t667r1936b738],
28	mutations	NNS	O	mutation	nsubj	29	SENT_120	[p10l1971t686r2134b739, p10l8t789r292b867],
29	occur	VBP	O	occur	ccomp	23	SENT_120	[p10l331t814r564b867],
30	at	IN	O	at	_	0	SENT_120	[p10l596t805r674b867],
31	an	DT	O	a	det	33	SENT_120	[p10l703t814r804b867],
32	early	JJ	O	early	amod	33	SENT_120	[p10l841t788r1041b889],
33	stage	NN	O	stage	prep_at	29	SENT_120	[p10l1073t805r1287b889],
34	in	IN	O	in	_	0	SENT_120	[p10l1322t789r1404b866],
35	the	DT	O	the	det	36	SENT_120	[p10l1440t788r1570b867],
36	development	NN	O	development	prep_in	33	SENT_120	[p10l1606t788r2140b889],
37	of	IN	O	of	_	0	SENT_120	[p10l8t916r108b995],
38	gliomas	NNS	O	glioma	prep_of	36	SENT_120	[p10l127t916r495b1017],
39	.	.	O	.	_	0	SENT_120	[p10l127t916r495b1017],

1	These	DT	O	these	det	2	SENT_121	[p10l134t1044r385b1123],
2	mutations	NNS	O	mutation	nsubj	14	SENT_121	[p10l420t1045r855b1123],
3	of	IN	O	of	_	0	SENT_121	[p10l892t1044r992b1123],
4	enzymes	NNS	O	enzyme	prep_of	2	SENT_121	[p10l1009t1070r1382b1145],
5	that	WDT	O	that	nsubjpass	7	SENT_121	[p10l1419t1044r1592b1123],
6	are	VBP	O	be	auxpass	7	SENT_121	[p10l1620t1070r1749b1123],
7	involved	VBN	O	involve	rcmod	4	SENT_121	[p10l1783t1044r2136b1123],
8	in	IN	O	in	_	0	SENT_121	[p10l7t1173r89b1250],
9	the	DT	O	the	det	10	SENT_121	[p10l126t1172r256b1251],
10	metabolism	NN	O	metabolism	prep_in	7	SENT_121	[p10l293t1172r795b1251],
11	of	IN	O	of	_	0	SENT_121	[p10l831t1172r931b1251],
12	citrate	NN	O	citrate	prep_of	10	SENT_121	[p10l949t1173r1210b1251],
13	might	MD	O	might	aux	14	SENT_121	[p10l1246t1172r1503b1273],
14	share	VB	O	share	_	0	SENT_121	[p10l1535t1172r1760b1251],
15	a	DT	O	a	det	16	SENT_121	[p10l1796t1199r1840b1251],
16	mechanism	NN	O	mechanism	dobj	14	SENT_121	[p10l1875t1172r2134b1251, p10l7t1301r266b1379],
17	that	WDT	O	that	nsubj	18	SENT_121	[p10l300t1300r473b1379],
18	promotes	VBZ	O	promote	rcmod	16	SENT_121	[p10l501t1317r909b1401],
19	tumorigenesis	NN	O	tumorigenesis	nn	21	SENT_121	[p10l946t1301r1559b1401],
20	(	CD	NUMBER	(	num	21	SENT_121	[p10l1601t1301r1784b1401],
21	Fig	NN	O	fig	dobj	18	SENT_121	[p10l1601t1301r1784b1401],
22	.	.	O	.	_	0	SENT_121	[p10l1601t1301r1784b1401],

1	1	CD	NUMBER	1	_	0	SENT_122	[p10l1831t1306r1927b1391],
2	)	NN	O	)	dep	1	SENT_122	[p10l1831t1306r1927b1391],
3	.	.	O	.	_	0	SENT_122	[p10l1831t1306r1927b1391],

1	Mutations	NNS	O	mutation	nsubj	14	SENT_123	[p10l1964t1308r2134b1379, p10l8t1429r302b1507],
2	of	IN	O	of	_	0	SENT_123	[p10l347t1428r448b1507],
3	fumarate	JJ	O	fumarate	amod	4	SENT_123	[p10l471t1428r865b1507],
4	hydratase	NN	O	hydratase	prep_of	1	SENT_123	[p10l907t1428r1320b1529],
5	and	CC	O	and	_	0	SENT_123	[p10l1361t1428r1519b1507],
6	succinate	NN	O	succinate	nn	7	SENT_123	[p10l1563t1429r1962b1507],
7	dehydrogenase	NN	O	dehydrogenase	prep_of	1	SENT_123	[p10l2005t1428r2134b1507, p10l7t1556r551b1657],
8	in	IN	O	in	_	0	SENT_123	[p10l585t1557r669b1634],
9	certain	JJ	O	certain	amod	10	SENT_123	[p10l705t1557r1006b1635],
10	cancers	NNS	O	cancer	prep_in	4	SENT_123	[p10l1042t1582r1363b1635],
11	are	VBP	O	be	cop	12	SENT_123	[p10l1400t1582r1530b1635],
12	recessive	JJ	O	recessive	_	0	SENT_123	[p10l1565t1557r1942b1635],
13	and	CC	O	and	_	0	SENT_123	[p10l1977t1556r2135b1635],
14	lead	VB	O	lead	conj_and	12	SENT_123	[p10l6t1684r181b1763],
15	to	TO	O	to	_	0	SENT_123	[p10l222t1701r304b1763],
16	a	DT	O	a	det	17	SENT_123	[p10l346t1711r391b1763],
17	reduction	NN	O	reduction	prep_to	14	SENT_123	[p10l431t1684r841b1763],
18	in	IN	O	in	prep	17	SENT_123	[p10l882t1685r966b1762],
19	or	CC	O	or	_	0	SENT_123	[p10l1008t1710r1096b1763],
20	elimination	NN	O	elimination	prep_to	14	SENT_123	[p10l1136t1684r1639b1763],
21	of	IN	O	of	_	0	SENT_123	[p10l1681t1684r1781b1763],
22	enzyme	NN	O	enzyme	nn	23	SENT_123	[p10l1805t1710r2136b1785],
23	function	NN	O	function	prep_of	20	SENT_123	[p10l7t1812r436b1908],
24	,5	CD	NUMBER	,5	num	23	SENT_123	[p10l7t1812r436b1908],
25	which	WDT	O	which	nsubj	26	SENT_123	[p10l483t1812r746b1892],
26	increases	VBZ	O	increase	rcmod	20	SENT_123	[p10l792t1813r1188b1891],
27	the	DT	O	the	det	28	SENT_123	[p10l1238t1812r1371b1891],
28	accumulation	NN	O	accumulation	dobj	26	SENT_123	[p10l1418t1812r2006b1892],
29	of	IN	O	of	_	0	SENT_123	[p10l2053t1812r2153b1891],
30	fumarate	NN	O	fumarate	prep_of	28	SENT_123	[p10l7t1941r401b2020],
31	and	CC	O	and	_	0	SENT_123	[p10l441t1941r599b2020],
32	succinate	NN	O	succinate	prep_of	28	SENT_123	[p10l640t1942r1062b2037],
33	,	,	O	,	_	0	SENT_123	[p10l640t1942r1062b2037],
34	respectively	RB	O	respectively	advmod	26	SENT_123	[p10l1107t1941r1623b2042],
35	.	.	O	.	_	0	SENT_123	[p10l1107t1941r1623b2042],

1	The	DT	O	the	det	2	SENT_124	[p10l1664t1941r1826b2020],
2	excess	NN	O	excess	nsubj	6	SENT_124	[p10l1867t1968r2133b2020],
3	of	IN	O	of	_	0	SENT_124	[p10l8t2069r107b2148],
4	these	DT	O	these	det	5	SENT_124	[p10l125t2069r344b2148],
5	metabolites	NNS	O	metabolite	prep_of	2	SENT_124	[p10l381t2069r871b2148],
6	inhibits	VBZ	O	inhibit	_	0	SENT_124	[p10l909t2069r1231b2148],
7	the	DT	O	the	det	9	SENT_124	[p10l1270t2069r1401b2148],
8	proline	NN	O	proline	nn	9	SENT_124	[p10l1435t2069r1736b2170],
9	hydroxy	NN	O	hydroxy	dobj	6	SENT_124	[p10l1771t2069r2134b2170],
10	—	NN	O	—	nn	11	SENT_124	[p10l1771t2069r2134b2170],
11	lases	NNS	O	lase	tmod	6	SENT_124	[p10l6t2197r209b2276],
12	that	WDT	O	that	nsubj	13	SENT_124	[p10l267t2197r439b2276],
13	suppress	VBP	O	suppress	rcmod	11	SENT_124	[p10l492t2223r864b2298],
14	the	DT	O	the	det	15	SENT_124	[p10l923t2197r1055b2276],
15	expression	NN	O	expression	dobj	13	SENT_124	[p10l1113t2198r1570b2298],
16	of	IN	O	of	_	0	SENT_124	[p10l1628t2197r1728b2276],
17	hypoxiainducible	JJ	O	hypoxiainducible	amod	18	SENT_124	[p10l1765t2197r2134b2298, p10l7t2325r400b2404],
18	factor	NN	O	factor	prep_of	15	SENT_124	[p10l443t2325r693b2404],
19	1	CD	NUMBER	1	number	20	SENT_124	[p10l736t2331r780b2403],
20	(	CD	NUMBER	(	num	24	SENT_124	[p10l828t2331r1149b2421],
21	HIF	NN	O	hif	nn	24	SENT_124	[p10l828t2331r1149b2421],
22	—	NN	O	—	nn	24	SENT_124	[p10l828t2331r1149b2421],
23	1	CD	NUMBER	1	num	24	SENT_124	[p10l828t2331r1149b2421],
24	)	NN	O	)	dep	18	SENT_124	[p10l828t2331r1149b2421],
25	,	,	O	,	_	0	SENT_124	[p10l828t2331r1149b2421],
26	a	DT	O	a	det	28	SENT_124	[p10l1196t2352r1241b2404],
27	transcription	NN	O	transcription	nn	28	SENT_124	[p10l1281t2326r1845b2426],
28	factor	NN	O	factor	appos	18	SENT_124	[p10l1888t2325r2138b2404],
29	implicated	VBN	O	implicate	partmod	28	SENT_124	[p10l7t2453r453b2554],
30	in	IN	O	in	_	0	SENT_124	[p10l491t2454r573b2531],
31	tumor	NN	O	tumor	nn	32	SENT_124	[p10l612t2470r877b2532],
32	angiogenesis	NN	O	angiogenesis	prep_in	29	SENT_124	[p10l912t2454r1459b2554],
33	and	CC	O	and	_	0	SENT_124	[p10l1500t2453r1655b2532],
34	tumor	NN	O	tumor	prep_in	29	SENT_124	[p10l1695t2453r2136b2532],
35	—	JJ	O	—	amod	37	SENT_124	[p10l1695t2453r2136b2532],
36	cell	NN	O	cell	nn	37	SENT_124	[p10l1695t2453r2136b2532],
37	glycolysis	NN	O	glycolysis	dep	11	SENT_124	[p10l7t2581r440b2682],
38	.	.	O	.	_	0	SENT_124	[p10l7t2581r440b2682],

1	This	DT	O	this	nsubj	2	SENT_125	[p10l483t2581r671b2660],
2	accounts	VBZ	O	account	_	0	SENT_125	[p10l715t2598r1093b2660],
3	for	IN	O	for	_	0	SENT_125	[p10l1136t2581r1260b2660],
4	the	DT	O	the	det	7	SENT_125	[p10l1299t2581r1431b2660],
5	highly	RB	O	highly	advmod	6	SENT_125	[p10l1474t2581r1747b2682],
6	vascular	JJ	O	vascular	amod	7	SENT_125	[p10l1779t2581r2138b2660],
7	nature	NN	O	nature	prep_for	2	SENT_125	[p10l7t2726r285b2788],
8	of	IN	O	of	_	0	SENT_125	[p10l333t2709r433b2788],
9	the	DT	O	the	det	10	SENT_125	[p10l461t2709r595b2788],
10	tumors	NNS	O	tumor	prep_of	7	SENT_125	[p10l642t2726r950b2788],
11	associated	VBN	O	associate	partmod	10	SENT_125	[p10l999t2709r1445b2788],
12	with	IN	O	with	_	0	SENT_125	[p10l1487t2709r1683b2788],
13	fumarase	NN	O	fumarase	nn	17	SENT_125	[p10l1730t2709r2135b2788],
14	or	CC	O	or	_	0	SENT_125	[p10l8t2863r97b2916],
15	succinate	NN	O	succinate	nn	17	SENT_125	[p10l134t2838r532b2916],
16	dehydrogenase	NN	O	dehydrogenase	nn	17	SENT_125	[p10l571t2837r1214b2938],
17	deficiency	NN	O	deficiency	prep_with	11	SENT_125	[p10l1254t2837r1703b2938],
18	.	.	O	.	_	0	SENT_125	[p10l1254t2837r1703b2938],

1	Deficiencies	NNS	O	deficiency	nsubj	11	SENT_126	[p10l135t2965r659b3044],
2	in	IN	O	in	_	0	SENT_126	[p10l716t2966r799b3043],
3	IDH1	NN	O	idh1	prep_in	1	SENT_126	[p10l853t2971r1107b3061],
4	,	,	O	,	_	0	SENT_126	[p10l853t2971r1107b3061],
5	IDH2	NN	O	idh2	prep_in	1	SENT_126	[p10l1166t2971r1424b3061],
6	,	,	O	,	_	0	SENT_126	[p10l1166t2971r1424b3061],
7	or	CC	O	or	_	0	SENT_126	[p10l1485t2991r1574b3044],
8	both	DT	O	both	conj_or	3	SENT_126	[p10l1627t2965r1825b3044],
9	might	MD	O	might	aux	11	SENT_126	[p10l1880t2965r2140b3066],
10	also	RB	O	also	advmod	11	SENT_126	[p10l7t3093r178b3172],
11	stabilize	VB	O	stabilize	_	0	SENT_126	[p10l228t3093r590b3172],
12	HIF	NN	O	hif	nn	13	SENT_126	[p10l637t3099r901b3172],
13	—	NN	O	—	dobj	11	SENT_126	[p10l637t3099r901b3172],
14	1	CD	NUMBER	1	num	13	SENT_126	[p10l637t3099r901b3172],
15	.	.	O	.	_	0	SENT_126	[p10l637t3099r901b3172],

1	In	IN	O	in	_	0	SENT_127	[p10l953t3101r1042b3171],
2	addition	NN	O	addition	_	0	SENT_127	[p10l1088t3093r1446b3172],
3	to	TO	O	to	_	0	SENT_127	[p10l1494t3110r1575b3172],
4	oxygen	NN	O	oxygen	prep_in_addition_to	14	SENT_127	[p10l1625t3119r1949b3194],
5	,	,	O	,	_	0	SENT_127	[p10l1625t3119r1949b3194],
6	the	DT	O	the	det	8	SENT_127	[p10l2003t3093r2135b3172],
7	proline	NN	O	proline	nn	8	SENT_127	[p10l6t3221r313b3322],
8	hydroxylases	NNS	O	hydroxylase	appos	4	SENT_127	[p10l350t3221r899b3322],
9	that	WDT	O	that	nsubj	10	SENT_127	[p10l937t3221r1110b3300],
10	suppress	VBP	O	suppress	rcmod	8	SENT_127	[p10l1143t3247r1514b3322],
11	HIF	NN	O	hif	nn	12	SENT_127	[p10l1551t3227r1792b3299],
12	—	NN	O	—	dobj	10	SENT_127	[p10l1551t3227r1792b3299],
13	1	CD	NUMBER	1	num	12	SENT_127	[p10l1551t3227r1792b3299],
14	require	VBP	O	require	_	0	SENT_127	[p10l1829t3222r2135b3322],
15	a	DT	O	a	nsubj	14	SENT_127	[p10l6t3349r659b3450],
16	:	:	O	:	_	0	SENT_127	[p10l6t3349r659b3450],
17	.	.	O	.	_	0	SENT_127	[p10l6t3349r659b3450],

1	—	NN	O	—	_	0	SENT_128	[p10l6t3349r659b3450],
2	.	.	O	.	_	0	SENT_128	[p10l6t3349r659b3450],

1	l	NN	O	l	_	0	SENT_129	[p10l6t3349r659b3450],
2	<	JJR	O	<	amod	3	SENT_129	[p10l6t3349r659b3450],
3	etoglutarate	NN	O	etoglutarate	dep	1	SENT_129	[p10l6t3349r659b3450],
4	as	IN	O	as	_	0	SENT_129	[p10l692t3376r776b3428],
5	a	DT	O	a	det	6	SENT_129	[p10l812t3376r856b3428],
6	substrate	NN	O	substrate	prep_as	3	SENT_129	[p10l889t3349r1294b3428],
7	.	.	O	.	_	0	SENT_129	[p10l889t3349r1294b3428],

1	Recent	JJ	O	recent	amod	3	SENT_130	[p10l1332t3356r1622b3433],
2	genetic	JJ	O	genetic	amod	3	SENT_130	[p10l1650t3350r1953b3450],
3	eviN	NN	O	evin	_	0	SENT_130	[p10l1986t3350r2134b3428, p10l543t3535r557b3550],

1	ENGLJ	NNP	O	ENGLJ	nn	3	SENT_131	[p10l571t3535r649b3557],
2	MED	NNP	O	MED	nn	3	SENT_131	[p10l664t3535r716b3550],
3	36o	NN	O	36o	_	0	SENT_131	[p10l726t3529r795b3557],
4	;	:	O	;	_	0	SENT_131	[p10l726t3529r795b3557],
5	8	CD	NUMBER	8	num	7	SENT_131	[p10l726t3529r795b3557],
6	NEJM.ORG	NN	O	nejm.org	nn	7	SENT_131	[p10l830t3535r954b3557],
7	FEBRUARY19	NN	O	february19	dep	3	SENT_131	[p10l991t3535r1155b3556],
8	,	,	O	,	_	0	SENT_131	[p10l991t3535r1155b3556],
9	2009	CD	DATE	2009	num	10	SENT_131	[p10l1167t3535r1231b3556],
10	813	CD	NUMBER	813	appos	7	SENT_131	[p10l1959t3525r2015b3548],

